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Abstract 
Bioactive lipids or lipids that activate specific signalling pathways are 
involved in the regulation and maintenance of normal bodily functions. 
Furthermore, bioactive lipid targets have been implicated in a number of 
conditions such as cancer, asthma and arthritis, all of which contain an 
inflammatory element. Additionally, a number of bioactive lipids are also 
known to target several different types of receptors. These include the 
cannabinoid receptors, peroxisome proliferator activated receptor alpha 
(PPARa) and transient receptor potential vanilloid-1 (TRPV1) ion 
channels. The assessment of bioactive lipid levels in biological systems is 
important for understanding their role in cell function and pathological 
events. 
The aims of this thesis were to develop an analytical method that allows 
the simultaneous identification and measurement of lipid mediators 
involved in inflammatory responses, including cyclooxygenase, 
lipoxygenase and cytochrome P450 metabolites, along with the 
endocannabinoids to determine the role of bioactive lipids in models of 
acute and chronic inflammatory pain. 
A validated liquid chromatography tandem mass spectrometry (LC-
MS/MS) method that allows the simultaneous identification and 
measurement of 42 bioactive lipids was developed, capable of measuring 
COX metabolites; PGD;JPGE2 , TXB2, LOX metabolites; 5-, 12-, 15-HETE, 
HODEs, oxoODEs, CYP metabolites; 8- and ll-HETE, EETs and the 
endocannabinoids; AEA and 2-AG and endocannabinoid-like compounds 
PEA and OEA. levels of these analytes were quantified in rat hindpaw, 
dorsal root ganglia, knee jOint, plasma, spinal cord and brain. This lC-
MS/MS method was then used to investigate how levels of these bioactive 
lipids were altered in inflammation and pain. 
Experiments in this thesis using a PPARa competitive binding assay 
showed that 8-HETE and PEA bind to PPARa, along with other lipids such 
as fatty acids and EETs. levels of PPARa ligands were altered in the 
carrageenan model of inflammatory pain, suggesting that changes in 
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bioactive lipid metabolism may influence the contribution of PPARa in 
inflammatory pain states. Additionally, in the same model of 
inflammatory pain, levels of TRPV1 ligands were altered, supporting the 
known role of TRPV1 in inflammatory pain states. Inhibition of 15-
lipoxygenase or blockade of the metabolites resulted in attenuation of 
hyperalgesia, which was supported by alterations in bioactive lipid levels 
in vitro but not in vivo. The role of bioactive lipids in a rat model of 
osteoarthritis was also investigated. Levels of TRPV1 ligands were altered 
in this model of osteoarthritis, accompanied by the time-dependent 
development of pain behaviour, supporting a contribution of TRPV1 to 
OA-induced pain. 
In conclusion, the development of a novel LC-MS/MS analytical method 
capable of measuring a large number of bioactive lipids in vitro and in 
vivo, have provided novel findings to support the involvement of these 
lipids in inflammation and pain. Overall, these data provide evidence for 
the involvement of PPARa and TRPV1 ligands in inflammatory pain states. 
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General Introduction 
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1. General Introduction 
1.1 Inflammation 
Inflammation is a term used to describe a series of responses of 
vascularised tissues of the body to injury (Ratnoff 1971, Larsen and 
Henson 1983). The regulation of inflammation is a highly complex 
biological process that involves many receptors, cells and molecules and 
the specific importance of lipid molecules is widely recognised. The 
release of inflammatory mediators changes in response to tissue injury or 
insult, and is mediated by distinct mechanisms such as vasodilatation, 
increased capillary permeability and infiltration of immune cells (Chopade 
and Mulla 2010). Macrophages, neutrophils and dendritic cells are the 
main sources of eicosanoids, which target local receptors. These regulate 
cytokine production, cell proliferation and migration, antibody formation 
and other components of the inflammatory process (Harizi et al 2008, 
Mbvundula et al 2004). Persistent immune activation can result in chronic 
inflammation, which has pathological consequences. 
1.1.1 Acute inflammatory response 
Inflammation is characterised by the movement of serum proteins and 
inflammatory cells from the blood to the extravascular tissue, which is 
regulated by the sequential release of vasoactive and chemotactic 
mediators that contribute to the cardinal signs of inflammation, i.e. heat, 
redness, swelling, pain and loss of function (Lawrence et al 2002)(Figure 
1). 
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Figure 1. Inflammation is an important biological process, where the body initiates a 
protective response following injury through physical damage or infection. This image 
illustrates the fundamental elements of this process. When an injury occurs, neutrophils, 
mast cells and macrophages are recruited to the site of injury, releasing inflammatory 
mediators. Eicosanoids such as prostaglandins, leukotrienes and thromboxanes are 
released to facilitate this process as are HETEs or hydroxyeicosatetraenoic acids, which 
are released through the action of cytokines. Overall, inflammation is a highly complex 
process that involves many bioactive lipids (Modified version of an image taken from 
www.wdict.net). 
Increased vascular diameter, increased flow and permeability are key 
elements in inflammation, which allow the maximum opportunity for 
recruitment of inflammatory cells and plasma proteins to the site of 
injury. This results in initiation or perpetuation of the response, followed 
ultimately by resolution of the process (Ryan and Majno 1977, Wilhelm 
1973). 
1.1.2 Vascular events 
Within minutes of tissue injury, there is an increase in vasodilatation 
resulting in an increase in the volume of blood in the area, accompanied 
by a reduction in the flow of blood. This increase in blood volume 
contributes to the heat and redness of the tissue. Vasodilatation is 
generally considered to be of central importance in the development of 
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acute inflammatory reactions because the degree of local blood flow 
determines the amount of exudate produced (Larsen and Henson 1983). 
Vascular permeability also increases, leading to fluid leakage particularly 
from the post-capillary venules, resulting in fluid accumulation (oedema) 
and extravasation of inflammatory cells. Most of the vascular changes are 
due to the direct effects of bradykinin and fibrinopeptides, but also to a 
lesser extent complement anaphylatoxins (C3a and C5a), which induce 
local mast cell degranulation and release histamine. Other mediators of 
the vascular response include the prostaglandins which contribute to the 
vasodilatation and increased vascular permeability associated with acute 
inflammation. In response to thrombin, histamine, interleukin-1 (IL-1), 
tumour necrosis factor-a (TNF-a), vascular endothelial cells express 
increased E- and P-selectin. This, along with neutrophil expression of 
mucins, enables neutrophil binding and attachment to the endothelium, 
allowing initiation of cellular events (Gabay and Kushner 1999). 
1.1.3 Cellular events 
In acute inflammation, the predominant infiltrating cell type is often the 
neutrophil, produced in the bone marrow. Within hours of the onset of 
vascular events, neutrophils adhere to endothelial cells and migrate out 
of the blood into the tissue (Figure 1), where infiltration usually peaks 
within the first 4 hours of an inflammatory response (Weksler and Coupal 
1973). Neutrophils phagocytose invading pathogens and release 
macrophage inflammatory proteins and chemokines that attract 
macrophages to the site of inflammation (Figure 1). These mononuclear 
cells arrive after the first 4 hours following peak neutrophil infiltration, 
and reach a sustained peak around 18 to 24 hours (Weksler and Coupal 
1973). Once activated, macro phages exhibit increased phagocytOSis and 
release of cytokines and other mediators that contribute to the 
inflammatory response. These include IL-1, IL-6 and TNF-a, which act 
locally to increase vascular permeability, as described earlier. IL-1 also 
induces intercellular adhesion molecules (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) expression, enabling binding to integrins 
on monocytes and lymphocytes and assisting in extravasation through 
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the vessel walls (Imhof and Aurrand-Lions 2004). IL-1 and TNF-a also 
activate macrophages and endothelial cells to produce chemokines, that 
contribute to the influx of inflammatory cells or chemotaxis. Additionally, 
TNF-a and interferon-y (IFN-y), activate macrophages and neutrophils to 
promote phagocytosis and lytic enzyme release. Cytokine release results 
in the influx of lymphocytes, neutrophils, monocytes, eosinophils, 
basophils and mast cells to the site of inflammation. Accumulation and 
activation of macrophages also induces a chronic inflammatory response. 
Cytokines, namely TNF-a and IFN-y, released by chronically activated 
macrophages, NK cells and T-cells, also stimulate fibroblast proliferation 
and collagen production. This, in turn, stimulates fibrosis and wound 
healing, which can interfere with normal tissue function (Gabay and 
Kushner 1999, Larsen and Henson 1983). Thus, inflammation is a highly 
complex process and only the basic elements of these series of events 
are described. In addition to the vascular and cellular events of 
inflammation, pain, is a key component of the inflammatory process 
involving many complex mechanisms, and these are described in more 
detail. 
1.2 Pain 
A generally accepted definition of pain is that it is 'an unpleasant sensory 
and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage' - International 
Association for the Study of Pain. There are several distinct types of pain 
that exist: nociceptive, inflammatory, neuropathic and functional as 
depicted in Figure 2 (Merskey 1999, Woolf 2004). 
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Figure 2. Schematic of the four distinct types of pain (Woolf 2004) . 
Nociceptive pain is a physiological, transient pain in response to a 
noxious stimulus. The nociceptive system extends from the periphery 
through to the spinal cord, brain stem and thalamus and to the cerebral 
cortex. The sensation of pain is perceived when nociceptive transducers 
are activated in the skin or other tissues in the body, even in the absence 
of tissue damage (Loeser and Melzack 1999, Woolf 2004). The function of 
such pain is to protect the body from physical damage by the 
environment or from stress to body tissues and is related to the speed of 
onset and offset of stimulation (Loeser and Melzack 1999). 
Acute pain arises as a result of substantial injury to tissue and 
subsequent activation of nociceptive transducers at the site of injury. The 
body's reparative mechanisms are not overwhelmed by such an injury 
and the process of healing occurs. Chronic pain may occur when the 
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injury to body tissue exceeds the body's capability for healing. The 
original injury may have damaged the nervous system such that the body 
is incapable of restoring physiological functions to normal homeostatic 
levels (Loeser and Melzack 1999). The nociceptive system, therefore, 
acts as an 'alarm system' that verifies the presence of a damaging 
stimulus. Patients with congenital insensitivity to pain lose the function of 
high-threshold sensory neurons due to a mutation in the nerve growth 
factor tyrosine-kinase-A receptor and studies have shown that these 
patients have a reduced life expectancy (Woolf 2004). Tissue damage or 
injury results in continuous input from nociceptive afferents that can 
drive spinal circuits to maintain a chronic pain state, resulting in central 
sensitisation (Winkelstein 2003, discussed later). 
1.2.1 Mechanisms of pain 
Nociception is comprised of several mechanisms. Transduction is the 
conversion of a noxious, mechanical, thermal or chemical stimulus into 
electrical activity in the peripheral terminals of nociceptive sensory fibres. 
Specific receptor ion channels expressed by nociceptors such as transient 
receptor potential vanilloid-1 (TRPV1), along with others, mediate this 
process. Conduction is the transfer of action potentials along axons from 
the peripheral terminals to the central terminals of nociceptors in the 
central nervous system and transmission is the process of synaptic 
transfer and modulation of an input from one neuron to the next (Woolf 
2004, Cho and Valtschanoff 2008). 
Nociceptors are a specialised subset of primary sensory neurons that 
respond to intense stimuli. They consist of fibres innervating regions of 
the head and body for which cell bodies are located in the trigeminal and 
dorsal root ganglia (DRG). Myelinated A(3-fibres are sensory fibres which 
are rapid conducting and have large diameter (> 10 ~ m ) ) cell bodies. 
These fibres are involved in the detection of innocuous stimuli applied to 
the skin, muscle and joints. The majority of nociceptors have small « 2 
~ m ) ) and medium «5 ~ m ) ) diameter cell bodies, and include the 
unmyelinated slow conducting C-fibres and thinly myelinated more 
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rapidly conducting A ~ ~ fibres. These fibres are involved in mediating the 
delayed, diffuse, dull pain and rapid, sharp, acute pain evoked by noxious 
stimuli, respectively (Purves et al 2004, Koltzenburg et al 1994). Most C-
fibre nociceptors are polymodal responding to mechanical, chemical and 
noxious thermal stimuli (Schmidt et al 1995). A ~ ~ nociceptors respond to 
intense mechanical and thermal stimuli. Some nociceptors are difficult to 
identify and are called 'silent' or 'sleeping' nociceptors, only responding 
when sensitised by tissue injury (Furst 1999, Julius and Basbaum 2001). 
There are two main mechanisms that contribute to post-injUry pain 
hypersensitivity; these are peripheral and central sensitisation. 
1.2.2 Peripheralsensitisation 
Changes to the chemical environment of the peripheral nerve terminals of 
nociceptors can be precipitated by injury and/or inflammation of tissue. 
Inflammatory mediators such as prostaglandins, nitric oxide, eXCitatory 
amino acids, bradykinin, histamine and substance P, induce inflammation 
and oedema which contribute to the healing process. However, the action 
of these mediators also sensitises nociceptors and new nociceptors are 
recruited, further enhancing pain (Furst 1999, Woolf 2004, Winkelstein 
2003). A cascade of events, which ultimately lead to the increased 
sensitivity, and excitability of the nociceptive terminal is known as 
peripheral sensitisation. Damaged cells release intracellular contents such 
as adenosine triphosphate into the extracellular space which activates 
ligand-gated P2X3 receptors expressed by the primary afferent 
nociceptors. Cytokines, chemokines and growth factors released from the 
site of injury either activate nociceptive terminals directly to produce pain 
(nociceptive activators) or sensitise the terminals (hypersensitivity) to 
subsequent stimuli (nociceptive sensitisers). Prostaglandin E2 and nerve 
growth factor (NGF) also sensitise the terminals activating the 
nociceptors directly. Following binding to its receptor, prostaglandin E2 
activates adenylyl cyclase to increase levels of cyclic adenosine 
monophosphate which, in turn, activates cyclic adenosine 
monophosphate-dependent protein kinase A (PKA). Calcium is released 
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from microsomal stores in the terminals and subsequently activates 
protein kinase C (PKC). Both kinases contribute to the phosphorylation of 
proteins, significantly altering the activity of receptors, ion channels, 
membrane excitability and action potential firing (Woolf 2004, 
Winkelstein 2003, Ji et al 2003). The primary afferents terminate in the 
dorsal horn of the spinal cord and transfer information to the spinal 
neurons via synaptic transmission. A wide range of transmitters are 
released including the neuropeptides substance P, CGRP etc and the 
excitatory amino acid glutamate which mediate the postsynaptic 
response, which is relayed to the supraspinal sites via the ascending 
pathways (Winkelstein 2003). 
1.2.3 Pain Pathways 
The manifestation and modulation of pain are controlled via ascending 
and descending pathways. In mammals, the 2 major ascending pain 
pathways are the spinothalamic tract, which encodes the sensory 
discriminatory aspect of pain, and the spinoparabrachial tract, which 
encodes the affective (emotional) aspects of pain (Rea et al 2007, Millan 
2002). Both these pain pathways are shown in Figure 3 (Hunt and 
Mantyh 2001). 
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Figure 3. Schematic detailing the main ascending and descending pathways. 
Spinoparabrachial pathway (red), Spinothalamic pathway (blue), Abbreviations are as 
follows: A, adrenergic nucleus; bc, brachium conjunctivum; cc, corpus callosum; Ce, 
central nucleus of the amygdala; Hip, hippocampus; ic, internal capsule; LC, locus 
coeruleus; PAG, periaqueductal grey; PB, parabrachial area; Po, posterior group of 
thalamic nuclei; Py, pyramidal tract; RVM, rostroventral medulla; V, ventricle; VMH, 
ventral medial nucleus of the hypothalamus; VPL, ventral posteriolateral nucleus of the 
thalamus; VPM; ventral posteriomedial nucleus of the thalamus (Rea et al 2007). 
Neurons in the ascending pain pathways receive inputs from peripheral 
primary afferent fibres and project from the dorsal horn of the spinal cord 
to several supraspinal sites. This information is projected to parts of the 
thalamus involved in nociceptive processing, such as the ventral 
posteriolateral and posteriomedial nucleus of the thalamus, and received 
in the somatosensory cortex (regulation of pain perception) (Rea et al 
2007). 
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The descending inhibitory pathways originate from the amygdala and 
hypothalamus and project to the lower brainstem and spinal cord via the 
periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) 
(Fields and Heinricher 1985). The descending pathways modulate 
neuronal activity in the ascending pathways by exerting either inhibitory, 
or facilitatory effects, on the spinal neurons. A form of homosynaptic 
activity-dependent plasticity is a phenomenon known as 'wind-up'. It is 
an acute form of pain amplification in which there is a progressive 
increase in the output from the dorsal horn neurons in response to a 
closely timed repeated input. Activation of these fibres leads to slow 
synaptic potentials at low afferent frequencies, depolarisation and 
activation of the N-methyl-D-aspartate (NMDA) receptor. At resting 
membrane potential, the NMDA receptor ion channel is physically blocked 
by a magnesium ion and no current flows. Activation following 
depolarisation results in increased responsiveness to glutamate, 
increased excitability and an amplified response to pain (hyperalgesia) 
and spread of sensitivity to non-injured areas (secondary hyperalgesia) 
(Woolf 2004, Ji et al 2003). The inhibitory mechanisms are capable of 
overriding nociception by blocking sensory inflow to pain perception areas 
in the cortex. These inhibitory and facilitatory mechanisms are able to 
provide additional modulation of the spinal processing of noxious inputs 
(Woolf 2004, Winkelstein 2003). 
1.2.4 CentralSensitisation 
Tissue damage or injury is associated with an increased neuronal 
excitability in the spinal cord which manifests as increased magnitude of 
responses, decreased activation thresholds and the expansion of the 
receptor fields of neurons. This continuous input from nociceptive 
afferents can drive spinal circuits to maintain a chronic pain state, 
resulting in central sensitisation (Winkelstein 2003). Intense peripheral 
noxious stimulation increases the frequency and duration of action 
potentials. High frequency action potentials lead to the release of 
neuropeptides such as substance P and glutamate from nociceptor central 
terminals in the spinal cord (Kidd and Urban 2001) and act on G protein 
24 
coupled receptors (GPCRs) to produce slow, persistent synaptic currents. 
The release of the neuropeptide, brain-derived neurotrophic factor 
(BDNF), acts on tyrosine receptor kinase B (TrkB) to modify membrane 
excitability. This along with glutamate activation of the NMDA ion channel 
receptor leads to activity-dependent plasticity (Woolf 2004). Activity-
dependent plasticity is a result of increases in synaptic efficacy 
characteristic of central sensitisation. Central sensitisation persists even if 
the stimulus is only sustained at low levels. In the case of neuropathic 
pain, central sensitisation is prolonged due to ongoing ectopic activity 
arising from sensory fibres in the injured nerve (Woolf 2004, Winkelstein 
2003, Ji et al 2003, Zimmermann 2001). 
The main focus of this thesis are the lipid mediators involved in the 
inflammatory pain response, their synthesis and metabolism, function, 
and potential molecular targets and is described in more detail. 
1.3 Lipid mediators of the inflammatory response 
A number of mediators including histamine, bradykinin, cytokines, 
chemokines and eicosanoids are involved in the regulation of blood flow, 
vascular permeability and cell infiltration. In particular, the bioactive 
lipids are implicated in many areas of inflammatory pain research, as 
they contribute to the initiation and resolution of inflammation. These are 
a complex group of fatty acid-derived lipids consisting of the 
prostaglandins, thromboxanes, leukotrienes, endocannabinoids and many 
more. The metabolism and function of these lipids are described in more 
detail later. 
1.3.1 Bioactive lipids 
Bioactive lipids or lipids that activate specific signalling pathways are 
involved in the regulation and maintenance of normal bodily functions. 
The synthetic, metabolic and signalling pathways for bioactive lipids are 
activated in response to the multicellular signalling status of the 
environment, allowing cells to respond appropriately (Evans and 
Hutchinson 2010). Bioactive lipid targets are important in a number of 
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conditions such as cancer, asthma and arthritis, which all have an 
inflammatory element. Interestingly, a number of bioactive lipids 
measured are known to target several different receptor groups. These 
include G protein-coupled receptors such as the cannabinoid receptors or 
peroxisome proliferator-activated receptor alpha (PPARa), and TRPVl ion 
channels. 
1.3.1.1 Cannabinoid receptors 
Since the discovery of ~ 9 - t e t r a h y d r o c a n n a b i n o l l (THC) as the psychoactive 
component of cannabis and its properties, there has been interest in the 
potential therapeutic applications of cannabis-like molecules (Freund 
2003, Pertwee 2008). The analgesic properties of the cannabinoids are 
well known, and are now explicable by the existence of the cannabinoid 
signalling system (Rice et al 2002). Research based on radioligand 
binding techniques and complementary DNA-encoding resulted in the 
cloning of the first cannabinoid receptor from rat brain, a GPCR now 
known as CB1 (Matsuda et al 1990, Herkenham et al 1991). 
Subsequently, a peripherally located cannabinoid GPCR, now termed CB2, 
was cloned from human pro-myelocytic leukaemia HL-60 cells 
(Bouaboula et al 1993, Jonsson et al 2006). CB1 receptors are the most 
abundant GPCRs in the central nervous system, but are also found in 
peripheral tissues including endothelial cells and adipose tissue (Galiegue 
et al 1995). CB2 receptors are expressed in cells of immune origin 
including the spleen, monocytes and Band T cells (Daaka et al 1995, 
Hohmann and Suplita 2006, Pacher et al 2006). CB2 receptors have also 
been identified in the brain, endocrine pancreas and in bone (Galiegue et 
al 1995, Pacher et al 2006). The distribution of CB1 receptors in the brain 
has been studied using techniques such as immunohistochemistry and 
receptor autoradiography. Cannabinoid receptors are frequently found 
localised on nerve endings conforming to the theory that they are 
presynaptic modulators of neurotransmitter release (Ahluwalia et al 
2000). They are densely populated in the periaqueductal grey (PAG) and 
the rostal ventromedial medulla (RVM), areas of the brain relating to 
descending pain modulation (Walker and Huang 2002, Fox and Bevan 
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2005, Rice et al 2002). Other areas where CB1 receptors have been 
found include the amygdala, hypothalamus, thalamus and parabrachial 
nucleus and brainstem (Finn and Chapman 2004), which reflect the 
importance of the cannabinoid system in motor control, memory 
processing and pain modulation (Grotenhermen 2005). CBl receptor 
density in the brainstem, however, is low, which explains the low toxicity 
of the cannabinoids, such as lack of respiratory depression, which is often 
seen with the opioids (Grotenhermen 2005). CB2 receptors are expressed 
in the brainstem (Van Sickle et al 2005), thalamus (Gong et al 2006) and 
cerebellum (Ashton et al 2006) of na"ive rats but their roles are still 
uncertain. High concentrations of cannabinoid receptors are also found in 
the superficial layers of the spinal dorsal horn and the dorsal root 
ganglion from where they are transported to peripheral and central 
primary afferent neuron terminals (Walker and Huang 2002, Rice et al 
2002, Jhaveri et al 2008a). 
Endogenous ligands of the cannabinoid receptors are known as 
endocannabinoids. These include N-arachidonoyl ethanolamide (AEA), 2-
arachidonoyl glycerol (2-AG) and N-arachidonoyl-dopamine (NADA). AEA 
has been shown to have intermediate (sub IJM) potency at CBl and CB2 
receptors (Felder et al 1995, Slipetz et al 1995, Sugiura et al 1999), 
compared to 2-AG, which has high (sub nM) potency for CBl and CB2 
receptors (Sugiura et al 1999, Mechoulam et al 1995). NADA has 
intermediate potency for only CB1 (Bisogno et al 2000). 
Endocannabinoids are synthesised and released from postsynaptic 
neurons and activate presynaptic CB1 receptors to modulate neuronal 
synapses, an example of retrograde signalling. Endocannabinoids also 
reduce the release of neurotransmitters including glutamate and GABA 
(Furst 1999, Hohmann and Suplita 2006). Once released, the 
endocannabinoids activate cannabinoid receptors on neighbouring cells. 
Cannabinoid receptors have been found to be functionally coupled to 
several intracellular signalling mechanisms including inhibition of adenylyl 
cyclase activity and voltage-gated calcium channels. They also activate G 
protein-sensitive inward rectifying potassium (GIRK) channels, causing 
27 
hyperpolarisation, and are rapidly inactivated by transmembrane 
transport and enzymatic hydrolysis (Freund et al 2003, Rang et al 2003, 
Di Marzo et al 2004). 
A number of related endogenous lipids with endocannabinoid-like activity 
have been detected. These include N-oleoyl ethanolamide (OEA), N-
palmitoyl ethanolamide (PEA) and N-arachidonoyl glycine (AraGly) 
(Hohmann and Suplita 2006, Randall and Kendall 1998). PEA does not 
bind to CBl or CB2 with high affinity, but is thought to enhance the effect 
of anandamide (AEA) via an unknown mechanism, possibly interference 
with its catabolism (Vandevoorde et al 2003, Sheskin et al 1997). OEA 
and AraGly also lack affinity for CBl and CB2 receptors (Sheskin et al 
1997, Lin et al 1998, Sipe et al 2005). AEA and 2-AG, along with the 
endocannabinoid-like compounds PEA and OEA have been implicated in 
inflammation and pain. PEA has anti-inflammatory properties (for a 
review see Schmid et al 1990). Oral administration of PEA produced a 
reduction in substance-P mast cell degranulation and extravasation, as 
well as an attenuation of carrageenan-induced hyperalgesia and oedema 
(Mazzari et al 1996). For comprehensive reviews on endocannabinoids 
and inflammatory hyperalgesia see Sagar et al 2009, De Petrocellis et al 
2000. In addition, PEA has been shown to activate peroxisome 
proliferator activated receptor alpha (PPARo), and it has been suggested 
that this contributes to the anti-inflammatory properties of this lipid (Sun 
et al 2007). 
1.3.1.2 PPAR receptors 
Peroxisome proliferator activated receptors are ligand-activated 
transcription factors that belong to the nuclear receptor superfamily and 
are reported to regulate gene transcription (Desvergne and Wahli 1999). 
Different PPAR genes have been identified and divided into subgroups, 
alpha, beta/delta and gamma (a, J3/t5 and V). Each subgroup displays 
distinct tissue (Braissant et al 1996, Auboeuf et al 1997, Cullingford et al 
1998, Granneman et al 1998) and developmental (Braissant and Wahli 
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1998) expression patterns; however, the focus of the experiments 
described in this thesis is on the PPARa (see Chapter 3). 
Each PPAR receptor has a N-terminal 'AlB' domain that has a ligand-
dependent activation function, a 'C' domain encoding the DNA binding 
region of the receptor, followed by a '0' or hinge region. The C-terminal 
'ElF' ligand binding domain contains the ligand-dependent activation 
function 2, important for heterodimerisation (Escher and Wahli 2000). 
Dimerisation is essential for the activity of the PPARs, which is similar to 
the majority of receptors in the nuclear superfamily. They heterodimerise 
with the 9-cis retinoid X receptor (RXR), forming a complex that is able to 
bind to the PPAR response elements located in the promoter of PPAR 
target genes (under PPAR transcriptional control) (Dowell et al 1999, 
Ijpenberg et al 1997). The consequence of the interaction of the 
activated heterodimer with the promoter is stimulation of target gene 
transcription that is implicated in various functions such as lipid 
metabolism and inflammation control (Michalik and Wahli 1999). 
PPARa receptors are expressed in rats, mice and humans; the rat and 
mouse PPARa proteins share 92% identity with the human receptor 
(Schmidt et al 1992, Borel et al 2008). Expression of PPARa protein has 
been reported in different areas of the gastrointestinal tract, liver, heart, 
adipose tissue and brain in humans (Huin et al 2000, Auboeuf et al 1997, 
Bunger et al 2007) and in rodents (Beck et al 1992, Braissant et al 1996, 
Bunger et al 2007). In the brain, expression of PPARa is highest in the 
brain stem and cerebral cortex, although it is also found in many regions 
including the hippocampus (Gofflot et al 2007). In the spinal cord, PPARa 
expression was also found to be lower in the grey matter compared to 
white matter and high expression of PPARa was found in astrocytes 
(Benani et al 2003a, Benani et al 2003b). Expression of PPARa is 
necessary for the development of inflammation; mice deficient in this 
receptor demonstrated an exacerbated inflammatory response to 
lipopolysaccharide stimulation (Delerive et al 1999)(See Chapter 3 for 
details on PPARa and inflammation). 
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Last but not least, another important receptor target of bioactive lipids 
are the transient receptor potential vanilloid 1 (TRPV1) receptors. In 
addition, this completes the set of superfamilies of receptors at which the 
cannabinoids act (GPCRs, nuclear receptors and ion channels). 
1.3.1.3 TRPV1 receptors 
Transient receptor potential vanilloid 1 (TRPV1) receptors are ligand-
gated, non-selective cation channels and the first subtype of the TRP 
family, to be discovered (Caterina et al 1997, Dhaka et al 2006). There 
are at least 28 different TRP subunits that have been identified in 
mammals, further divided into six subfamilies, of which the vanilloid TRPs 
are one (Clapham 2003, Moran et al 2004). The primary structure of the 
TRP channels consists of six transmembrane segments with a pore 
domain between transmembrane segments 5 and 6 and with both the C-
and N- termini located intracellularly (Doyle et al 1996, Clapham et al 
2005). TRP channels are tetramers of four subunits, which are opened or 
closed by conformational changes in the channel protein (Voets et al 
2004, Bandell et al 2007). In general, TRP channels are only weakly 
sensitive to depolarisation, but open in response to activation of the 
channel protein (Clapham et al 2005). TRPV1 channels are activated by 
different stimuli such as heat (>43 °C) (Caterina et al 1997), capsaicin 
(Hwang et al 2000), AEA (Smart et al 2000) and low pH (Tominaga et al 
1998). Activation involves increased membrane permeability to cations, 
including sodium, but mainly calcium in the case of TRPVl (Wood et al 
1988, Caterina et al 1997, Caterina and Julius 2001). 
TRPVl is mainly found in small- to medium-diameter neurons of primary 
sensory neurons (dorsal root ganglia, trigeminal ganglia and sympathetic 
ganglia), which explains the selectivity of capsaicin for these neurons 
(Szallasi and Blumberg 1999, Vay et al 2012). TRPVl has also been 
shown to be expressed on the terminals of primary afferent sensory 
nerve fibres A and C, in addition to being present in the brain, including 
areas involved in nociceptive transmission (Mezey et al 2000, Toth et al 
2005). Areas of the brain in which TRPVl expression has been found 
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include the cortex, amygdala, striatum, hippocampus and hypothalamus 
(Mezey et al 2000). In addition, fibres of the primary sensory neurons 
innervate virtually all tissues of the body including bone, internal organs 
and the vascular system. However, TRPV1 has been shown to be more 
prevalent in visceral then somatic afferent nerves (Robinson et al 2004, 
Brierley et al 2005, Hwang et al 2005, Christianson et al 2006). 
Furthermore, it is known that TRPV1 expression is important for the 
development of inflammatory hyperalgeSia (Caterina et al 2000) and that 
expression is up-regulated under inflammatory conditions (Ji et al 
2002)(See Chapter 4 for details on TRPV1 and inflammatory 
hyperalgesia) . 
Sensitisation of the TRPV1 channel is known to occur and several 
mechanisms have been suggested. Phosphorylation of the ion channel by 
PKA, PKC and other kinases plays an important role in the regulation of 
TRPV1 receptor activity (Zhang and McNaughton 2006, Shave et al 2003, 
Vellani et al 2001). Phosphorylation by PKA increases TRPV1 receptor 
responses to lipid activators such as AEA and PGE2 (Lopshire and Nicol 
1998, Schnizler et al 2008). Mice deficient in a regulatory subunit of PKA 
exhibit reduced PGE2 and formalin-induced inflammatory hypersensitivity 
(Malmberg et al 1997), demonstrating the importance of PKA 
phosphorylation in TRPV1-mediated inflammation. Increased TRPV1 
activity by bradykinin, nerve growth factor, prostaglandins and AEA via 
PKC-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate is 
another mechanism of TRPV1 sensitisation (Caterina et al 1997, 
Tominaga et al 1998, Prescott and Julius 2003), and altering the 
threshold of receptor activation. In addition, the rapid recruitment of an 
intracellular pool of TRPV1 to the cell membrane also enhances ligand 
responses, a process that involves phosphoinositide 3-kinase and Src 
kinase (Stein et al 2006, Zhang et al 2005). Dephosphorylation of TRPV1 
by protein phosphatases promotes desensitisation of the receptor and is 
a mechanism of inhibitory regulation (Mohapatra and Nau 2005). There 
are also stimulus-dependent differences in TRPV1 desensitisation; 
capsaiCin depends on extracellular calcium for desensitisation, whereas 
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heat does not (Bandell et al 2007). It appears that the 
activation/desensitisation state of the channel is dependent on the 
dynamic balance between phosphorylation and dephosphorylation 
(Mohapatra and Nau 2005). In addition to having multiple receptor 
targets, bioactive lipid metabolism and function is also complex and this 
is described in more detail. 
1.3.2 Metabolic pathways of the bioactive lipids 
Eicosanoids are synthesised mainly from arachidonic acid (AA), which is 
released from membrane phospholipid stores through the activity of 
several phospholipase enzymes, predominantly phospholipase A2 (PLA2). 
PLA2 is activated by several cellular agonists including IL-8 and platelet 
activating factor (PAF), phagocytic particles and microorganisms (Piper 
and Vane 1971). Once in the cytosol, AA can then be further metabolised 
by three enzymatic pathways: cyclooxygenases (COXs), lipoxygenases 
(LOXs) and cytochrome P450 epoxygenases (CYPs); see, Figure 4 
(Samuelsson et al 1987, Serhan et al 1984, Capdevila et al 1990). 
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Figure 4. Metabolic pathways of bioactive lipids analysed with this LC-MS/MS method. 
Lipid abbreviations: DHET - dihydroxyeicosatrienoic acids, EET - epoxyeicosatrienoic acid, 
HETE - hydroxyeicosatetraenoic acid, HPETE - hydroperoxyeicosatetraenoic acid, AEA -
N-arachidonoyl ethanolamide, 2-AG - 2-arachidonoyl glycerol, EA - ethanolamide, G -
glycerol, LA - linoleic acid, HODE - hydroxyoctadecadienoic acid, OxoODE -
oxooctadecadienoic acid, PG - prostaglandin, TX - thromboxane, AA - arachidonic acid, 
LT - leukotriene. Enzyme abbreviations: COX - cyclooxygenase, CYP450 - cytochrome 
P450, LOX - lipoxygenase, FAAH - fatty acid amide hydrolase, MAGL - monoacyl glycerol 
lipase, FLAP - five lipoxygenase (S-LOX) activating protein. 
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1.3.2.1 Cyc/ooxygenases 
COX enzymes (COX-1 and COX-2), are responsible for the production of 
PGG2 (bisoxygenation and cyclisation of AA) and PGH 2 (reduction of 
PGG2 ) (Pagels et al 1983, Hamberg et al 1973, Nugteren and Hazelhof 
1973). PGH 2 is then further converted to prostaglandins (PGs) and 
thromboxanes (TXs), collectively known as the prostanoids, via individual 
prostaglandin and thromboxane synthases (Figure 4) (Shimizu et al 
1982, Tanaka et al 1987, Hayashi et al 1989, DeWitt et al 1983, Ullrich et 
al 1983). The type of prostanoid produced is dependent on differential 
enzyme expression within cells. Mast cells predominantly produce PGD2, 
whilst macrophages produce PGE2 and TXA2 • The profile of prostanoid 
synthesis can alter upon cell activation. Resting macrophages produce 
more TXA2; however, once activated, PGE2 is favoured. COX-1 is 
constitutively expressed in most cells and tissues, COX-2 is usually 
undetectable, however, it is constitutively expressed in the spinal cord 
and brain (Fosslien 2000). In addition COX-2 is rapidly induced under 
inflammatory conditions (Dubois et al 1998). Prostanoids have been 
shown to modulate the inflammatory process via a number of 
mechanisms, including modulation of smooth muscle tone (Eckenfel and 
Vane 1972, Ferreira et al 1972, Main 1964), vascular permeability 
(Williams 1979, Williams and Jose 1981), hyperalgesia (Ferreira et al 
1978), fever (Feldberg and Gupta 1973, Feldberg and Saxena 1971, 
Milton and Wendlandt 1971) and platelet aggregation (Moncada et al 
1976). They exert their biological effects by binding to specific cell 
surface receptors that have been characterised in mice and humans. 
These include PGD2 receptors; DP1, DP2, PGE2 receptors; EP1, EP2, EP3, 
EP4, PGF2a receptor; FP, PGh receptor; IP and the TXA2 receptor; TP 
(Hirai et al 2001, Monneret et al 2001, Xue et al 2005). PGE2 and PGh 
are the predominant pro-inflammatory prostanoids and both increase 
vascular permeability, particularly in the presence of histamine, 
bradykinin, 5-HT (Hata and Breyer 2004, Higgs et al 1978, Komoriya et 
al 1978, Lewis et al 1975, Moncada et al 1973, Williams and Morley 
1973) and enhance vasodilatation and oedema (Kaley et al 1985). PGE2 
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is the most potent pyretic agent, with elevated concentrations found in 
cerebrospinal fluid taken from patients with bacterial or viral infections 
(Saxena et al 1979). PGh and PGE2 also cause peripheral and central 
hyperalgesia when bound to IP and EP1, EP3 and EP4 receptors 
respectively and achieves this by reducing nociceptor sensory neuron 
threshold to stimulation (Ferreira et al 1972, Ferreira et al 1978, Ahmadi 
et al 2002, Lin et al 2006, McAdam et al 2000, Moriyama et al 2005, 
Murata et al 1997, Reinold et al 2005, Ueno et al 2001). In addition to 
pro-inflammatory properties, some prostanoids also exert 
immunosuppressive effects through up-regulation of intracellular cyclic 
adenosine monophosphate (cAMP) (Aronoff et al 2006, Luo et al 2004, 
van der Pouw Kraan et al 1995). The ability of inflammatory leukocytes 
to phagocytose and kill microorganisms is reduced by the action of PGE2 
and PGI2 (Aronoff et al 2004, Rossi et al 1998, Serezani et al 2007, 
Weinberg et al 1985), which also inhibit the production of downstream 
inflammatory mediators (Kunkel et al 1988, Takayama et al 2002, van 
der Pouw Kraan et al 1996, Xu et al 2008) and enhance the production of 
IL-6 and IL-l0 (Harizi et al 2002, Hinson et al 1996). PGE2 has also been 
shown to induce transcription of enzymes required for the generation of 
potent pro-resolution lipid mediators such as resolvins and protectins 
(Marcheselli et al 2003, Serhan et al 2000, Serhan et al 2002). 
1.3.2.2 Lipoxygenase 
The LOX pathways consist of 5-LOX, 12-LOX and 15-LOX enzymes found 
in leukocytes, platelets and endothelial cells respectively (Lewis et al 
1980). An 8-LOX enzyme has been shown to produce 8-HETE in mouse 
skin (Gschwendt et al 1986) and, recently, in human skin (Rhodes et al 
2009). Unlike COX, 5-LOX only becomes functional following cell 
activation via increases in intracellular calcium (Rouzer and Samuelsson 
1985, Ochi et al 1983) or by phosphorylation independent of calcium 
changes (Werz et al 2002). The LOX enzyme pathway is responsible for 
the production of leukotrienes (LTs), HPETEs 
(hydroperoxyeicosatetraenoic acids) and HETEs (hydroxyeicosatetraenoic 
acids) (Figure 4). Following activation, AA is converted into 5-HPETE via 
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5-LOX-activating protein (FLAP) and this intermediate is then rapidly 
reduced to 5-HETE (Figure 4). 5-HPETE can also be converted to LTA4, an 
unstable 5,6-epoxide containing a conjugated triene, which is 
metabolised either via LTA4 hydrolase to LTB4 (Funk 2001, Minami et al 
1987) or via y-glutamyl-S-transferase to L T ~ ~ (Hammarstrom et al 
1985). Subsequently, 5-HETE, LTB4 and LTC4 are thought to be exported 
from the cell (Lam et al 1990, Leier et al 1994), where LTC4 is 
metabolised by y-glutamyl transpeptidase to LTD4 and further modified 
by cysteinyl glycinase to LTE4 (Rouzer and Samuelsson 1985). 
Collectively, LTC4, LTD4 and LTE4 are termed the cysteinyl leukotrienes 
(Okubo et al 2010). LTs act via specific receptors; B leukotriene receptor 
1 and 2 (BLT1 and BLT2) and cysteinyl leukotriene receptor 1 and 2 
(cysLT1 and cysLT2) located on the plasma membrane of structural and 
inflammatory cells (Tager et al 2003, Lynch et al 1999). Ligand binding to 
the receptors results in increased intracellular calcium and blocks cAMP 
formation, altering cellular activities such as motility and transcriptional 
activation (Lynch et al 1999). BLT1, a high affinity receptor for LTB4, has 
chemo-attractant and pro-inflammatory properties (Tager et al 2003), 
whereas LTB4 activation of PPARa has been shown to be anti-
inflammatory in vitro and in a mouse model of inflammation (Devchand 
et al 1996, Krey et al 1997, Lin et al 1999). LTs act primarily as pro-
inflammatory lipid mediators, generated primarily by neutrophils, 
macrophages and mast cells at the site of inflammation (Tager et al 
2003). LTB4 works by attracting and activating inflammatory cells such as 
neutrophils and leukocytes (Tager et al 2003, Borgeat and Naccache 
1990, Ott et al 2003), whereas LTD4 mainly targets eosinophils 
(Woodward et al 1991). The cysteinyl LTs increase vascular permeability 
and plasma leakage, contributing to oedema formation (Bjork et al 1982, 
Orange et al 1969, Svensjo 1978). 5-HETE, a 5-LOX metabolite, has also 
been shown to be pro-inflammatory. This lipoxygenase product of 
leukocytes promotes neutrophil and eosinophil chemotaxis and is 
elevated under inflammatory conditions (Goetzl et al 1982). 12-HETE is 
also pro-inflammatory and is a potent keratinocyte-derived 
chemoattractant, shown in vitro to attract neutrophils and lymphocytes 
36 
(Bacon et al 1988, Dowd et al 1985). 15-HETE has also been shown to 
have pro-inflammatory properties, causing chemotaxis of inflammatory 
cells into the lumen in the airways (Johnson et at 1985). However, the 
12/15 LOX pathway has been shown to be highly complex in the 
regulation of inflammation (See Kuhn and O'Donnell 2006 for a 
comprehensive review). 
1.3.2.3 Cytochrome P450 
Cytochrome P450 (CYPs) are membrane-bound, haem-containing 
enzymes found in the liver, brain, kidneys and heart (Nelson et al 1996, 
Scarborough et al 1999). Particular CYPs catalyses AA to produce HETEs 
along with epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic 
acids (DHETs) (Figure 4) (Roman 2002). In the vascular endothelium, AA 
is metabolised by CYP epoxygenase to the EETs, which are then 
converted by soluble epoxide hydrolase to the DHETs (Roman 2002, 
Zhang et al 2001). In vascular smooth muscle, AA is converted by CYP 
hydrolases to 20-HETE (Wang et al 1999). In inflammation, EETs are 
converted via CYPs 2C8, 2C9 and 2J2 and block the adhesion of 
neutrophils and eosinophils to the vascular wall, by suppressing VCAM-1 
and E-selectin expression (Fleming 2007, Node et al 1999). EETs have 
been suggested to modulate the NF-KB pathway and, as a consequence, 
may prevent expression of various cytokine-induced pro-inflammatory 
enzymes including COX-2 (Inceoglu et al 2007, Inceoglu et al 2008). In 
addition, EETs have been shown to display hyperalgesic actions in models 
of inflammatory pain (Inceoglu et al 2006, Inceoglu et al 2007, Inceoglu 
et al 2008). Recently, it has been suggested that the anti-inflammatory 
properties of the EETs are due to binding to a monocytic cell-surface 
receptor, an 'EET receptor', coupled to G proteins (Behm et al 2009). In 
terms of the HETEs, 16-HETE has also been shown to prevent leukocyte 
adhesion to the endothelium and suppress production of pro-
inflammatory LTs in rabbits (Bednar et al 2000). 8- and 11-HETE are 
potent neutrophil chemoattractants in vitro and in in vivo experimental 
models (Goetzl et al 1980a, Goetzl et al 1980b). However, their 
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derivation is uncertain and is thought to be from a combination of CYP, 
LOX and non-enzymatic oxidation pathways (Kuhn and O'Donnell 2006). 
Eicosanoid production has been shown to increase following 
inflammation; however, the different metabolites of AA can be pro-
inflammatory (e.g. LTs, PGs) and anti-inflammatory (e.g. PGs, EETs and 
HETEs) (Harizi et al 2008, Funk 2001, Bednar et al 2000, Fleming 2007), 
suggesting that the changes in pro-inflammatory and anti-inflammatory 
lipids are part of a dynamic process. 
These COX, LOX and CYP pathways are also involved in the metabolism 
of other bioactive lipids involved in inflammation and pain, such as the 
endocannabinoids, AEA and 2-AG (Figure 4). 
1.3.2.4 Other bioactive lipids involved in inflammation and pain 
Other bioactive lipids that either promote or attenuate the inflammatory 
process include the polyunsaturated fatty acids, such as linoleic acid (LA) 
and the endocannabinoids and endocannabinoid-like compounds 
described. LA is a precursor of AA and can only be obtained from plant 
material in the diet. It is a key source for AA and, therefore, in eicosanoid 
synthesis (Chopade and Mulla 2010, Tapiero et al 2002). LA also 
generates hydroxyoetadecadienoic acids (HODEs), which are oxidised to 
oxooetadecadienoic acids (oxoODEs). These are generated through the 
action of 1S-LOX and have been shown to be anti- and pro-inflammatory 
(See Chapter 4 for details, Vangaveti et al 2010). 
1.3.3 Interaction of the bioactive lipids with different 
receptor systems 
As mentioned previously, a number of bioactive lipids target several 
different receptor groups. These include cannabinoid receptors, PPARs 
(Harizi et al 2008) and TRPVl. These receptor groups are implicated in 
inflammation and pain; for example, PPARa (See Chapter 3) and TRPV1 
(See Chapter 4). Several of these lipids, including AA, S-HETE, 12-HETE, 
1S-HETE, S-HPETE, 12-HPETE, 9-HODE, 13-HODE, 9-oxoODE, 13-
oxoODE are agonists of TRPV1 receptors (Meves et al 2008, Patwardhan 
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et al 2009, Patwardhan et al 2010, Fowler 2007). PPARa activators 
include endogenous lipids such as 8-HETE, 20-HETE, 5,6-EET, 8,9-EET, 
11,12-EET, 14,15-EET, 9-HODE, 13-HODE, LA, AA and LTB4 (Yu et al 
1995, Devchand et al 1996, Kliewer et al 1997, Delerive et al 2000, 
Cowart et al 2002). In addition to activating the cannabinoid receptors, 
the endocannabinoid AEA is also a PPARa agonist (Sun et al 2007), along 
with the endocannabinoid-like compounds OEA and PEA (Fu et al 2003, 
LoVerme et al 2005, Sun et al 2007, Moraes et al 2006). AEA and 
another endocannabinoid, NADA, also activate TRPVl receptors (Huang 
et al 2002). The COX metabolites of AEA, the prostaglandin 
ethanolamides PGD2-EA, PGE2-EA and PGF2o-EA, are also agonists of the 
cannabinoid receptors (Matias et al 2004, Fowler 2007), as are the CYP 
metabolites of AEA and 2-AG, S,6-epoxyeicosatrienoyl-ethanolamide 
(S,6-EET-EA) and 2-(14,15-epoxyeicosatrienoyl) glycerol (2-(14,15-EET)-
G) respectively. S,6-EET-EA has been shown to activate CB2 receptors 
(Snider et al 2009) and 2-(14,lS-EET)-G activates both CBl and CB2 
receptors (Figure 4). The biological actions of some of these lipids are 
summarised in Table 1 (See Appendices for chemical structures). 
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Table 1. Receptor targets of the bioactive lipids of interest and evidence in inflammatory pain models 
Chemical name Synonym CBI CB2 TRPV 1 PPAR-a Action in inflammatory pain models 
weak weak 
Prostaglandin 0z ethanolamide PGOz-EA a ~ o n i s t t agonist . _ Yet to be ~ I l . o w n n (Matias etal 2004, Fowler et al 2007) 
Prostaglandin El ethanolamide PGE1-EA Yet to be shown 
weak 
Prostaglandin Ez ethanol amide PGEz-EA agonist Yet to be shown (Matias et al 2004, Fowler et al 2007) 
Prostaglandin F 20 ethanolamide PGF2o-EA 
weak Pro-inflammatory, produces allodynia following administration (Matias et al 
agonist agonist 2004, Minami et al 2001, Minami et al1992, Fowler et al 2007) 
5 , 6 - e p o x y e i c o s ~ t r i e n a m i d e e 5,6-i:ET-.EA agonist Yet to be shown (Snider et al 2009) 
2-(14, 15-epoxyeicosatrienoyl) 14,15-EET-
glycerol G. agonist Agonist Yet to be shown (Chen et al 2008) 
5-hydroperoxyeicosatetraenoic 
acid 5-HPETE agonist Yet to be shown (Hwang et al 2000) 
12-hydroperoxyeicosatetraenoic 
acid 12-HPETE a ~ o n i s t t .. _..Yetto bJ!.s.hown (Kim et al 200B, Hwang et al 2000) 
Yet to be shown, but DHETs thought to be pro-inflammatory (Inceoglu et al 5,6- dihydroxyeicosatrienoic 
add 5,6-0HET 2006) 
8,9- dihydroxyeicosatrienoic 
acid 
Yet to be shown, but DHETs thought to be pro-inflammatory (Inceoglu et al 
8,9-DHET 2006) 
~ g g
Chemical name 
11,12- dihydroxyeicosatrienoic 
acid 
14,15- dihydroxyeicosatrienoic 
acid 
Synonym 
11,12-
DHET 
14,15-
DHET 
CBI CBz TRPV I PPAR-a Action in inflammatory pain models 
Yet to be shown, but DHETs thought to be pro-inflammatory (Inceoglu et al 
2006) 
Yet to be shown, but DHETs thought to be pro-inflammatory (Inceoglu et al 
2006) 
Yet to be shown, thought to be pro-inflammatory (Goetzl et al 1982, Ross et 
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5- hydroxyeicosatetraenoic acid 5-HETE agonist al 2003, Hwang et al 2000) 
Yet to be shown, thought to be pro-inflammatory (Goetzl et al 1980a, Goetzl 
8- hYtiroxyeicosatetraenoic add _ j i ~ H E T E E agonist et al 1980b, Krey et al 1997, Flink 2001) 
9- hydroxyeicosatetraenoic acid 
11- hydroxyeicosatetraenoic 
acid 
12- hydroxyeicosatetraenoic 
acid 
15- hydroxyeicosatetraenoic 
acid 
16- hydroxyeicosatetraenoic 
acid 
19- hydroxyeicosatetraenoic 
acid 
20- hydroxyeicosatetraenoic 
9-HETE 
11-HETE 
12-HETE 
15-HETE 
16-HETE 
19-HETE 
Yet to be shown 
Yet to be shown, thought to be pro-inflammatory (Goetzl et al 1980a, Goetzl 
et al 1980b) 
Yet to be shown, thought to be pro-inflammatory (Bacon et al 1988, Dowd et 
agonist al 1985, Kim et al 2008) 
Yet to be shown, thought to be pro-inflammatory (Johnson et al 1985, Hwang 
agonist et al 2000) 
Yet to be shown, thought to be anti-inflammatory (Bednar et al 2000) 
Yet to be shown 
acid 20-HETE agonist Yet to be shown (Cowart et al 2002) 
i EET levels through soluble epoxide hydrolase (sEH) inhibition attenuated 
thermal hyperalgesia in inflammatory model (LPS model) (Cowart et al 2002, 
5,6-epoxyeicosatrienoic acid _ 5L6-EJ:T_ _ __ _ agonist _ Inceogh.J.et al 2006) 
, . ) 
,. I, ~ ' " "
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Chemical name Synonym CB l CBz TRPVl PPAR-a Action in inflammatory pain models 
1 EET levels through soluble epoxide hydrolase (sEH) inhibition attenuated 
thermal hyperalgesia in inflammatory model (LPS model) (Cowart et al 2002, 
8,9- epoxyeicosatrienoic acid .. __ 8,9-EET agonist Inceoglu et al 2006) 
1 EET levels through soluble epoxide hydrolase (sEH) inhibition attenuated 
thermal hyperalgesia in inflammatory model (LPS model) (Cowart et al 2002, 
11,12- epoxyeicosatrienoic ac:Ld__ ll,12-EET agonist Inceoglu et al 2006) 
1 EET levels through soluble epoxide hydrolase (sEH) inhibition attenuated 
thermal hyperalgesia in inflammatory model (LPS model) (Cowart et al 2002, 
14,15- epoxyeicosatrienoic C I ~ i d _ _ 14,15-EET agonist Inceoglu et al 2006) 
partial !AEA in rat paw tissue (Carrageenan model), no change in rat paw tissue 
N-arachidonoyl ethan9IamLd_e__ AEA agonist Agonist agonist agonist (Formalin model)(Sagar et a12009) 
N-oleoyl ethanolamide OEA agonist agonist No change in levels in rat paw tissue (Carrageenan model)(Sagar et al 2009) 
!PEA in rat paw tissue (Carrageenan model), no change in rat paw tissue 
N-palmitQ}'l_etl'1anolamide PEA agonist (Formalin model)(Sagar et al 2009) 
!2-AG in rat paw tissue (Carrageenan model), no change in rat paw tissue 
2-arachidonoyl g l ~ e r o l l 2-AG agonist Agonist (Formalin model)(Sagar et al 2009) 
Yet to be shown (Bisogno et al 2000, Huang et al 2002). Intraplantar 
injection of the higher dose of NADA (5 1-19/50 I-IL) significantly inhibited 
innocuous mechanically evoked responses of dorsal horn neurons compared 
N-arachidonoyl dopamine NADA agonist agonist to vehicle (Sagar et al 2004). 
AraGly reduces allodynia and hyperalgesia in Freund's complete adjuvant-
N-arachidonoyLglycine AraGIY __ n ___________ _ _induced modelof inflammatory pain in rats (Succar et al 2007) 
Leukotriene-B4 LTB4 
L e u k o t r i e n e - ~ ~ LTE4 
LTB4 produces hyperalgesia in humans (Bisgaard and Kristensen 1985, 
agonist Devchand et al1996, Krey et al 1997) 
Yet to be shown, thought to be prO-inflammatory (Bjork et al 1982, Orange 
et al 1969, Svensjo 1978) 
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Chemical name Synonym CBl CB;z TRPV 1 PPAR-a Action in inflammatory pain models 
Thromboxane-Bz TXBz ___ Yet to be shown, thought to be pro-inflammatory (Kitchen et al 1978) 
Prostaglandin Dz PGDz Yet to be shown, thought to be prO-inflammatory (Hirai et al 2001) 
Prostaglandin Ez PGEz .. Yet to be shown, thought to be pro-infiammatQIy(Kitchen et al 19781 
Arachidonic add M agonist agonist Yet to besh.owlLlMeves et al 2008) 
Unoleic acid LA 
Yet to be shown, conjugated linoleic acid thought to be anti-inflammatory (Yu 
et al 2002) 
9, 13-HODE, 9- and 13-oxoODE produced behavioural 
pain responses following peripheral and spinal administration 
9-hydroxyoctadecadienoic acid 9-HODt;_ agonist agQIl!sL_(Patwardhan et al 2010, Patwardhan . .E!LaI 2010) 
9, 13-HODE, 9- and 13-oxoODE produced behavioural 
pain responses following peripheral and spinal administration 
13-hydroxyoctadecadienoic add 13-HODE agonist agonist (Patwardhan et al 2010, f».at\,,@rdhan et al 2010) 
9, 13-HODE, 9- and 13-oxoODE produced behavioural 
pain responses following peripheral and spinal administration 
9-oxooctadecadienoic acid 9-oxoODE agonist (Patwardhanet al 2010, p .. !twardhan et al 2010) 
9, 13-HODE, 9- and 13-oxoODE produced behavioural 
pain responses following peripheral and spinal administration 
13-oxooctadecadienoic acid 13-oxoODE agonist .(Patwardhanet al 2010,£cItwardhan et al 2010) 
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There is evidence for the interaction of the cannabinoid, PPARa and 
TRPVl receptor systems in inflammatory hyperalgesia, which is briefly 
described below. A number of bioactive lipids such as AEA and OEA, are 
activators of all these receptor systems. Attenuation of inflammatory 
hyperalgesia has been shown in the carrageenan model following 
inhibition of catabolic enzymes, fatty acid amide hydrolase (FAAH) and 
COX-2, and these effects were blocked by the PPARa antagonist GW6741 
but not a PPARy antagonist, suggesting that the effects observed were 
PPARa-mediated (Jhaveri et al 2008b). Other research groups have 
shown that PEA causes PPARa-mediated effects in several animal models 
of pain behaviour (LoVerme et al 2006, D'Agostino et al 2009). Studies 
have also demonstrated the involvement of CSl, TRPVl and PPARa in the 
hyperalgesic effects of PEA (Costa et al 2008). Furthermore, the synthetic 
CSl/CS2 agonist, WIN552l2-2, binds to and increases the transcriptional 
activity of PPARa, indicating cannabinoid modulation of this nuclear 
receptor system (Sun et al 2006). Cannabinoid receptors and TRPVl 
channels have been shown to be co-expressed in dorsal root ganglia 
(Ahluwalia et al 2000) and to be functionally active (Ahluwalia et al 
2003). Cannabinoid receptors also have the ability to both enhance and 
attenuate TRPV1-mediated actions (Hermann et al 2003, Millns et al 
2001). NADA has been shown to activate cannabinoid and TRPVl 
channels (Huang et al 2002). Intraplantar injection of a high dose of 
NADA (5 ~ g / 5 0 0 ~ L ) ) Significantly inhibited innocuous mechanically evoked 
responses of dorsal horn neurons compared to vehicle (Sagar et al 2004). 
These effects were blocked by intraplantar injection of rimonabant, a CS1 
receptor antagonist. Furthermore, noxious-evoked responses of dorsal 
horn neurons were also significantly inhibited by NADA (5 ~ g / 5 0 0 ~ L ) , , and 
these effects were blocked by intraplantar injection of a TRPVl 
antagonist, iodo-resiniferatoxin (Sagar et al 2004), again demonstrating 
an interaction between the cannabinoid and TRPVl receptor systems. 
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1.4 Animal models of inflammatory pain 
Experiments involving human subjects are ethically-challenging and the 
perception of pain can also be subjective; therefore, many animal models 
of inflammatory pain have been devised for this area of research (Kidd 
and Urban 2001). Animal models of inflammatory pain have been widely 
used to study the mechanisms of tissue injury-induced persistent pain 
and to investigate the anti-inflammatory and analgesic actions of novel or 
existing compounds. Studies conducted in animals can give an insight 
into certain aspects of human pain under inflammatory conditions and 
can lead to improved pain management or the discovery of novel 
treatments for patients. Although animal models of inflammatory pain do 
not simulate every aspect of chronic pain, they do model key features of 
human inflammatory pain. A variety of inflammatory agents and irritants 
have been used to produce tissue injury, inflammation and hyperalgesia 
in subcutaneous tissues, jOints and muscles. These include complete 
Freund's adjuvant (CFA), carrageenan, formalin, capsaicin, 
lipopolysaccharide, mustard oil, acidic saline, inflammatory cytokines and 
sodium urate crystals (Mogil 2009, Kidd and Urban 2001, Chapman et al 
1985). The carrageenan inflammatory pain model is described in more 
detail in Chapter 3. 
1.5 Current analgesic treatments for inflammatory pain 
Paracetamol is used in the treatment of mild to moderate pain. Non-
steroidal anti-inflammatory drugs (NSAIDs) include aspirin, ibuprofen, 
naproxen and diclofenac are anti-inflammatory and analgesic treatments 
for mild to moderate pain. Non-selective inhibition of COX is considered 
to be the main mechanism of action of these drugs (Rainsford 2007), 
preventing the production of pro-inflammatory and pro-nociceptive 
prostanoids (See cyclooxygenase section). Adverse effects include 
gastrointestinal (GI) bleeding and ulceration, with long-term use leading 
to gastrointestinal damage and renal irritation (Koeberle and Werz 2009, 
Scott et al 2000). These GI side effects are a consequence of COX-1 
inhibition, which is involved in the production of GI-protective 
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prostaglandins (Chan et al 1995). These adverse effects lead to the 
development of the selective COX-2 inhibitors, celecoxib and rofecoxib. 
However, both these drugs were shown to have adverse cardiovascular 
effects and were withdrawn from sale (Brophy 2005, Burnier 2005). 
Analgesics such as opioids, may be used for treatment of moderate to 
severe pain, due to the relative lack of effectiveness and side effects 
associated with the long-term use of NSAIDs (Scott et al 2000). These 
include codeine, morphine, fentanyl and oxycodone; however, many 
adverse effects such as nausea, constipation, respiratory depression and 
tolerance can limit their use (Labianca et al 2012). It is, therefore, 
necessary to develop novel drugs for the treatment of inflammatory 
pain, potentially involving novel anti-inflammatory and anti-nociceptive 
targets, including specific lipids and/or receptors. Evidence for the anti-
inflammatory effects of PPARa ligands has emerged (See Chapter 3 for 
details), along with TRPVl receptor antagonism and TRPVl ligands (See 
Chapter 4 for details). However, a substantial amount of work remains to 
be done to fully understand the roles of the different receptor systems 
involved in inflammatory pain mechanisms. In order for this to be 
achieved, quantification of a large number of bioactive lipids in tissues 
involved in inflammation and pain processing is necessary. 
1.6 Analytical methodology for the identification and 
quantification of bloactive lipids 
Metabolomics has been defined as the systematic study and quantitative 
measurement of either the unique chemical fingerprints that specific 
cellular processes leave behind or the total biochemical complement of a 
cell or a particular organ (Fiehn 2002, Daviss 2005). However, as the 
field of global metabolite profiling has developed, this distinction has 
become blurred and the use of terms is now usually based on personal 
preference (For a review, see Lindon and Nicholson 2008). In general, 
analytical strategies are applied to collect targeted or untargeted 
analytical data to investigate the patterns and concentrations of low 
molecular weight lipids in biofluids, cells or tissues. An ideal analytical 
method would involve little or no sample preparation, providing direct 
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analysis of the samples, rapidly and at the same time being highly and 
equally sensitive to all lipids present in samples and be robust and 
reproducible (Lenz and Wilson 2007). However, unsurprisingly, no such 
method providing all these desired properties currently exists. 
Lipidomics is defined as the systems-level analysis and characterisation 
of lipids and their interacting moieties (Wenk 2005), and is a relatively 
young field of biomedical research. The importance of lipidomics is now 
widely recognised and is reflected by international initiatives that aim at 
investigating lipid function in physiology and disease (Wenk 2005). An 
example of this, is the LIPID MAPS initiative, a consortium with the 
mission to comprehensively measure all of the lipids in a human 
macrophage cell line. Lipids involved in signalling are not very abundant 
in resting conditions but may accumulate dramatically upon stimulation 
of a cell (Wenk 2005). The protein machinery responsible for such 
changes can be a single enzyme or a set of enzymes working in sync. The 
levels of these enzymes might well be relatively constant, which makes it 
difficult to detect such cases by expression profiling or the measurement 
of protein levels. In fact, it could be proposed that even enzymatic 
activities might change only moderately in different functional states of 
the cell. Careful inspection of the lipid metabolites involved will help to 
pinpoint underlying metabolic pathways in such events. Such information 
can now be determined with high precision analytical methodologies 
including gas chromatography mass spectrometry (GC-MS) and liquid 
chromatography mass spectrometry (LC-MS). A disadvantage of early 
mass spectrometry was fragmentation of the lipid analyte during 
ionisation, making assignments of free fatty acids, backbones and 
headgroups a difficult task. This and the high chemical backgrounds 
observed in early studies with fast-atom bombardment and chemical 
ionisation were further disadvantages, in particular for the analysis of 
complex lipid mixtures (Wenk 2005). However, over time, methodology 
and techniques for measuring lipid species have improved and these 
developments in methodology are supported by the more widespread 
availability of reagents and tools, such as synthetiC lipid standards. These 
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developments highlight the importance of high quality analytical methods 
in lipid research. 
1.6.1 Analytical methodologies 
GC-MS is commonly used for identification and quantification of trace 
compounds in complex sample mixtures. It is most advantageous for 
analysis of trace amounts of organically extractable, non-polar, volatile 
compounds because the analyte is required to be in the gas phase and 
also applies to mass spectrometry analysis. GC-MS provides a powerful 
tool with strengths resulting from its sensitivity and metabolite 
identification potential but also weaknesses due to its poor ability to 
analyse large and/or non-volatile molecules without prior derivatisation 
(Muccio and Stella 2008, Prakash et al 2007). Sample preparation can 
often be time-consuming and labour-intensive (Fiehn et al 2000, Kanani 
et al 2008, Strehmel et al 2008). However, because the majority of the 
metabolites encountered in biological samples are not volatile and due to 
the need to obtain the maximum possible coverage of the metabolome, 
profiling by LC-MS is usually favoured (Theodoridis et al 2008). 
LC-MS has become a favoured method among researchers for bioactive 
lipid analysis due to the improved speed, sensitivity and specificity and 
also enhanced resolution, especially seen with the LC-tandem MS (LC-
MS/MS). High performance liquid chromatography (HPLC) coupled to MS 
requires less sample 'clean-up' and there is no need for chemical 
derivatisation or exposure to excessive heat and sample throughput is 
generally greater than with GC-MS. An effective ion source to convert the 
solution of molecules from the liquid phase to the gas phase is important 
in LC-MS. The most common vaporisation techniques used are 
electrospray ionisation (ESl) and atmospheric pressure chemical 
ionisation (APCl) (McMaster 2005, Prakash et al 2007). 
Currently, ESl is the method of choice in LC-MS, because it produces a 
large number of ions via charge exchange in solution (Sana et al 2008). 
APCl on the other hand produces ions by charge exchange in the gas 
phase and may provide a wider dynamic range (Want et al 2005), lower 
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signal intensities, background noise and in-source fragmentation 
compared to ESI (Aharoni et al 2002). ESI-MS was also found to show 
excellent reproducibility of results from the same samples (Aharoni et al 
2002). Baseline noise can be a problem with low abundance species like 
the bioactive lipids of interest and tandem mass spectrometric analysis is 
able to reduce this problem and simplify the spectrum (Han and Gross 
2005). 
1.6.2 Measurement of bioactive lipids 
Various analytical techniques have been employed for investigating 
bioactive lipids in biological samples. The low abundance of these 
compounds means they are usually quantified by isotope dilution assays 
using mass spectrometry coupled to either LC or GC as discussed 
(Hardison et al 2006). Mass spectrometry allows a complex mixture to be 
analysed for trace amounts of a particular compound and this technique 
can be used to confirm the presence of a compound based on the precise 
mass of compounds and a fragment ion spectrum can also be generated 
to help determine the structure of an unknown molecule (McMaster 2005, 
Prakash et al 2007). 
Many analytical LC-MS/MS methods utilise targeted lipidomics, and 
measure the eicosanoids (Blewett et al 2008, Kortz et al 2009, Yue et al 
2007, Yoshida et al 2008, Zhang et al 2007) or the endocannabinoids 
(Zhang et al 2010, Balvers et al 2006, Chen et al 2009, Palandra et al 
2009, Richardson et al 2007) separately (See Chapter 2 for details). 
However to date, a targeted analytical method that is able to identify and 
quantify both these lipid classes within the same method still remains to 
be developed. This would enable maximum coverage of the metabolome, 
in this case the lipid mediators involved in the inflammatory process. A 
major advantage of such lipidomics-based discovery is that, together with 
our relatively good understanding of many biosynthetic and metabolic 
pathways, it will lead to further clarification of the involvement of these 
pathways and enzymes in this area of research. The development of an 
analytical method that is able to identify and quantify a large number of 
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bioactive lipid mediators in the inflammatory process, combined with 
pharmacological studies evaluating the effects of these lipids in 
inflammation and hyperalgesia may address any unexplained questions in 
this area of research. 
1.7 General Aims and Objectives 
The aim of the thesis is to develop a sensitive, robust and reproducible 
LC-MS/MS method for the simultaneous measurement of bioactive lipids 
discussed in this chapter and to apply this method to understand better 
the role of these bioactive lipids in inflammation and pain. 
The specific objectives were: 
• To develop an LC-MS/MS method capable of simultaneously 
measuring bioactive lipids including eicosanoids 
• To determine whether levels of these bioactive lipids are altered in 
a model of acute inflammatory pain 
• To determine the potential role of these bioactive lipids in different 
receptor-mediated pathways such as PPARa and TRPVl 
• To determine whether levels of these bioactive lipids are altered in 
a model of chronic joint pain 
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Chapter 2. 
Development of an LC/MS-
MS analytical method to 
identify and quantify levels 
of bioactive lipids in 
different tissues. 
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2. Development of an LC/MS-MS analytical method to 
identify and quantify levels of bioactive lipids in different 
tissues. 
2.1 Introduction 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) has 
played an important role in lipidomics since its introduction. LC-MS/MS 
has led to major breakthroughs in the field of quantitative bioanalysis 
since the 1990s due to inherent specificity, sensitivity and speed (Xu et al 
2007). 
There are a number of factors in LC-MS/MS method development that 
bioanalysts would consider to be of prime importance including sample 
preparation, chromatographic separation and mass spectrometry 
conditions. Bioanalysts must also take into account and reduce matrix 
effects, which can have a considerable effect on the way the analysis is 
conducted and the quality of the results obtained (see later). After an 
analytical method has been optimised in terms of LC mobile phase, mass 
spectrometric parameters and chromatographic peak efficiency, there is 
little a bioanalyst can do to further optimise sensitivity (Jemal 2000). 
2.1.1 Validation 
The next process following extensive method development involves a full 
validation of the analytical methodology. Validation of a method is the 
accepted way to ensure confidence in bioanalytical data, where the 
procedure is designed to assess the performance of the method in a 
biological matrix. There are few analytical methodologies that are fully 
validated according to these guidelines, many of which are industry-
based. This can be an intensive and extensive process, particularly if the 
methodology involves a large number of analytes. 
Validation comprises several elements; accuracy, precIsion, linearity, 
recovery and ion suppression. Guidelines are set by the Food and Drug 
Administration (FDA 2001 Guidance for Industry-Bioanalytical method 
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validation-November 2010), which generally applies to bioanalytical 
procedures such as GC, HPLC and combined GC and HPLC mass 
spectrometric procedures GC-MS, GC-MS/MS, LC-MS and LC-MS/MS. 
These procedures are performed for quantitative determination of drug 
and/or metabolites in biological matrices including blood, serum and 
plasma (FDA 2001 Guidance for Industry-Bioanalytical method validation-
November 2010). The accuracy of an analytical method describes the 
closeness of mean test results obtained by the method to the 
concentration of the analyte. The mean value should be within 15% of 
the actual value (concentration chosen) except at the lower limit of 
quantification (LLOQ), where it should not deviate by more than 20%. 
The deviation of the mean from the true value serves as a measure for 
accuracy. The precision of an analytical method describes the closeness 
of individual measures of an analyte when the procedure is repeatedly 
applied to multiple aliquots of a single homogenous volume of biological 
matrix. This is further divided into inter- and intra- batch precision. The 
precision should not exceed 15% of the coefficient of variation (CV) 
except for the LLOQ, where it should not exceed 20% of the CV (FDA 
2001 Guidance for Industry-Bioanalytical method validation-November 
2010). Linearity is determined by a standard calibration curve 
(relationship between instrument response and known concentrations of 
the analyte), where standard concentrations are chosen based on the 
concentration range expected in a particular study. Recovery is the 
detector response obtained from an amount of the analyte added to and 
extracted from the biological matrix, compared to the detector response 
obtained for the true concentration of a pure standard. Quantitative 
analysis with electrospray ionisation (ESI) or atmospheric pressure 
chemical ionisation (APel) can be substantially affected by the occurrence 
of ion-suppression or -enhancement, otherwise known as matrix effects. 
This phenomenon is caused by the presence of a matrix or other 
interferences in the sample and is responsible for poor and unreliable 
data in a quantitative assay. Matrix effects can also affect the 
reproducibility, linearity and accuracy of the method (Trufelli et al 2011). 
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It is important to consider all these factors during the method 
development process. 
2.1.2 LC-MS/MS analysis of bioactive lipids 
Biological processes such as inflammation and pain, which involve lipid 
mediators are complex events and often include significant regional 
changes in the levels of many lipid species. To fully understand these 
biochemical events it is now appreciated that measurement of changes in 
the profile of these bioactive lipids is essential. Although LC-MS/MS 
methods have been developed for bioactive lipids such as Buczynski et al 
2010, who utilise the resources of the Lipid Maps database mentioned 
earlier (Lipid Maps-Nature Lipidomics Gateway, February 2010). It is 
often the case that the methods have been limited to a relatively small 
number of lipids or for a specific type of tissue. Structural similarity and 
isomerisation are a challenge and this has been addressed in a number of 
papers (Masoodi et 2010, Jiang et al 2004). However although the 
majority of lipid analysis by LC-MS/MS is in negative ionisation mode, a 
significant number of modified bioactive lipids have to be identified in 
positive mode. The endocannabinoids (altered in inflammatory pain 
models) (Sagar et al 2009, Mbvundula et al 2004) are an example of this, 
where these lipids and structurally-related species do not ionise well in 
negative ion mode. A number of LC-MS/MS profiling methods have been 
published (Table 1). 
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Table 1. Current literature on the lipid profiling of the eicosanoids or endocannabinoids in 
different tissues and species. 
Reference Analytical Ionisation Type of lipids Tissues 
Method mode analysed analysed 
De Grauw et al LC-MS/MS Negative ESI Eicosanoids Equine synovial 
2011 mode fluid 
Ferreiro-Vera SPE-LC-MS/MS Negative ESI Eicosanoids Human serum, 
et al 2011 mode bone marrow, 
mesenchymal 
cell cultures 
Buczynski et al LC-MS/MS and One method in Eicosanoids and Rat cerebral 
2010 GC-MS/MS negative and endocannabinoids spinal fluid and 
one method in spinal cord 
positive ESI 
mode 
Kortz et al SPE-LC-MS/MS Negative ESI Eicosanoids Human plasma 
2009 mode 
Lundstrom et RP-HPLC- Negative ESI Eicosanoids Human 
al 2009 MS/MS mode bronchoalveolar 
lavage fluid 
Richardson et LC-MS/MS Positive ESI Endocannabinoids Rat brain regions 
al 2007 mode 
Masoodi et al LC-MS/MS Negative ESI Eicosanoids Rat brain, liver 
2008 mode and plasma 
Yang et al RP-HPLC- Negative ESI Eicosanoids Mouse xenograft 
2006 MS/MS mode tumour model, 
hamster 
squamous cell 
carcinoma 
model, mouse 
prostatic lobes 
Although a number of LC-MS/MS methods have been published to date 
(Table 1), focussing on a large proportion of the lipid cascade, there is 
not yet a method available that incorporates negative to positive 
ionisation mode switching for quantification of bioactive lipids in both 
ionisation modes. The main difficulty that a bioanalyst has to overcome is 
the difference in mass spectrometry ionisation modes. Eicosanoids are 
readily ionised in negative ionisation mode (mainly acid based 
molecules), whereas the endocannabinoids are better ionised in positive 
ionisation mode (some are nitrogen containing molecules). This would 
enable maximum coverage of the inflammatory lipidome, in this case the 
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lipid mediators involved in the inflammatory process. Currently, the 
utilisation of ion sources capable of fast switching between ionisation 
modes is not common. This is due to the loss of sensitivity that is 
incurred as a result of the switching process and, also, because the 
capacity for polarity switching in older machines is often poor. In such 
cases, the samples are first analysed in positive mode and then re-
analysed in negative mode to overcome this. However, this doubles 
analysis time and may not be suitable for samples of poor stability or 
those prone to degradation. Triple quadrupole mass spectrometers can 
provide automatic polarity switching and, hence, enable reduced analysis 
time, but by sacrificing some sensitivity. However, even with these 
instruments, there are still many chromatography-based challenges that 
need to be overcome for the methodology to succeed and is discussed 
later. 
Many analytical LC-MS/MS methods measure the eicosanoids (Blewett et 
al 2008, Yue et al 2007, Yoshida et al 2008" Zhang et al 2007, 
Nithipatikom et al 2001) or the endocannabinoids (Zhang et al 2010, 
Balvers et al 2006, Chen et al 2009) separately, however there are very 
few LC-MS/MS methods that provide a full lipid profile of important 
inflammatory mediators and when this occurs, it is usually achieved with 
two or more different methods (Buczynski et al 2010). Lipid profiling of a 
large number of eicosanoids have previously been achieved in rat spinal 
cord (Buczynski et al 2010) and rat brain, liver and plasma have been 
used in the validation of a profiling method (Masoodi et al 2008). The 
majority of LC-MS/MS methods focus on a selective small group of lipids 
and validated methods often use human plasma as the biological tissue of 
interest. 
Profiling of these bioactive lipids involve many difficulties as many 
eicosanoids have very similar or even identical (isomeric) chemical 
structures and therefore a single m/z transition may not be as specific to 
individual compounds as desired (De Grauw et al 2011). Another 
challenge is the analytical determination of a large number of bioactive 
lipids in a single biospecimen, often necessary to fully characterise the 
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relevant biochemical processes. These bioactive lipids are all produced 
under related cascades of biochemical signalling events and the lipid 
species produced are often enzymatically linked to one another. An 
analytical method that can incorporate all these lipids in a single 
analytical assay would be ideal to determine all relevant lipids involved in 
a particular biological process. An analytical method which is highly 
selective and able to distinguish between similar structures and has 
sufficiently high sensitivity to be able to detect small amounts in 
biological tissue is therefore required. 
2.1.3 LC-MS/MS analysis of bioactive lipids in different 
tissues 
Numerous analytical methods have also identified and quantified the 
eicosanoids and endocannabinoids in different tissues (Table 2 and 3). As 
mentioned previously, the majority of the methods in the literature only 
measure a selective number of lipids in the different tissues, which may 
be due to the reasons discussed earlier. An overview of current literature 
on the separation and quantification of eicosanoids (Table 2) and 
endocannabinoids and endocannabinoid-like compounds (Table 3) in 
different species and tissues were presented. 
.,...- .. 
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Table 28. Current literature on the identification and quantification of eicosanoids (-ve ionisation mode) in different tissues and species. 
EICOSANOIDS Analytical COnditions Extraction Method Analyte Summary References 
Rat Spinal Cord A: ACN:H20:acetic acid, Extraction with SPE Eicosanoid profiling Buczynski et al 2010 
B:ACN:isopropyl alcohol. C18 SPE-LC- (Phenomenex Strata-X) with 
MS/MS 10% MeOH 
Trigeminal A:H20, B:ACN, both with 0.002% Extraction with MeOH 8 eicosanoids detected Iliff et al 2010 
Neurons acetic acid. C18 ESI-LC-MS/MS including EETs, HETEs and 
DHETs 
Brain A:MeOH:H20, B:ACN:H20, both with Extraction with SPE Eicosanoid profiling Masoodi et al 2008 I I 
acetic acid. C18 ESI-LC-MS/MS (Phenomenex Strata-X) with 
<15% MeOH 
Brain A:Acetic acid buffered with NH4OH, Extraction with SPE Eicosanoid mediators of Farias et al 2008 
I B:ACN:MeOH. C18 ESI-LC-MS/MS (Phenomenex Strata-X) with arachidonic acid and 
<15% MeOH docosahexaenoic acid J 
Brain A:H20, B:ACN, both with 0.1% formic Extraction with SPE (Oasis Eicosanoid profiling Yue et al 2007 
acid. C18 ESI-LC-MS/MS HLB) with <15% MeOH 
Brain A:H20, B:MeCN:formic acid (100:0.1), Extraction with SPE (Oasis Eicosanoid profiling Yoshikawa et al 2006 
C:H20:fonnic acid (100:0.1), HLB) with <15% MeOH 
D:MeOH:formic aCid(100:0.2). C18 
ESI-LC-MS/MS 
i 
Kidney A:ACN, B:H20, both with 0.1% formic Extraction with SPE (Oasis Profiling of 23 eicosanoids Blewett et al 2008 
acid. C18 ESI-LC-MS/MS HLB) with 10% MeOH (with 
formic acid and ethyl acetate) 
Uver A:MeOH:H20, B:ACN:H20, both with Extraction with SPE Eicosanoid profiling Masoodi et al 2008 
acetic acid. C18 ESI-LC-MS/MS (Phenomenex Strata-X) with I 
<15% MeOH 
-- - -- -- ---- - - -- --- --- ------
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Table 2b. Current literature on the identification and quantification of eicosanoids (-ve ionisation mode) in different tissues and species. 
EICOSANOIDS Analytical Conditions Extraction Method Analyte Summary References 
Rat Serum A: 10mM ammonium formate in H2O, Extracted with ACN 6 eicosanoids including AA, Bai et al 2010 
B:ACN with 0.1% formic acid. C18 PGD2 and L TB4 
ESI-LC-MS/MS 
Plasma A:MeOH: H20, B:ACN:H20, both with Extraction with SPE Eicosanoid profiling Masoodi et al 2008 
acetic acid. C18 ESI-LC-MS/MS (Phenomenex Strata-X) with 
<15% MeOH 
Mouse Spinal Cord A: H20, B:MeCN:formic acid (100:0.1), Extraction with SPE (Oasis Eicosanoid profiling Kihara et al 2009 
I C: H20:formic acid (100:0.1), HLB) with <15% MeOH I 
D:MeOH:formic acid 
I (100:0.2). C18 ESI-LC-MS/MS I 
Brain A: H20, B:ACN, both with 0.1% Washed with hexane and Prostaglandins Brose et al 2011 
I formic acid. C1S ESI-LC-MS/MS formic acid, then extracted 
with chloroform 
I 
Brain A: H20, B:ACN, both with 0.1% Extraction with ACN EETs Marowsky et al 2009 
formic acid. C18 RP-ESI-LC-MS/MS 
Human Synovial A: H20:ACN:acetic acid (70:30:0.02), Extraction with Eicosanoid profiling Blaho et al 2009 
Auid B: ACN-isopropyl alcohol (50: 50). MeOH:EtOH:H20 (2:1:1) 
C18 ESI-LC-MS/MS 
Uterine A:0.05% formic acid in H2O, Extraction with SPE 13 eicosanoids including Zhang et al 2007 I Tissue B:MeOH:ACN (20:80). C1S ESI-LC- (Phenomenex Strata-X) with HETEs and EETs 
MS/MS 25% EtOH I 
Uver A: 2mM ammonium acetate in H2O, Extraction with 10 eicosanoids including Yoshida et al 2008 
B:MeOH:ACN (5:95) C18 ESI-LC- chloroform: ethyl acetate HETEs and HODEs 
MS/MS (4:1) 
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Table 2c. Current literature on the identification and quantification of eicosanoids (-ve ionisation mode) in different tissues and species. 
EICOSANOIDS Analytical Conditions Extraction Method Analyte Summary References 
I 
Human Plasma Isocratic gradient of ACN/ H2O Extraction with CHCIJlCH30H 5 eicosanoids, including EETs, Minuz et al 2008 
/MeOH/acetic acid (75:15:10:0.05). (2:1) 20-HETE 
C18 ESI-LC-MS/MS 
Plasma A:2mM ammonium acetate in H2O, Extraction with 10 eicosanoids including Yoshida et al 2008 
B:MeOH:ACN (5:95) C18 ESI-LC- chloroform: ethyl acetate HETEs and HODEs 
MS/MS (4:1) 
Plasma A:1mmol/L formic acid in H2O, Extraction by C18 SPE (Bond Prostaglandins Komaba et al 2009 
B:ACN. Inertsil ODS-3 LC column, LC- Elut) with ethyl acetate, 
MS/MS MeOH, H20 and 1 % acetic 
acid 
Urine A: H20, B:ACN, both with 0.1% Extraction with C18 SPE (Sep- 15 eicosanoids including Martin-Venegas et al 
formic acid. C18 ESI-LC-MS/MS Pack) with ethyl acetate HETEs, EETs and 13-HODE 2011 
Urine Isocratic gradient of ACN / H2O/ Extraction with CHCIJlCH30H 5 eicosanoids, including EETs, Minuz et al 2008 
MeOH/acetic acid (75: 15: 10:0.05). (2:1) 20-HETE 
C18 ESI-LC-MS/MS 
"------ --- - -- - - -
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Table 3a. Current literature on the identification and quantification of endocannabinoids (+ve ionisation mode) in different tissues and species. 
ENDOCANNABINOIDS Analytical Conditions Extraction Method Analyte Summary References 
Rat Hindpaw A: H20, B:ACN, both with 19/L Extraction with ethyl Endocannabinoids and Jhaveri et al 2008 
ammonium acetate and 0.1% acetate/hexane (9: 1) endocannabinoid-like compounds 
formic acid. C8 ESI-LC-MS/MS 2-AG, AEA, OEA and PEA. 
Hindpaw A: H20, B:MeOH. C18 ESI-LC- Extraction with Endocannabinoids 2-AG and AEA Guindon et al 2011 
MS/MS chloroform:HzO (2: 1) 
Spinal Cord A: ACN: H20:acetic acid, Extraction with SPE Ethanolamine profiling Buczynskietal2010 
! B:ACN:isopropyl alcohol. C8 (Phenomenex Strata-X) 
RP-LC-MS/MS with 10% MeOH 
Spinal Cord A: H20, B:ACN, both with 19/L Extraction with ethyl Endocannabinoids and Staniaszek et al 2010 
I ammonium acetate and 0.1% acetate/hexane (9: 1) endocannabinoid-like compounds i 
formic acid. C8 ESI-LC-MS/MS 2-AG, AEA, OEA and PEA. 
DRGs Isocratic gradient of H2O Extraction with ACN Endocannabinoids 2-AG and AEA Mitrirattanakul et al 2006 I 
/MeOH with 0.005% acetic 
acid and ImM ammonium I 
acetate. C18-RP-APCI-LC- i 
MS/MS 
Brain A: 5% methanol in H2O, Extraction with ACN 3 endocannabinoids Chen et al 2009 I 
B:MeOH, both with 1mM 
I ammonium acetate and 0.1% 
acetic acid. C18 ESI-LC-MS/MS 
Brain A:ACN, B: H20, both with Homogenised with MeOH, Endocannabinoids 2-AG and AEA Malinen et al 2009 I 
0.1 % formic acid. C18 ESI -LC- followed by extraction 
MS/MS with chloroform 
- -----
~ ~
iIIlff"!'''''''' 
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Table 3b. Current literature on the identification and quantification of endocannabinoids (+ve ionisation mode) in different tissues and species. 
ENDOCANNABINOIDS Analytical Conditions Extraction Method Analyte Summary References 
Rat Brain A: H20, B:ACN, both with Extraction with Endocannabinoids and Artmann et al 2008 
0.05% formic acid. C18 ESI- chloroform:MeOH (2:1) endocannabinoid-like compounds 
LC-MS/MS 2-AG, AEA, OEA and PEA. 
Brain A: H20, B:MeOH, both with Extraction with Endocannabinoids 2-AG and AEA Bequet et al 2007 
10mM ammonium acetate. customised micro5PE 
C18 micro ESI-micro LC- (Spark Holland) with 
M5/M5 MeOH/H2O 
Brain A: H20, B:ACN, both with 19/L Extraction with ethyl Endocannabinoids and Richardson et al 2007 
ammonium acetate and 0.1% acetate/hexane (9:1) endocannabinoid-like compounds 
formic acid. C8 E5I-LC-M5/M5 2-AG, AEA, OEA and PEA. 
Brain A: 10mM ammonium acetate, Extraction with Profiling of ethanolamine and Williams et al 2007 
B:MeOH. Zorbax 5B-CN APCI- chloroform: MeOH (2: 1) glycerol products from different 
LC-M5/M5 fatty acids 
Brain Isocratic gradient of H2O Extraction with ACN Endocannabinoids 2-AG and AEA Mitrirattanakul et al 2007 
/MeOH with 0.005% acetic 
acid and ImM ammonium 
acetate. C18 E5I-LC-M5/M5 
Brain TraceD5Q equipped with Rtx- Extraction with Endocannabinoids 2-AG and AEA Hardison et al 2006 
5M5 column. GC/Chemical chloroforrn:HzO, followed 
ionisation M5 by C18 5PE (Bond Elut) 
with MeOH 
--- -- -- - - - -
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Table 3c. Current literature on the identification and quantification of endocannabinoids (+ve ionisation mode) in different tissues and species. 
ENDOCANNABINOIDS Analytical Conditions Extraction Method Analyte Summary References 
Rat Plasma A:2mM ammonium acetate, Extraction with SPE Endocannabinoid AEA and Fonseca et al 2010 
B:ACN, both with 0.1% formic (Oasis HLB) with endocannabinoid-like compounds 
acid. C18 UPLC-MS/MS MeOH:H2O PEA and OEA 
Mouse Brain Ethanolamines derivatised to Extraction with Ethanolamines Kilaru et al 2010 
TMS-ethers and analysed by chloroform, isopropanol 
GC-MS and H2O 
Brain A: H20, B:MeOH:H20 (9:1), Extraction with C18 SPE Endocannabinoids including 2-AG Placzek et al 2010 
both with 7 0 ~ M M silver acetate. (Bond Elut) with and AEA 
C8 ESI lC-MS/MS MeOH/H2O 
Human Brain Isocratic gradient with H2O Extraction with Endocannabinoids AEA, NADA Lehtonen et al 2011 
/ACN/formic acid (33:67:0.1). chloroform:H 20, followed and 2-AG and endocannabinoid-
C18 ESI LC-MS/MS by C18 SPE (Bond Elut) like compounds PEA and OEA 
with MeOH 
Human Plasma A: H20, B:MeOH, both with Extraction with ACN 2-AG, 1-AG and AA Zhang et al 2010 
0.2% acetic acid. C1S ESI LC-
MS/MS 
Plasma A: H20, B:ACN, both with 19/L Extraction with ethyl Endocannabinoids AEA and 2-AG, Jean-Gilles et al 2009 
ammonium acetate and 0.1 % acetate/hexane (9: 1) endocannabinoid-like compounds 
formic acid. C8 ESI-LC-MS/MS OEA and PEA 
Plasma A:ACN, H20, both with 0.1 % Extraction with Endocannabinoids AEA, NADA Thomas et al 2009 
formic acid. ><Terra column. heptane/ethyl acetate and 2-AG 
LC-MS/MS. (1:1) 
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Table 3d. Current literature on the identification and quantification of endocannabinoids (+ve ionisation mode) in different tissues and species. 
EN DOCANNABINOIDS Analytical Conditions Extraction Method Analyte Summary References 
Human Plasma A:H20:MeOH (95:5), B:MeOH, Extraction by C8 SPE Endocannabinoids AEA and Balvers et al 2009 
both with 19/L ammonium (Bond Elut) with ACN NADA, including 
acetate and 0.1% formic acid. endocannabinoid-like compounds 
C8 ESI-LC-MS/MS PEA and OEA 
Plasma A: H20, B:ACN, both with 19/L Extraction with ethyl Endocannabinoids and Jhaveri et al 2008 
ammonium acetate and 0.1% acetate/hexane (9: 1) endocannabinoid-like compounds 
formic acid. C8 ESI-LC-MS/MS 2-AG, AEA, OEA and PEA 
-------
~ ~
- - - ----------------
~ ~ ~ ~
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A large proportion of the current literature reviewed here utilised C18-
ESI-LC-MS/MS methodology for eicosanoid analysis, whereas C8- and 
C18-ESI-LC-MS/MS methodology was employed for endocannabinoid 
analysis. The analytical conditions were also very similar for both these 
lipid classes reviewed, with the majority having used methanol or 
acetonitrile along with acetic or formic acid and their salts, including 
ammonium salts to control the pH of mobiles phases (Bai et al 2010, 
Fonseca et al 2010, Yoshida et al 2008, Mitrirattanakul et al 2007, 
Williams et al 2007). Extraction methods on the other hand, were more 
variable, with some methods having used solid phase extraction 
(SPE)(Buczynski et al 2010, Masoodi et al 2008, Farias et al 2008, 
Richardson et al 2007). SPE was found to increase MS specificity and 
sensitivity and also prolong HPLC column life (Richardson et al 2007). It 
is a useful technique when large amounts of tissue (>200mg) are used 
by preventing HPLC overload and for sample clean-up, however when 
small tissue weights are involved «70mg) this can interfere with analyte 
recovery (Poole 2003). 
A number of the eicosanoids were shown to be unstable to oxidation (Iliff 
et al 2010, Blewett et al 2008). 5,6-epoxyeicosatrienoic acid (5,6-EET) 
was initially undetectable in trigeminal ganglion neurons, but the 
spontaneous oxidative breakdown product of 5,6-EET, 5,6-
dihydroxyeicosatrienoic acid (5,6-DHET) was detectable, however this 
issue was resolved through sample collection and storage modifications 
(Iliff et al 2010). The lipoxygenase metabolites, leukotriene C4 (LTC4) and 
leukotriene D4 (LTD4) are also inherently unstable in vivo and ex vivo. In 
vivo, peptidase enzymes catalyse the cleavage of amino acid residues on 
LTC4 and LTD4 and ex vivo, autooxidative degradation occurs (Blewett et 
al 2008). Therefore, some methods may include an antioxidant, which is 
normally added during sample extraction to minimise formation of 
oxidation products prior to analysis. These include butylhydroxytoluene 
(Blewett et al 2008, Yoshida et al 2008, Zhang et al 2007) and 
triphenylphosphine (Minuz et al 2008). 
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The majority of the methods listed in Table 2 and 3 focus on singular 
pathways or phases of the inflammatory response, which increase our 
knowledge of the inherent potential of certain molecules. However, this 
provides an incomplete picture and gives the impression that some lipids 
function in isolation. In reality, this is more complex and are likely to be 
governed by upstream mediators, which in turn, regulate other 
metabolites to produce the overall outcome of inflammatory responses. 
Ideally, an analytical method that can measure a large proportion of the 
inflammatory cascade and fully characterise this biochemical process is 
therefore needed. However, another difficulty in analytical method 
development is that a number of compounds that are biologically active 
in vivo are not readily available as commercial standards. These include 
lS-hydroperoxyeicosatetraenoyl glycerol (1S-HPETE-G), a peroxisome 
proliferator activated receptor alpha (PPARa) agonist (Vandevoorde 
2007) and 2-(11,12-epoxyeicosatrienoyl)-glycerol (11,12-EET-G), a 
cannabinoid receptor-1 (CB1) and cannabinoid receptor-2 (CB2) agonist 
(Chen et al 2008). Experiments involving these compounds could be 
conducted if the compounds were either synthesised (Chen et al 2008) or 
through qualitative analysis (Blewett et al 2008, Vue et al 2007). 
Therefore, in order to develop an analytical method that can achieve this, 
it would involve overcoming the challenges in method development as 
discussed earlier. The ability to measure and investigate all relevant 
bioactive lipids in the same methodology would aid our understanding of 
this complex system and to be able to fully appreciate what is happening 
in vivo. 
66 
2.1.4 Aims and Objectives 
• To develop and validate an LC/MS-MS analytical method that can 
simultaneously measure a wide range of bioactive lipids including 
eicosanoids and endocannabinoids 
• To measure and determine the levels of these bioactive lipids in 
different biological tissues in the rat 
• To compare the distribution of measured lipids between the 
different biological tissues 
2.2 Materials and Methods 
2.2.1 Chemicals 
Acetonitrile, ammonium hydroxide, ethanol, ethyl acetate, hexane, formic 
acid and methanol were all purchased from Fisher Scientific 
(Loughborough, UK). All solvents were HPLC grade and far UV grade 
acetonitrile was also used. Prostaglandin D2 ethanolamide (PG02-EA), 
prostaglandin El ethanolamide (PGE1-EA), prostaglandin E2 ethanolamide 
(PGE2-EA), prostaglandin F20 ethanolamide (PGF2o-EA), 5,6-
dihydroxyeicosatrienoic acid (5,6-0HET), 8,9-dihydroxyeicosatrienoic acid 
(8,9-0HET), 11,12-dihydroxyeicosatrienoic acid (11,12-0HET), 14,15-
dihydroxyeicosatrienoic acid (14,15-0HET), 8,15-
dihydroxyeicosatetraenoic acid (8, 15-0iHETE), 9-hydroxyeicosatetraenoic 
acid (9-HETE), I1-hydroxyeicosatetraenoic acid (11-HETE), 12-
hydroxyeicosatetraenoic acid (12-HETE), 15-hydroxyeicosatetraenoic acid 
(15-HETE), 16-hydroxyeicosatetraenoic acid (16-HETE), 19-
hydroxyeicosatetraenoic acid (19-HETE), 20-hydroxyeicosatetraenoic acid 
(20-HETE), arachidonic acid (AA), linoleic acid (LA), 5-
hydroperoxyeicosatetraenoic acid (5-HPETE), 9-hydroxyoctadecadienoic 
acid (9-HODE), 13-hydroxyoctadecadienoic acid (13-HODE), 9-
oxooctadecadienoic acid (9-oxoODE), 13-oxooctadecadienoic acid (13-
oxoOOE), leukotriene-B4 (LTB4), leukotriene-E4 (LTE4), prostaglandin O2 
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(PGD2), prostaglandin E2 (PGE2), thromboxane-B2 (TXB2) N-arachidonoyl 
ethanolamide (AEA), 2-arachidonoyl glycerol (2-AG), N-palmitoyl 
ethanolamide (PEA), N-oleoyl ethanolamide (OEA), N-arachidonoyl 
dopamine (NADA), N-arachidonoyl glycine (AraGly), 5,6-
epoxyeicosatrienamide (5,6-EET-EA), 2-( 14, 15-epoxyeicosatrienoyl)-
glycerol (14,15-EET-G), arachidonic acid-d8 (AA-d8), prostaglandin D2-d4 
(PGDrd4), prostaglandin F20 ethanolamide-d4 (PGF2o-EA-d4), N-
arachidonoyl ethanolamide-d8 (AEA-d8) and 2-arachidonoyl glycerol-d8 
(2-AG-d8) were purchased from Cambridge Bioscience (Cambridge, UK). 
5-hydroxyeicosatetraenoic acid (5-HETE), 8-hydroxyeicosatetraenoic acid 
(8-HETE), 5,6-epoxyeicosatrienoic acid (5,6-EET), 8,9-
epoxyeicosatrienoic acid (8,9-EET), 11,12-epoxyeicosatrienoic acid 
(11,12-EET), 14, 15-epoxyeicosatrienoic acid (14,15-EET), 12-
hydroperoxyeicosatetraenoic acid (12-HPETE) and 15-
hydroxyeicosatetraenoic acid-d8 (15-HETE-d8) were all purchased from 
Biomol International (Exeter, UK). HPLC grade water (ELGA Ltd. High 
Wycombe, UK) was used in all experiments. 
2.2.2 Preparation of standards 
All stock solutions of each compound were prepared in ethanol, except 
for 2-AG and 2-AG-d8 which is known to be more stable in acetonitrile 
and is therefore diluted in this solvent. All stock solutions were stored at -
80aC. Serial dilutions of these compounds were used for calibration and 
stored for no longer than two weeks, comparison of each LC-MS/MS 
analysis showed no evidence of degradation in these conditions. 
2.2.3 Tissue Collection 
Male Sprague-Dawley rats (250-300 g, Charles River Laboratories) were 
used and all experiments were conducted in accordance with the UK 
Home Office regulations. Animals were killed by stunning and 
decapitation followed by rapid dissection by Professor David Kendall, 
Professor Vicky Chapman and Paul Millns and transferred into liquid 
nitrogen. Tissues were stored immediately at -80 0C until analysis. 
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2.2.4 Sample Extraction 
Tissue samples from brain (100-700mg), spinal cord (20-50mg), and 
dorsal root ganglia (DRGs, ~ ~ 10mg were weighed and then homogenised 
with hand-held pestles in glass tubes and 1 mL ELGA water. Internal 
standards (100 IJL of 2-AG-d8 (10 IJM) and 15 IJL of AEA-d8 (28 nM), 10 
IJL of PGF2a-EA-d4 (2.49 IJM), 10 IJL of AA-d8 (100 nM), 10 IJL of PGD2-
d4 (1 IJM), 10 IJL of 15-HETE-d8 (7.6 IJM» were added to each sample or 
blank sample (0.2 ml water), along with 10 IJL (0.005g in lmL of 
ethanol) of an antioxidant butylhydroxytoluene (BHT). For each sample 
2.5 mL of ethyl acetate: hexane (9: 1 v/v) was used to extract the 
compounds from the tissue, followed by a slow vortex stage (10 min) and 
centrifuged (3200 g, 4°C) for 15 min. The supernatants were transferred 
to glass tubes, the procedure repeated and the supernatants pooled and 
evaporated under nitrogen. The samples were then reconstituted in 200 
IJL of acetonitrile:water (50:50 v/v) and analysed immediately. 
Paw tissue (40-80mg) was weighed and homogenised in glass tubes and 
1 mL ELGA water. Internal standards were added and the procedure 
followed as for brain tissue. The samples were then left to shake for one 
hour on a flat-bed shaker to allow for slow partitioning of lipids and 
centrifuged (3200 g, 4°C) for 15 min. The supernatants were transferred 
to glass tubes, the procedure repeated replacing the one hour shaking 
with a 10 min slow vortex stage and the supernatants pooled and 
evaporated under nitrogen. The samples were then reconstituted in 200 
IJL of acetonitrile: water (50:50 v/v) and analysed immediately. 
Knee joints were weighed (400-600mg) and crushed with surgical pliers 
in glass tubes and 1 mL ELGA water. Internal standards were added and 
the procedure followed as for paw tissue. 
Plasma samples ( ~ l m L ) ) were thawed and 0.4 mL added to 2.5 mL of 
ethyl acetate: hexane (9: 1 v/v) per sample, followed by 1 mL ELGA 
water. Internal standards were added and the procedure followed as for 
brain tissue. 
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2.2.5 LC-MS/MS Method 
The majority of the initial method development was carried out using the 
Quattro Ultima mass spectrometer (Waters Micromass, Manchester, UK) 
coupled to an Agilent 1100 LC system (Agilent Technologies, Waldbron, 
Germany). The methodology was later transferred onto the Applied 
Biosystem MDS SCIEX 4000 Q-Trap hybrid triple-quadrupole-linear ion 
trap mass spectrometer (Applied Biosystem, Foster City, CA, USA) used 
in conjunction with a Shimadzu series lOAD VP LC system (Shimadzu, 
Columbia, MD, USA). Analytes were separated chromatographically using 
a complex gradient that was systematically optimised to provide 
separation of two different types of lipid; ones containing a carboxylic 
acid group and ones that did not (Table 4). 
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Table 4. Detailed final gradient applied for this LC-MS/MS method. 
Time Pump A Pump B Pump C Total Flow 
(min) (%) (%) (%) (ml./min) 
0.00 55 45 0 0.2 
5.25 55 45 0 0.2 
7.50 50 50 a 0.2 
7.60 50 50 a 0.3 
13.50 30 70 0 0.3 
13.60 30 70 0 0.25 
18.00 0 100 0 0.25 
20.00 0 100 0 0.25 
20.10 55 45 0 0.25 
22.50 0 a 100 0.3 
26.00 55 45 0 0.2 
26.10 55 45 0 0.2 
29.00 55 45 a 0.2 
30.00 STOP 
At 22.5 minutes the system controller is switched from event 0 to event 2, this allows 
100% of pump C to pass through and wash the column. At 26 minutes, it switches back 
from event 2 to event 0, allowing 45% B to pass through at 0.2mL/min allowing the 
column to equilibrate back to initial conditions. This gradient was the final version 
following completion of method development, which, along with mass spectrometry 
conditions, took over 12 months to complete. 
Mobile phase A consisted of 0.05% formic acid in water, pH adjusted with 
dilute ammonium hydroxide, whilst mobile phase B was methanol: 
acetonitrile (20:80 v/v) and mobile phase C was 100 % acetonitrile. A 
Phenomenex Luna C18 (150 x 2.0 mm, 3 ~ m m 1.0.) column fitted with a 
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guard column was used and the autosampler temperature was 
maintained at 40 C throughout analysis. During method development 
different LC conditions were investigated and will be discussed in this 
chapter. 
Multiple reaction monitoring (MRM) of individual compounds in negative 
and positive mode using specific precursor and product mass-to-charge 
(m/z) ratios allowed simultaneous measurement of 42 compounds in the 
same method along with 6 internal standards. MS conditions were 
carefully optimised using product ion scans to optimise the product ions 
used for the MRM transitions to allow simultaneous measurement of 
similar lipids. Source parameters, declustering potential, collision energy 
and collision cell exit potential were optimised by direct infusion or 
injection to maximise sensitivity (Table 5). 
Retention 
Time 
Analyte (min) Ql mass QJ mass DP (V) 
PGDz 1.9 351.22 271.21 -40 
PGE2 1.9 351.22 271.21 -50 
TXB 2 1.9 369.23 169.09 -50 
PGEcEA 3.7 396.28 360.20 -55 
PGFZ3 -EA 3.7 396.2S 334.21 -70 
S,15-DIHETE 4.1 335.23 127.20 -60 
PGEz-EA 
PGDz-EA 
14,15-DHET 
lTB;I 
lTE" 
l1,12-DHET 
19-HETE 
20-HETE 
13-HODE 
15-HETE 
S,9-DHET 
9-HODE 
13-oxoODE 
15-HETE 
14,15-EET 
9-oxoODE 
5,6-DHET 
ll-HETE 
11,12-EET 
12-HETE 
S-HETE 
8,9-EET 
9-HETE 
12-HPETE 
5-HETE 
5-HPETE 
5,6-EET 
ARAGlV 
LA 
AA 
14,15-EET-G 
5,6-EET-EA 
AEA 
NADA 
2-AG 
PEA 
OEA 
AEA-dS· 
2-AG-dS· 
PGDz-d4* 
PGF.,.-EA-d4* 
15-HETE-d8* 
AA-d8* 
4.3 
4.4 
5.0 
5.6 
6.0 
6.7 
7.2 
S.3 
8.0 
8.3 
9.1 
9.7 
9.7 
11.6 
10.1 
10.4 
10.S 
12.8 
11.1 
11.7 
13.4 
11.9 
12.1 
13.1 
13.9 
13.9 
16.3 
17.8 
18.0 
18.9 
19.1 
20.7 
21.0 
21.1 
21.6 
21.9 
20.6 
21.0 
1.9 
3.7 
9.5 
17.S 
394.26 
394.26 
337.25 
335.23 
438.23 
337.25 
319.24 
319.24 
295.23 
319.24 
337.25 
295.23 
293.21 
319.24 
319.24 
293.21 
337.25 
319.24 
319.24 
319.24 
319.24 
319.24 
319.24 
317.23 
319.24 
317.23 
319.24 
360.25 
279.23 
303.23 
395.27 
364.28 
348.28 
440.31 
379.28 
300.28 
326.30 
356.33 
387.33 
355.24 
400.26 
327.29 
311.28 
35S.24 
203.12 
207.15 
335.23 
438.23 
167.11 
275.20 
289.22 
195.14 
233.15 
127.11 
171.10 
113.10 
219.14 
219.14 
185.12 
145.06 
167.11 
167.11 
179.11 
155.07 
155.08 
123.00 
153.10 
115.04 
203.18 
191.18 
74.02 
279.23 
259.00 
285.21 
62.06 
62.06 
137.06 
287.22 
62.06 
62.06 
63.03 
95.11 
193.15 
338.24 
226.25 
267.29 
-70 
-55 
-75 
-60 
-50 
-70 
-85 
-67 
-60 
-65 
-74 
-60 
-75 
-65 
-72 
-S5 
-71 
-85 
-65 
-70 
-65 
-72 
-70 
-80 
-64 
-75 
-70 
-60 
-60 
-so 
so 
90 
25 
25 
88 
25 
25 
SO 
70 
-45 
-70 
-67 
·50 
CE (VI CXP (V) 
-25 -20.00 
-25 -15.00 
-25 -10.00 
-15 -10.00 
-25 -10.00 
-30 -10.00 
-17 
·34 
-25 
·15 
-12 
-26 
-27 
-30 
-28 
-20 
-28 
-30 
-2S 
-18 
-15 
-28 
-26 
-23 
-21 
-21 
-20 
-17 
-23 
-24 
-20 
-30 
-16 
-45 
-15 
-20 
23 
40 
30 
33 
22 
30 
32 
45 
61 
-29 
-23 
-20 
-20 
-10.00 
-15.00 
-3.24 
-15.00 
-10.00 
-10.90 
-7.23 
-6.27 
-10.00 
-3.91 
-8.41 
-10.00 
-8.00 
-3.78 
-3.50 
-12.00 
-10.02 
-2.01 
-7.89 
-3.00 
-9.89 
-9.74 
-6.60 
-10.75 
-7.00 
-12.00 
-13.60 
-10.00 
-7.00 
-15.00 
10.02 
9.00 
8.56 
23.98 
4.90 
9.22 
8.19 
15.00 
7.08 
-10.00 
-10.00 
-3.97 
-10.00 
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Table 5. Mass 
spectrometer values 
for all compounds 
where the prod uct 
ions, declustering 
potential, collision 
energy and collision 
exit potential were 
optimised increased 
sensitivity. The 
internal standards 
are denoted with * 
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Quantification was performed using Analyst 1.4.1 (Applied Biosystems, 
Foster City, CA, USA). Identification of each compound in biological tissue 
was confirmed by LC retention times of each standard and precursor and 
product ion m/z ratios. Integration of each analyte was conducted to 
obtain peak areas and imported into Microsoft Excel for further data 
processing. 
2.2.6 Data Analysis 
Data were quantified and presented using Microsoft Excel 2010 and Prism 
(version 5.01; GraphPad, USA), and are expressed as mean ± SEM. 
Outliers greater than twice the standard deviation were excluded, which 
usually involved one or two samples in each batch analysed. 
Principal component analysis (PCA) was used for further data processing. 
PCA, a multivariate data analysis technique was used to identify and 
detect similarities and differences between datasets, which were 
translated into distances and can be easily visualised (See references in 
Witkamp 2005). Datasets for n variables are displayed as vectors in an n-
dimensional space and PCA was developed for statistical analysis of high 
dimensional data (small number of objects and a large number of 
variables). Any observed clustering of samples resulting from PCA 
provides strong evidence for statistically significant differences between 
or among datasets (Witkamp 2005). PCA was performed by importing the 
levels of each individual lipid measured from different tissue types from 
Microsoft Excel into the SIMCA-P software package (Version 11, Umetrics 
AB, Umea, Sweden). The data were reduced to two latent variables (or 
principle components) that will describe the maximum variation within 
the data (Law et al 2008) to create a two-component model expressed as 
scores and loadings plots. The principle components obtained from the 
scores highlighted clusters, trends and outliers within the dataset. 
2.2.7 Validation 
The majority of the analytes are found endogenously and there is no 
appropriate 'blank' matrix available for the validation. Therefore all the 
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analytes were spiked into rat brain tissue as a standard biological matrix 
to determine the accuracy, precision, recovery and ion suppression of the 
method. The rat brain tissue was frozen with liquid nitrogen and 
homogenised in a pestle and mortar, before distributing into 
approximately 100 mg aliquots. This was conducted to ensure that the 
background concentrations of all the endogenous analytes were equal 
between the replicate brain tissue sample aliquots used for validation. 
These endogenous concentrations of analytes were accounted for in all 
subsequent validation calculations. 
Seven-point calibration curves spiked into rat brain tissue were used for 
each of the thirty analytes at concentrations of 0.01, 0.025, 0.05, 0.1, 
0.5, 2 and 5 nmol/g. 2-AG was spiked at concentrations of 0.1,0.25,0.5, 
1, 5, 20 and 50 nmol/g to account for the high endogenous levels of this 
analyte in rat brain. These spiked validation samples were then extracted 
following the method described in the sample extraction section for brain 
tissue. Linearity was calculated using the peak area of each analyte 
expressed as a ratio to the peak area of the internal standard. This was 
chosen based on structural similarities and these calibration lines were 
also used to determine slope, intercept and the regression coefficient. 
Accuracy and precision values for intraday (n=5) and interday (n=4) 
were determined using rat brain tissue, spiked with each analyte added 
at concentrations of 0.02 (low), 0.2 (medium) and 0.8 (high) nmol/g. 2-
AG was spiked in at concentrations of 0.2, 2 and 8 nmol/g, reflecting its 
much higher endogenous concentration. 
Accuracy and precision values were calculated from the relative standard 
deviation (RSD) of the replicates. Accuracy values were determined as a 
ratio of the measured levels of each analyte to the expected 
concentration. An RSD of 15% was considered acceptable for the 
accuracy and precision values of each analyte for each concentration. The 
lower limit of quantification (LLOQ) was defined as the concentration at 
which the RSD of the analyte was found to be 20% or more. The limit of 
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detection (LOD) is defined as the concentration at which the signal to 
noise ratio is greater than 3: 1. 
Recovery values were calculated by comparing the peak area of each 
analyte at all three concentrations with the peak area of 100% standard. 
The endogenous levels of the analytes were taken into account when 
necessary for the calculations. 
Ion suppression values were calculated by spiking the analytes at the end 
of the extraction process to rat brain extracts. This was calculated by 
comparing the peak area of each analyte to 100% standard. 
2.2.8 Measurement of lipids in rat tissues 
Male Sprague-Dawley rats (340-450 g, Charles River Laboratories) were 
used and these experiments were conducted in accordance with the UK 
Home Office regulations. Animals were killed by stunning and 
decapitation and the blood collected by Professor David Kendall followed 
by rapid dissection of the spinal cord by Professor Vicky Chapman. The 
brain divided into frontal cortex, midbrain, hippocampus, rest of cortex 
and rest of brain regions were rapidly dissected by Professor David 
Kendall, the DRGs by Paul Millns, whilst I removed the knee joints. All 
tissue samples were transferred into liquid nitrogen immediately and the 
blood was centrifuged for separation and the plasma collected and 
frozen. All samples were stored immediately at -80 DC until analysis. 
Individual tissue samples were extracted following the different extraction 
procedures described in the sample extraction methods section. 
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2.3 Results and Discussion 
2.3.1 Development and optimisation of analytical method 
The incorporation of important inflammatory mediators alongside the 
endocannabinoids forms the rationale behind the development of this 
method. Previously it has been necessary to use separate methods for 
this purpose in our group (Richardson et al 2007, Zhang et al 2007). 
Addition of further eicosanoids to the method since the validation has 
resulted in a targeted analytical LC-MS/MS method of 42 compounds, 
which includes 6 internal standards (See Materials and Methods). 30 
compounds within this method have been fully validated and discussed 
later in the chapter. The different bioactive lipids have been combined 
into different groups according to the major route of synthesis or 
biological class (Table 6) to facilitate discussion of the validation and 
tissue distribution results. 
Table 6. Analyte groups of the bioactive lipids analysed with this LC-MS/MS method. 
Analyte groups COX LOX CYP450 ECs 
Metabolites PGs, TXs, LTs, HODEs, HETEs, EETs, AEA,OEA, 
PG-EAs, PG- oxoODEs, DHETs, PEA,2-AG, 
Gs HPETEs, HETE-EAs, AraGly, 
HETEs HETE-Gs, NADA 
EET-EAs, 
EET-Gs 
Lipid abbreviations: EET - epoxyeicosatrienoic acid, HETE - hydroxyeicosatetraenoic acid, 
HPETE - hydroperoxyeicosatetraenoic acid, AEA - N-arachidonoyl ethanolamide, 2-AG -
2-arachidonoyl glycerol, PEA - palmitoyl ethanolamide, OEA - oleoyl ethanolamide, 
AraGly - arachidonoyl glycine, NADA-N-arachidonoyl dopamine, EA - ethanolamide, G -
glycerol, LA - linoleic acid, HODE - hydroxyoctadecadienoic acid, oxoODE -
oxooctadecadienoic acid, PG - prostaglandin, TX - thromboxane, DHET -
dihydroxyeicosatrienoic acid, LT - leukotriene, ECs-endocannabinoids. Enzyme 
abbreviations: COX - cyclooxygenase, CYP450 - cytochrome P450, LOX - lipoxygenase. 
Profiling of both the endocannabinoids and eicosanoids within the same 
LC-MS/MS method was a difficult process due to the structural 
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differences between these two sets of compounds. In particular 
quantitative methodologies of this type require versatility, high 
sensitivity, selectivity and reproducibility, due to the small amounts 
detectable in different tissue types. This is also true for separation within 
the eicosanoids where the structural similarities between the HETEs, EETs 
and DHETs have been challenging with regards to selectivity (Figure 1). 
a) 
c 01-+ 
HO 
b) Ot-! 
1"1 
.I 
HO 
c) 
0 
HO 
Figure 1. Structures of a) 5,6-0HET, b) 5-HETE and c) S,6-EET. 
These structural complications require careful fine-tuning of LC and MS 
conditions and are discussed in detail in this chapter. 
2.3.1.1 Investigating the effects of temperature and pH on 
eicosanoid and endocannabinoid retention time 
The main factor for optimisation of the method was to allow simultaneous 
identification and detection of a large number of analytes in negative and 
positive mode. Significant factors that may alter the separation between 
the two groups of compounds are temperature and pH. Retention time 
variation with pH and temperature of the eicosanoids, which have an 
ionisable carboxylic acid group, was investigated (Figure 2). The initial pH 
of mobile phase A was measured to be 2.6 and increases in pH from this 
point were considered. Retention time was shown to decrease as pH 
increased (Figure 2a), with the greatest difference observed between pH 
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4 and pH 5, possibly around the pKa of this group of lipids. Fatty acids 
with a carboxylic group, such as the eicosanoids are classed as weak 
acids and short-chain fatty acids have a pKa typically around 4 and 5 
(Kanicky and Shah 2002). There was little change in the retention time of 
the endocannabinoids with pH (data not shown), as expected, due to 
absence of a -COOH group, with the exception of arachidonoyl glycine, 
the only endocannabinoid with a -COOH group that followed the 
eicosanoid trend (data not shown). 
Analysis of the compounds under the same conditions other than 
temperature change found that a temperature decrease at pH 7.1 from 
50 °C to 30°C had minimal effects on the retention time of the 
eicosanoids (Figure 2b) and endocannabinoids (data not shown). All other 
pH values were also investigated (pH 2.6-8.6) between SooC to 300 C and 
the results indicated that temperature had little effect (data not shown). 
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Figure 2. Retention time variation of the eicosanoids against a) pH at 30°C and b) 
temperature at pH 7.1, according to the gradient and cond itions in Table 7. 
Separation was achieved by optimising the pH of the mobile phase A to 
alter the retention times of the eicosanoids that contained an ionisable 
carboxylic acid group, thereby decreasing the retention time of these 
analytes. This allowed time for switching mass spectrometry ionisation 
modes to detect for the endocannabinoids in positive ion mode. pH was 
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adjusted initially by adding ammonium hydroxide to the desired pH and 
the final amount decided on was 6 ml of 1 in 10 dilution and 6 mL of 1 in 
100 dilution of 28 mM stock concentration of ammonium hydroxide to 
give a final pH around 8. Temperature was shown to have minimal effect 
and was therefore maintained at 30°c' 
2.3.1.2 Optimisation of the gradient to allow separation of two 
different classes of bioactive lipids 
The analytical challenge in this case was that there were two groups of 
lipids, one with a free carboxylic acid group suitable for negative 
ionisation mode; the other group were conjugated lipids better detected 
in positive ionisation mode. The method was optimised to allow 
simultaneous identification and detection of these two groups of lipid 
mediators. One method originally developed at the University of 
Nottingham, Zhang et al 2007, was chosen as an initial starting pOint, 
incorporating a simpler gradient for separation of both classes of 
bioactive lipids. Investigation of a suitable gradient initially involved a 
great deal of trial and error and the initial gradient is shown in Table 7. 
Table 7. Initial gradient used for the separation of eicosanoids and endocannabinoids 
Time (min) A-O.050J0 formic acid In B-methanol:acetonitrile 
water (%) (20:80 v/v) (Ofo) 
0 40 60 
18 a 100 
25 0 100 
25.1 40 60 
31 40 60 
The same method was used to analyse a 100 ~ M M stock solution of the 
endocannabinoids to investigate whether any of these compounds would 
be detectable in negative mode. Even at this high concentration, none of 
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the endocannabinoids gave a response in negative ion mode, hence 
confirming that it was essential to use electrospray positive ion mode for 
these compounds (data not shown). Analysis was repeated using positive 
mode, which produced effective detection of the compounds using the 
conditions of the eicosanoid LC-MS/MS method and the initial gradient. 
The next step was to alter the gradient and improve the chromatography 
of both sets of compounds, to optimise run time and separate the 
compounds further to avoid co-elution. Initial conditions were increased 
to a higher percentage of organic solvent, 65% and 70%, which 
decreased the elution time of both sets of compounds by almost 5 min, 
minimising run time. 15 different gradients were compared, which 
involved altering the initial percentage of mobile phase B and extending 
the time that mobile phase B was maintained at a lower percentage. This 
was chosen to extend the elution time of the endocannabinoids and to 
increase the time interval between eicosanoid and endocannabinoid 
elution. Further alterations to the gradient were made by altering the 
length of time held at 80% organiC, as this was found to be the starting 
organic percentage for endocannabinoid elution. All gradients were tested 
with initial starting conditions of 65% and 70% mobile phase B. However, 
there was still a degree of overlap between the last eicosanoid and the 
first endocannabinoid, so a shallower gradient was required. Further 
analysis found that the elution of the eicosanoids was around 70%, so 
this was held for a further 11 min. AEA elution was also found to be 
around 75% B and therefore this was held for around 7 min to give the 
final gradient (Table 8). Comparison of the initial gradient (Table 7) and 
the final gradient (Table 8), found that the compounds eluted much 
earlier in the run, however the separation was still not apparent. 
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Table 8. Last gradient used for the separation of eicosanoids and endocannabinoids, 
which was further optimised following the addition of prostaglandins, leukotrienes, HODEs 
and oxoODEs, as discussed later. 
Time (min) A-O.OS% formic acid in B-methanol:acetonitrile 
water (%) (20:80 v/v) (%) 
0 30 70 
11 30 70 
18 25 75 
25 0 100 
25.1 30 70 
31 30 70 
Following the addition of new lipid mediators to the method, the gradient 
was further optimised to allow incorporation of these compounds. The 
percentage of mobile phase B was decreased to 45% to allow better 
separation of the early eluting compounds such as PGD2IPGE2 and TXB2 , 
where the chromatography was extremely poor at the higher 70% 
organic phase. To further delay the elution time and therefore improve 
separation of the 35 analytes detected in negative mode, the gradient 
was modified to increase from 45% to 50% organic at 7.50 min (Table 3) 
before increasing to 70% at 13.50 min. The modifications to the flow rate 
from 0.2 mL/min starting flow rate up to 0.25 mL/min and 0.3 mL/min 
was also optimised to alter elution time of some of the analytes. Thereby 
increasing the gap between the last analyte in negative mode and the 
first analyte in positive mode and extending time for switching modes. 
The final gradient is a mixture of fine tuning between the length of time 
and percentage of organic phase coupled to the speed of the flow rate. 
The negative to positive mode switch is around 18.50 min and during this 
time the gradient was increased from 70% to 100% organic. This enabled 
the elution of the endocannabinoids and the two metabolites, 5,6-EET -EA 
and 14,15-EET-G, which were established during the initial gradient 
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development stage. At 22.50 min, a third pump C was used to introduce 
100% acetonitrile as a mobile phase. The reason for this extra step was 
to ensure a complete column wash at the end of each run to minimise 
carryover between injections. The difference in gradient between this 
new method and the original endocannabinoid method (Richardson et al 
2007) was that the original method utilised 100% acetonitrile as mobile 
phase B which may have helped wash the column at the end of each 
analytical run. The mobile phase B of this new method contained 
methanol:acetonitrile (20:80 v/v) and this 80% acetonitrile may not be 
sufficient to diminish any carryover. At 22.50 min, an event triggers the 
valve to rotate from position 0 to position 2, this in turn allows flow from 
pump C only for 3.50 min. Following this, a second event triggers the 
valve to rotate back to position 0, with the gradient set at initial 
conditions and the column is re-equilibrated for the remaining 4 min of 
the analytical run. 
Optimisation of peak shape and resolution of the HETEs and EETs were 
also achieved using a longer length column, changing the original 100 
mm length column to a 150 mm. This was found to produce improved 
separation for these two groups of eicosanoids. 
Chromatographic separation of the structurally similar DHETs, HETEs and 
EETs (Figure 1) were also achieved by a combination of this complex 
gradient (Table 3), timing of organic phase changes and a longer column 
length. Elution times based on organic phase percentage was carefully 
considered to enable separation of these analytes. Some of the standards 
purchased, namely the EETs, are racemic mixtures of the analyte. The 
chromatography of this method is able to separate these into two clear 
peaks, an example of which is shown in Figure 3. 
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Figure 3. Separation of ll - HETE and ll,12-EET according to the final gradient in Table 4, 
there are clearly two distinct peaks for ll,12-EET as the standard is purchased as a 
racemic mixture or (± )ll,12-EET. 
Jiang et al have previously mentioned the existence of cis- and trans-
EETs, which vary in potency in their biological actions and 5,6-trans-EET 
has been identified in erythrocytes (Jiang et al 2004). 5,6-cis-EET has 
been shown to elute first followed by 5,6- trans-EET (Jiang et al 2004). 
2.3.1.3 Optimisation of mass spectrometry parameters 
Unique product ions for each analyte were used to distinguish between 
analytes and to enable quantification either by retention time or MRM 
transition. For example, the MRM transition m/z 319.24-155.08 was used 
for detection of 8-HETE (retention time 11.5 min) and 8,9 -EET (retention 
time 13.2 min). Detection by retention time at the same MRM transition 
also applied to 11-HETE and 11,12-EET and also to 15-HETE and 14,15-
EET. MRM transitions used were based on previous methods (Richardson 
et al 2007, Zhang et al 2007), Lipid Maps database (Lipid Maps-Nature 
Lipidomics Gateway, February 2010) and further optimisation conducted 
experimentally using product ion scans. The approach of combined 
measurement of 1-AG and 2-AG was also adopted in this method as in 
previous methods (Richardson et al 2007). 
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Further optimisation was necessary for 12-HPETE; using the precursor 
ion [M-H]- of m/z 335, the abundance was low. Previous methods have 
also mentioned the difficulties of HPETE analysis, where the 
fragmentation of these lipids was investigated in relation to modifying 
orifice potentials (MacMillan and Murphy 1995). They observed a 
reduction in abundance of the precursor ion m/z 335 with increasing 
orifice potential. This was also applicable in this method where 
optimisation of the declustering potential to -85 V resulted in a low 
abundance of the m/z 335 ion, but higher abundance of the m/z 317. The 
stability of this analyte was also questioned due to the presence of a 
hydroperoxy- or -O-OH group. HPETEs are thermally labile and if 12-
HPETE is unstable and loses water in the ion source producing a m/z 317 
ion, this could then be monitored as the precursor ion. Therefore, product 
ions of this analyte were investigated and the spectra confirmed this 
hypotheSis (Figure 4). 
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Figure 4. Product ion spectra of 12-HPETE, including the structure of this analyte, 
according to the mass spectrometry conditions in Table 5, m/z 317.23>153.10, DP -80V, 
CE -24V and CXP -10.7SV. 
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The focus of optimisation work was to look for strong product ions of this 
analyte, so the scan was set from m/z 50 to m/z 350. The strongest 
product ion was m/z 317, the precursor ion minus water [M-H20r, which 
is a common trait in this type of lipid analysis (Garscha et al 2008, 
Havrilla et al 2000, MacMillan and Murphy 1995). This was followed by a 
product ion of m/z 273 which is a further loss of COO-, to give [M-H 20-
COO]-, however the m/z 273 product ion was common to both 5-HPETE 
and 12-HPETE. A unique product ion of m/z 153 of the 12-HPETE was 
therefore selected for the MRM transition. The precursor ion of m/z 317 
was also applied to 5-HPETE during the optimisation of this analyte. 
Further work was also required to distinguish between PGD2, PGE2 and 
TXB2 , due to the similarities in structure (Figure 5). 
o 
a) OH c) OH 
HO 
Figure 5. Structures of a) PGD2, b) PGE2 and c) TXB 2• 
All three analytes have the same retention time in this method and also 
share identical product ions. Several concentrations of individual PGD2 , 
PGE2 and TXB2 standards and a mixture of the three were analysed using 
product ions scans, along with an unspiked brain sample known to 
contain these three analytes. The spectrum of the sample for each 
analyte was compared to the concentration most closely resembling the 
concentration detected in the sample. Investigation of the individual 
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product ion spectra of each analyte confirmed the unique product ion of 
m/z 169.09 of TXB2 (Figure 6), which was apparent in both the sample 
and standard spectra. 
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Figure 6. Product ion spectra of a) TXB2 standard, b) TXB2 peak in a brain sample, c) PGD2 
standard and d) PGE2 standard according to the mass spectrometer conditions in Table 5. 
Therefore the MRM transition of m/z 369.23> 169.09 was used for 
detection of TXB2 • However, PGD2 and PGE2 have very simi lar product ion 
spectra and it was extremely difficult to find a unique product ion where 
the MRM transition provided a reasonable signal to noise ratio greater 
than four. A unique product ion of m/z 175.11 was found for PGE21 but 
using this MRM transition of m/z 351.22>175.11 did not give a 
detectable signal where the Signal to noise ratio was greater than four. 
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Figure 7. 3D chromatogram of the individual separation of each analyte. 
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This issue has also been discussed in an LC-MS/MS analytical method of 
15 eicosanoids, where these two lipids were only differentiated by low-
abundance product ions and a degree of cross-detection was apparent 
(Margalit et al 1996). Consequently these two analytes were expressed 
as a mixture, because the product ion for the MRM transition used was 
common to both PGD2 and PGE2 (Figure 6). Other groups have managed 
to separate these two analytes chromatographically, however all these 
methods only use negative ionisation mode and/or focus on a selective 
number of lipids (Brose et al 2011, Masoodi et al 2010). Thus, the 
inability to separate PGD2 and PGE2 is a limitation of the developed 
method but was deemed acceptable in view of the comprehensive 
analysis of a wide range of bioactive lipids. 
Selectivity of the method was investigated during the validation by 
examining individual MRM chromatograms. No significant interfering 
peaks were found in the MRM channels of each analyte or internal 
standard, demonstrating the lack of 'crosstalk' between these channels 
which might compromise selectivity. This was particularly important for 
the HETEs and EETs that shared the same MRM transition and were only 
distinguishable by retention time. 
A 3D chromatogram showing the separation of all 42 analytes, with the 
exception of PGD2 and PGE2, highlights the complexity of this method 
(Figure 7, Table 5). 
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2.3.1.4 Investigating the effects of reconstitution and injection 
volume on sensitivity 
Initially the endocannabinoids were used as a basis for optimisation work 
since these were the analytes with the least solubility in polar solvents 
and hence any conditions would be readily suitable for the more polar 
eicosanoids. Firstly, reconstitution was investigated to determine whether 
this factor could be optimised to increase sensitivity. Reconstitution with 
100% acetonitrile was found in previous work to give the best recovery of 
the endocannabinoids without detrimental effects on peak shape 
(Richardson et al 2007). Inclusion of the eicosanoids meant the 
possibility of introducing a more polar injection solvent such as water, 
specifically with a view to allowing a greater injection volume without 
degradation of peak shapes. 
1 g of rat brain tissue was extracted following the methods described 
earlier. This extract was further divided into 7 replicate aliquots, labelled 
tubes A-G, and the contents of each tube was evaporated to dryness 
under nitrogen. Each tube was then reconstituted with different 
percentages of water, with one containing 100% acetonitrile. All the 
chromatograms showed good separation and detection of the 
endocannabinoids without losing resolution and reconstitution with the 
various aqueous combinations found that acetonitrile:water (50:50 v/v) 
gave the best total peak area value for all the endocannabinoids without 
loss of peak shape (Table 9). 
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Table 9. Total peak areas of the endocannabinoids in the reconstitution experiment, 
using a C18 Phenomenex Luna (100 x 2.0, 3 IJm 1.0) column with mobile phase A (0.05% 
formic acid in water) and mobile phase B (methanol:acetonitrile (20:80 v/v) according to 
the initial conditions in Table 7. 
Reconstitution 
Tube Water (%) Total EC (Peak Area) 
A 0 217519 
B 25 240299 
C 50 259412 
D 60 70372 
E 70 24729 
F 80 24772 
G 90 31452 
Increasing the percentage of aqueous above 50% decreased the peak 
areas as expected due to the lipophilic nature of these compounds. These 
results were also applicable for the eicosanoids due to the similarities in 
chemical structures and the more polar nature of these lipids. 
Afterward, sample injection volume was investigated using 
acetonitrile:water (50:50 v/v). The standard injection volume used was 5 
IJL, however, with a higher reconstitution percentage of aqueous, the 
tolerable injection volume for the column was investigated. Under the 
same conditions, 5, 10, 15, 20 and 25 IJL injection volumes were 
considered. Again, all injection volumes investigated showed good 
chromatographic separation of the endocannabinoids, with 20 and 25 IJL 
displaying the highest signal intensity (Table 10). However, 20 IJL gave 
the greatest peak areas for all the endocannabinoids. 
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Table 10. Total peak areas of the endocannabinoids in the injection volume experiment, 
using a C18 Phenomenex Luna (100 x 2.0, 3 101m I.D) column with mobile phase A (0.05% 
formic acid in water) and mobile phase B (methanol:acetonitrile (20:80 vlv) according to 
the initial conditions in Table 7. 
Tube Injection Volume (ilL) Total EC (Peak Area) 
A 5 40152 
B 10 113442 
C 15 576385 
D 20 1616691 
E 25 1284331 
The eicosanoids were also found to be detectable following the conditions 
and parameters of the existing LC-MS/MS method (data not shown). 
Optimisation of sensitivity was achieved following minor alterations to the 
existing method, which was applied to future development work, and the 
structural similarities of the endocannabinoids and eicosanoids were 
taken into account. 
2.3.2 Validation 
The validation results for this method are shown in Table 11 and it is 
important to note that there are few published lipid profiling methods 
that have provided full validation data. Values are represented as %RSD 
(relative standard deviation) of individual replicates and conducted 
according to the validation section in methods described earlier. 
--' 
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Table tta. Validation table of all 30 compounds investigated, n = 6 for accuracy and precision values for low, medium and high concentrations. 
AIUIIyte RZ s!!e! ConcentnItion , £112 ~ l l l 
PGDrEA 0.993 y=1.47x+0.161 0.02 60 ± 3 61 % 6 5 105 10 96 
0.2 50 ± 5 60 % 7 9 103 9 102 
0.8 60 ± 5 74 % 4 101 5 103 
PGE,-EA 0.993 y=15.2x+2.09 0.02 59 ± 4 50 % 3 3 92 14 86 
0.2 60 ± 3 60 % 7 6 114 9 108 
0.8 67 ± 4 78 % 6 2 112 7 102 
PGEz-EA 0.993 y=I.47x+0.161 0.02 60'" 3 61 * 6 5 105 10 96 
0.2 50 * 5 60 % 7 9 103 9 102 
0 .• 60 ± 5 74 %4 101 5 103 
PGFza-EA 0.999 y=24.7x+1.10 0.02 51 % 4 48 * 2 5 94 13 88 
0.2 51 % 3 54 * 7 5 112 7 105 
0 .• 57 *3 72 * 5 2 110 7 102 
5,6-DHET 0.993 y=0.733x+0.0635 0.02 89* 9 43 * 6 15 93 11 98 
0.2 70 ± 3 75 * 11 6 98 10 99 
0 •• 69 * 4 87 * 6 4 96 11 100 
.,9-DHET 0.998 y= 1. 70x+0, 136 0.02 83 % 9 55 * 4 9 96 13 88 
0.2 76 * 3 74 % 11 9 114 8 101 
0 •• 70 * 5 93 * 5 4 112 9 101 
11,12-DHET 0.995 y=4.43x+0,399 0.02 93 * 9 56 * 4 7 100 14 103 
0.2 77 % 3 81 * 11 9 111 11 100 
0 •• 70 % 5 94 * 6 4 111 10 99 
14,lS-DHET 0.994 y= 1, 7lx+0.171 0.02 34 * 6 21 * 3 8 90 14 87 
0.2 25 ± 2 23 ± 3 12 103 7 96 
0 •• 26'" 2 36 * 2 6 109 11 104 
~ . .
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Table llb. Validation table of all 30 compounds investigated, n = 6 for accuracy and precision values for low, medium and high concentrations. 
R' 5 Conc:entratIon 
0.931 y=0.285x+0.0625 0.02 36 ± 4 72 ± 22 12 92 27 101 
0.2 24 ± 3 40 ± 8 15 103 19 111 
0.8 18 ± 2 70 ± 20 5 96 15 85 
5-HETE 0.991 y=2.59x+0.266 0.02 69 ± 11 57 ± 3 10 94 6 100 
0.2 84 ± 8 80 ± 10 13 111 11 105 
0.8 86 * 8 99 ± 7 8 106 14 103 
IHtETE 0.998 y=3.10x+0.106 0.02 67 * 19 80 ± 7 13 106 13 102 
0.2 86 * 7 82 ± 11 8 103 8 101 
0 .• 68 ± 4 99 ± 9 3 101 5 98 
9-HETE 0.995 y=0.897x+0.0743 0.02 74 * 21 58 * 9 14 103 10 98 
0.2 75 * 7 83 ± 13 7 107 7 100 
o.a 66 * 5 99 ± 8 4 108 7 98 
ll-HETE y=7.91x+0.0967 0.02 64*11 63 ± 3 7 103 6 105 
0.2 83 ± 9 76 ± 9 14 107 9 103 
0 .• 74 ± 4 96 * 6 3 98 8 101 
12-HETE 0.997 y=3.11x+1.75 0.02 87 ± 9 97 * 7 14 106 10 105 
0.2 85 ± 2 91 ± 15 2 104 5 104 
o.a 85 * 4 103 ± 13 5 107 5 104 
15-HETE y=1.90x+0.121 0.02 54 ± 24 78 ± 3 2 114 13 102 
0.2 91 ± 10 85 ± 11 15 98 10 98 
0.8 77 * 5 100 ± 8 2 93 6 99 
16-HETE y=2.32x-0.0024 0.02 86 ± 9 55 ± 4 9 97 14 91 
0.2 75 * 5 78 ± 9 9 105 9 99 
0.8 74 ± 5 100 ± 8 4 107 8 104 
..,. 
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Table lie. Validation table of all 30 compounds investigated, n = 6 for accuracy and precision values for low, medium and high concentrations. 
Ana!!!! R' S!!:I!! CoIIclentratIon 
I .. HETE y=1.12x+0.008 0.02 99 * 14 6 110 15 101 
0.2 82 * 4 56 * 7 9 105 7 95 
0 •• 76 * 4 74 * 5 4 105 10 101 
2G-HETE y=0.325x-0.0008 0.02 90 * 9 54*11 12 102 21 102 
0.2 69 * 9 81 * 13 12 99 9 100 
0 •• 79 * 6 99 * 7 3 98 10 100 
5,6-EET y=1.16x+0.0144 0.02 103 * 16 61:% 12 14 99 13 92 
0.2 99:% 4 109:% 16 5 89 11 99 
0 •• 92 * 7 116*8 10 113 14 97 
.,9-£ET 0.991 y=0.896x+0.0876 0.02 58:% 10 46:% 4 10 98 13 93 
0.2 72:t 7 79:t 9 13 105 10 104 
0.8 62:% 4 97 *7 5 108 13 105 
11,12-£ET 0.991 y=0.742x+0.0742 0.02 80::t 12 44 * 7 11 104 11 89 
0.2 81 * 7 68::t 9 10 103 12 101 
0.8 79::t 8 95 * 9 9 112 14 99 
14, 15-EET 0.995 y=1.63x+0.0427 0.02 73::t 3 52 * 6 12 104 8 111 
0.2 75 * 11 76:% 11 11 103 7 99 
0.8 67:% 6 110*8 9 112 10 102 
5-HPETE y=0.399x+0.0194 0.02 31::t 6 38 * 4 11 93 14 97 
0.2 23::t 3 35 * 3 15 102 14 95 
0.8 25 * 3 5S * 4 7 103 14 101 
5,6-EET-EA 0.999 y=0.166x+0.0047 0.02 61 * 8 Sl * S 10 93 13 98 
0.2 64 * 6 68::t 10 7 100 12 99 
0.8 70 * 7 93 * 7 S 94 12 101 
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Table lid. Validation table of all 30 compounds investigated, n = 6 for accuracy and precision values for low, medium and high concentrations. 
R2 5 Concentration 
0.995 y=1.39x+0.108 0.02 80 ± 14 51 ± 7 13 102 13 99 
0.2 74 ± 8 70 ± 10 11 94 12 94 
0 •• 66 ± 6 99 ± 9 12 107 15 103 
PEA 0.999 y=2.25x+0.0495 0.02 75 ± 5 45 ± 2 14 105 15 103 
0.2 75 ± 10 39 ± 5 4 111 13 109 
0 •• 82 ± 2 72 ± 2 12 104 10 98 
OEA 0.971 y=2. 71x+ 1.04 0.02 52 ± 17 62 ±4 3 102 13 101 
0.2 67 ± 9 68 ± 6 11 lOB 7 97 
0 •• 53 ± 6 92 ± 4 6 112 16 99 
Au. 0.996 y=1.08x+0.134 0.02 34 ± 8 72 ± 2 15 113 4 106 
0.2 56 ± 9 78 ± 10 8 111 9 106 
O.S 5B ± 5 111 ± B 5 103 7 101 
2-AG 0.99 y=3.93x+3.79 0.02 54 ± 11 102 ± 6 11 95 15 100 
0.2 51 ± 6 133 ± 19 6 113 13 111 
O.S 51 ± 1 87 ± B 12 104 11 110 
NADA 0.996 y=18.1x-l.20 0.02 92 ± B 45 ± 7 8 96 13 92 
0.2 66 ± 10 86 ± 15 8 100 10 104 
O.S 62 ± 4 109 ± 11 5 101 11 100 
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Linearity of the method was confirmed by a 7-point calibration curve of 
each analyte over a range of 0.01 - 5 nmol/g. The correlation coefficients 
( ~ ) ) in the validation ranged from 0.9311 to 0.9999 (Table 10). Recovery 
values also show that this method provided good recoveries (50-103%) 
for the majority of the analytes for low, medium and high concentrations, 
although some were below 50% (18-36%). Some of the analytes 
validated such as 12-HPETE has been shown to be fairly unstable and 
consequently gave much lower recovery values (18-36%). 12-HPETE has 
been shown to partly dehydrate to the corresponding oxoeicosatetraenoic 
acid (OETE) in the heated capillary of the mass spectrometer during 
electrospray ionisation (Liminga and Oliw 2000, Piomelli et al 1988). The 
strongest product ion in our method as discussed earlier was m/z 317, 
the precursor ion of 12-HPETE minus water [M-HzOr and may explain the 
poor recovery values for this particular lipid. Calculations of recovery, 
particularly for the lowest validation concentrations of endocannabinoids 
and some eicosanoids, were impeded due to endogenous levels of these 
in rat brain. High endogenous background concentrations subtracted from 
low concentrations of spiked standard can often lead to an overestimation 
of recovery. The results are comparable to previous work 49-90% (De 
Grauw et al 2011), 67-251% (Masoodi et al 2010), 54-92% (Zhang et al 
2007) and there were a greater number of validated analytes in this 
method compared with other published methods. The limit of 
quantification (LOQ) for all lipids was found to range from 0.05 to 2.5 
pmol/g and comparable to other methods (Richardson et al 2007, Zhang 
et al 2007), however some methods express this as a ratio of signal to 
noise rather than a calculated value (Masoodi et al 2008). 
The phenomenon of matrix effects is widely reported in LC-MS/MS 
(Trufelli et al 2011, Kittlaus et al 2011, Matuszewski et al 2003, King et al 
2000), which can be detrimental to the sensitivity of the method. Hence, 
ion suppression was also investigated where 100% represented the value 
for the absence of a biological matrix. The results range from 20% to 
110%, with the lowest concentration generating the poorest figures 
(Table 11). As mentioned, matrix effects can affect sensitivity and 
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decrease the response of an analyte, which unsurprisingly has a greater 
effect on the lowest concentration. Overall, the results showed that the 
majority of the analytes were minimally affected by the matrix. Previous 
work on ion suppression looked at the internal standards 15-HETE-d8 
(104%) and 11,12-EET-d8 (96%) along with 8,1S-diHETE (112%) and 
also showed that there were minimal matrix effects (Zhang et al 2007). 
The accuracy and precision data for intraday (n = 5) and interday (n = 4) 
are shown in Table 10. The results for each analyte were within the 
recommended RSD of <±1S% for accuracy and precision for intraday and 
accuracy for interday. A few values for interday precision were not within 
this recommended range, 12-HPETE at the low (27%) and medium 
(19%) concentration and 20-HETE (21%) at the low concentration. The 
intraday precision range was between 1.4 and 14.9% and the interday 
precision range was between 3.8 and 26.8%. The intraday accuracy 
range was between 89.2 and 114.3% and the interday precision range 
was between 85.2 and 111.4%. 
A few of the values that were slightly higher than the recommended 
RSD% can be explained by the poor sensitivity of 12-HPETE and 20-
HETE. Looking at the chemical structure and spectra (Figure 4 and 8), 
both 12-HPETE and 20-HETE have a limited number of product ions at 
detectable intensities. 20-HETE has been found previously to only show 
dissociation at higher collision energies and also this particular lipid did 
not exhibit a large number of structurally significant product ions like the 
other HETEs (Masoodi et al 2010). This finding agrees with the results 
seen in this method, where it was also a challenge to find a product ion 
with sufficient sensitivity for MRM detection. 
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Figure 8. Product ion spectra of 20-HETE and the fragmentation of this lipid. 
99 
Both 20-HETE and 12-HPETE had reduced sensitivity compared with the 
other analytes, and this should be noted in view of the lack of detection 
of these lipids in any of the biological samples studied. 
2.3.3 Measurement of bioactive lipids in rat tissues 
The newly developed method was evaluated by analysing the bioactive 
lipid profiles of a range of rat tissues/biofluids which would be 
representative of studies planned for future work (included in later 
chapters of this thesis). 
2.3.3.1 Comparison of the lipid profiles in different rat tissues 
Spinal cord, dorsal root ganglia (ORGs; L3-LS), knee jOint, plasma and 
five brain regions: frontal cortex, midbrain, hippocampus, rest of cortex 
and rest of brain were collected from saline treated rats according to the 
methods described earlier. These samples were analysed using the 
validated method to measure levels of bioactive lipids in different tissues. 
A profile of the different bioactive lipids in each type of tissue was created 
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to look at the overall distribution. 9-HODE was yet to be incorporated into 
the method at the time when this analysis was performed, therefore the 
data presented do not include this analyte. For convenience, the bioactive 
lipids have been grouped into four analyte groups related to their 
biosynthetic pathways, this is clearly shown earlier in this chapter in 
Table 6. These include the cyclooxygenase (COX), lipoxygenase (LOX), 
cytochrome p450 (CYP450) and endocannabinoid (EC) groups. 
In the rat knee joint 5-, 11-, 12-, 15-HETE, AEA, PEA, OEA, 2-AG, 
AraGly, PGD2IPGE2 , TXB2, AA, LA, 13-HODE, 9-, 13-oxoODE were all 
detected (Figure 9, Table 11). The majority of the analytes measured in 
the tissue are from AA (90%), LA (2%) and 2-AG (5%) and have 
therefore been excluded to give a clearer distribution of the other 
analytes in the tissue (Figure 9b). Likewise in rat plasma, 5-, 11-, 12-
HETE, AEA, PEA, OEA, 2-AG, AraGly, PGD2IPGE2 , AA, LA, 13-HODE, 9-
and 13-oxoODE were all detected (Table 12) with the major lipids being 
AA, LA and 2-AG (99%). 8-, 15-HETE, TXB2 and AraGly were all below 
the limit of quantification in these samples. Again, AA and 2-AG have 
been excluded for reasons of clarity in all figures to provide a better 
distribution of all the other lipids detected (Figure 9). 
The distribution of bioactive lipids in plasma and knee (Figure 9) were 
clearly different to the distribution of lipids found in neural tissue such as 
spinal cord, DRGs and brain (Figure 9). The majority of the bioactive lipid 
profile of knee joint and plasma were made up of LA, AA and 2-AG, 
whereas in neural tissue the proportion of LA is relatively small and the 
major lipids are AA and 2-AG (Table 12). 
a) 
2500 
2000 
~ ~
~ ~ 1500 
~ ~
.. 
c 
61000 
E 
<C 
b) 
500 
o 
2000 
1800 
1600 
tiD 1400 
-~ ~ 1200 
~ 1 0 0 0 0
c 
6 800 
E 
<C 600 
400 
200 
o 
101 
COX 
iii LOX 
Cyp 
LA 
II ECs 
Knee Spinal Cord DRGs Brain Plasma 
COX 
LOX 
Cyp 
II ECs 
Knee Spinal Cord DRGs Brain Plasma 
Figure 9. a) Lipid distribution of the measured analytes in knee joint, spinal cord, DRGs, 
brain and plasma, excluding 2-AG and AA in wet weight tissue, n=8. All values for knee, 
joint, spinal cord, DRGs and brain are in pmol/g and plasma in pmol/mL. b) Lipid 
distribution of the measured analytes in knee joint and plasma, excluding LA, 2-AG and 
AA. 
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Table 12. Levels of individual analytes measured in knee joint, spinal cord, DRGs, brain regions; frontal cortex, midbrain, hippocampus, rest of cortex, 
rest of brain and plasma in pmol/g in all wet weight tissue and pmol/mL in plasma, except for 2-AG, which is in nmol/g and nmol/mL respectively. 
araln Regions 
Knee JoInt nalCord Frontal Cortu Midbrain Rest of Cortex Rest of Brain Plasma 
PGD2/PGE2 282 * 26 587%195 496 t46 236 * 13 128 * 28 76 * 28 257 * 40 307 * 114 0.5 * 0.6 
TXa2 48 * 4 399*133 608 t63 64 * 12 61 * 14 23 * 8 32 * 9 35 * 13 BLOQ 
13-HODE 21 * 3 9*3 18 * 4 3*2 3*1 23 * 12 14 * 8 19 * 9 23 * 2 
13-oxoODE 0.5 * 0.1 NO NO NO NO NO NO NO 8 * 1 
lS-HETE 23 * 2 22 * 6 BLOQ 6*4 2 * 1 2 * 1 7 * 1 7*2 BLOQ 
9-oxoODE 2 * 0.3 NO NO NO NO NO NO NO 6 * 1 
ll-HETE 8*1 15 * 3 31 * 6 9 * 1 3 * 0.4 4 * 0.2 7 * 1 3 * 0.5 2 * 0.5 
12-HETE 71 * 7 82 * 22 358 * 68 8*2 9*2 6*2 8*2 16 * 3 34 * 4 
a-HETE 2 * 0.2 2 ± 1 BLOQ 2 * 1 BLOQ BLOQ 1 * 0.4 0.3 * 0.2 BLOQ 
5-HETE 2 ± 0.2 11 * 4 BLOQ 3 * 1 1 ± 0.4 1 * 0.2 1 * 0.3 1 * 0.2 2 ± 0.2 
AnGIy 0.3 *0.1 1 ± 0.5 BLOQ 1 ± 0.3 1 ± 0.5 1 * 0.4 1 ± 0.4 1 * 0.4 BLOQ 
LA 300 * 40 74 ± 10 80 * 19 24 ± 3 24 * 3 19 * 4 26 * 3 36 * 5 221 * 22 
AA 16 * 1 84 ± 17 31 ± 4 15 * 3 11 * 2 9*3 10 * 3 8±3 27 ± 4 
AEA 1.4 * 0.1 4 * 0.5 4 * 1 3 ± 0.3 3 ± 1 2 * 0.4 3*1 2 ± 0.5 1 * 0.1 
2-AG 1 ± 0.1 8 ± 1 1.3 ± 0.1 3 ± 0.5 6 ± 1 4 * 0.5 3 ± 0.5 3 * 1 48 * 15 
PEA 9*2 116 * 19 233 * 33 23 * 5 46 * 7 22 * 2 13 ± 2 20 * 3 7 ± 0.3 
OEA 4 * 1 60 * 9 118 * 18 11 * 1 23 * 4 9 * 1 8*1 10 ± 1 6 ± 1 
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All values are expressed as mean ± SEM in pmol/g for tissues, except for AA and 2-AG in 
nmol/g, n=8. All values for plasma are in pmol/mL, except for AA in nmol/mL. All outlier 
values greater than 2 standard deviations from the mean were excluded, maximum of 
one per tissue group for each lipid measured. Some lipids were not detected (NO) in any 
of the samples, others were only detected in a few samples and were therefore below the 
limit of quantification (BLOQ). 
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In neural tissue, levels of several lipids found in the DRGs were very high 
when compared to the spinal cord and brain (Figure 9). In the DRGs, 11-, 
12-HETE, AEA, PEA, OEA, 2-AG, PGD2iPGE2 , TXB2 , AA, LA and i3-HODE 
were all detected (Figure 9, Table 11). This was similar to the spinal cord 
(Figure 9, Table 11), although AraGly along with 5-, 8- and 15-HETE 
were below the limit of quantification in the DRGs. In the DRGs 91% of 
the distribution of lipids measured consisted of AA, with 2-AG making up 
4%. In the spinal cord, 5-, 8-, 11-, 12-, 15-HETE, AEA, PEA, OEA, 2-AG, 
AraGly, PGD2iPGE2, TXB2 , AA, LA and 13-HODE were all detected (Figure 
9, Table 11) and consisted mainly of AA (90%) and 2-AG (8%)(both 
excluded). The distribution of lipids found in the spinal cord was also very 
similar to the brain (Figure 9). The main difference between neural tissue 
and the knee and plasma was the huge amounts of AA compared to LA. A 
reason could be because neurons are not capable of synthesis of AA from 
LA by elongation and desaturation, which occurs in other cells. Free AA is 
rapidly stored by esterification to membrane phospholipids until needed 
for regulation of neuronal activity (Piomelli 1994, Piomelli 1993). Once 
released AA can either be metabolised by COX, LOX or CYP450s to 
produce lipids that act within neurons to modulate the activities of ion 
channels, ion pumps, protein kinases and neurotransmitter uptake 
systems (Piomelli 1994). These three routes of AA metabolism have also 
been extensively described in the brain for many years (Farooqui et al 
2007, Phillis et al 2006, Kauffmann et al 1997, Needleman et al 1986). 
Additionally, brain tissue was subdivided into regions for analysis (See 
methods). 5-, 8-, 11-, 12-, 15-HETE, AEA, PEA, OEA, 2-AG, AraGly, 
PGD;JPGE2, TXB2, AA, LA and 13-HODE were all detected in the frontal 
cortex, rest of cortex and the rest of brain. All of these were also 
detected in the midbrain and hippocampus except 8-HETE, which was 
below the limit of quantification (Figure 10, Table 11). In the frontal 
cortex AA made up 82% of the distribution, with 2-AG the remaining 
16% (both excluded). This was similar for the midbrain, hippocampus, 
rest of cortex and rest of brain regions, where AA made up 66-76% of 
the distribution with 2-AG a large proportion of the remainder. The main 
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components of brain tissue were the fatty acids AA and LA, 
endocannabinoid-like compounds OEA and PEA and the COX-2 
metabolites TXB2 and PGD:JPGE2 • PGE2 is the main product of the COX 
pathway and is involved in brain maturation and the regulation of 
synaptic activity and plasticity (Alix et al 2008). The fatty acids as 
mentioned in the introduction are important instigators of many neuronal 
processes by production of a cascade of products via different enzymatic 
pathways (Table 6). 
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Figure 10. Lipid distribution of the measured analytes in rat brain divided into five 
regions; frontal cortex (Fe), midbrain (MID), hippocampus (HIP), rest of cortex (ROC) 
and rest of brain (ROB) in pmol/g, n=8. All outlier values greater than 2 standard 
deviations from the mean were excluded, maximum of one per tissue group for each lipid 
measured . 
The main difference when comparing the DRGs to spinal cord and brain 
are the high levels of 12-HETE. In the plasma and knee joint, high levels 
of the precursor LA can be found (Figure 9, Table 11), whereas in the 
DRGs this is not as apparent (Figure 9, Table 11). 
A qualitative comparison between the different tissues was conducted 
using PCA (See Materials and Methods) to complement the discussion of 
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the differential distribution of lipids between the different tissue types 
(Figure 11). 
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Figure 11. Individual samples were independently analysed using Principle Component 
Analysis (PCA) to look at variation between samples represented by (A) scores plot of a 
two-component PCA model of the dataset and (6) loadings plot of the same model 
dataset. Each sample was colour coded according to tissue type: yellow= knee jOint, 
green=plasma, red=DRGs, black=spinal cord, lime= frontal cortex, blue=hippocampus, 
purple=midbrain, maroon=rest of cortex and turquoise=rest of brain. These tissue groups 
have been circled in black for better visualisation. Samples that fit within the 95% 
confidence interval are included within the blue circle. 
AlXB2 
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Each individual sample represented a measured concentration of the lipid 
analysed (variable 1) from a tissue type (variable 2). Individual pOints 
were then mapped in the space spanned by principal components 1 and 2 
and colour coded for tissue type (Figure 11) and any variance or 
connection was mapped into distinct areas of the plot. PCA has been 
widely used in metabolomics for further analysis of complicated datasets 
(Wang et al 2011, Gu et al 2010, Kikuchi et al 2010, Chen et al 2009, 
Law et al 2008) to identify trends and outliers. 
In Figure 11.A the scores plot illustrated visible groupings of samples into 
each distinct tissue type, with separation apparent for knee joint, plasma, 
DRGs, spinal cord and brain. Each individual brain sample measured for 
the five brain regions are also clearly grouped together in this plot. This 
shows that the lipids measured and the concentrations of these are 
distinct for each tissue type. It is also apparent from the positioning of 
the samples in the scores plot that the spinal cord and DRGs are also 
distinct from the knee joint and plasma. This is due to changes 
represented in the loadings plot (Figure 11.6), where levels of the LOX 
metabolites 13-HODE and S- and lS-HETE and the fatty acid precursor of 
13-HODE, LA, are shown to be the key lipids that distinguish the knee 
joint and plasma from the other tissues. The COX metabolites TXB2 and 
PGD;JPGE2, along with 11-, 12-HETE and the endocannabinoid AEA and 
endocannabinoid-like compounds PEA and OEA are clearly the prominent 
features in the spinal cord and DRGs. 
2.3.3.2 Comparison of quantitative levels of the bioactive lipids in 
literature on rat tissues 
Plasma 
Profiling of bioactive lipids has previously not been reported in rat 
plasma, so for the first time, this work is presented in this chapter. 
Eicosanoids however have been profiled in human serum from obese 
individuals using SPE-LC-MS/MS (Ferreiro-Vera et al 2011). 12-HETE (10 
ng/mL), PGE2 (0.1 ng/mL), PGE3 (9 ng/mL), 9-HODE (6 ng/mL) and 13-
HODE (S ng/mL) were all detected in the human serum, S-, 8-, 11- and 
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lS-HETE were all measured and not detected (Ferreiro-Vera et al 2011). 
PGD2 , AA and LA have previously been measured in rat serum and the 
control levels of these lipids ranged from 2-6 I.Ig/mL, much higher 
compared to this method (Table 11; Bai et al 2010). A possible 
explanation for this could be that the method by Bai et al only managed 
to separate and quantify six lipids, whereas in our method there were 42 
lipids. Therefore this large difference in lipid numbers may contribute to 
the sensitivity of the method. Also, rat serum contains lipids associated 
with the coagulation process and consequently the lipid composition of 
this biological sample is very different to plasma. AEA, PEA and OEA have 
also been measured in rat plasma; levels are 3.1±0.6 pmol/mL, 9.4±1.6 
pmol/mL and 9.2±1.8 pmol/mL respectively (Guiffrida et al 2000). 12-
HETE has previously been measured in rat plasma at levels of 
approximately 100 ng/mL. There are a number of LOX metabolites of LA 
and AA found in plasma, such as 13-HODE, 9-, 13-oxoODE and the 
HETEs mainly 12-HETE. 12-HETE is primarily formed from the 
metabolism of AA by 12-lipoxygenase (12-LOX; Hampson and Grimaldi 
2002), whereas the HODEs are formed through the metabolism of LA by 
lS-lipoxygenase (lS-LOX) and are further reduced by dehydrogenase to 
the oxoODEs (Vangeveti et al 2010). Lipoxgenases have been shown to 
be highly expressed in blood and immune cells (Hampson and Grimaldi 
2002), which may account for the high levels of LOX products in plasma. 
Also positional specificity of enzymes may be of pathophysiological 
importance because lipoxygenases in the rat favour production of 12-
HPETE which is further metabolised to 12-HETE, whereas in humans 15-
HPETE is favoured (Kuhn and O'Donnell 2006). 
Knee Joint 
Prostaglandins have previously been investigated in rabbit and human 
synovial fluid (Alstergren and Kopp 2000, Schumacher et al 1996, Gold et 
al 1976) and endocannabinoids in human synovial fluid (Richardson et al 
2008). However, profiling of lipids in the knee joint is yet to be 
investigated until now, therefore the profiling of lipids in the knee joint is 
novel data. A higher proportion of LOX metabolites such as 12-, lS-HETE, 
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13-HODE, 9- and 13-oxoODE are found in the knee joint compared to 
plasma, along with a greater proportion of COX-2 metabolites, PGD2IPGE2 
and TXB2 . 9- and 13-oxoODE which are the oxidative metabolites of the 
HODEs are only detected in the knee joint and plasma but are not 
detectable in the other tissues (Table 11). The level of LA detected in the 
knee joint is significantly higher than the other tissues, especially when 
this is expressed as a ratio of AA. The majority of research investigating 
expression of LOX in bone is conducted in mouse models, where 
increased expression is shown to be detrimental to skeletal development 
(Almeida et al 2009, Klein et al 2004). Higher levels of the precursor may 
contribute to the greater levels of LOX metabolites of LA observed in the 
knee jOint. PGD2 , PGE21 TXB21 5-, 12-HETE, 9- and 13-HODE were all 
previously measured in the tibiotarsal joint of mice, where concentrations 
of LA metabolites were also several fold higher than AA metabolites 
(Blaho et al 2009). The importance of COX-2 in this joint and bone 
formation has been discussed (Blaho et al 2009, Tang et al 2006, Zhang 
et al 2002, Sato et al 1997), where knockout models show not only a 
decrease in COX metabolites but also 5-LOX metabolites, suggesting a 
link between these two metabolic pathways (Blaho et al 2009). 
DRGs 
Profiling of the bioactive lipids has previously not been conducted in the 
DRGs, however individual lipids have been measured, again, shown here 
for the first time. AEA and 2-AG have previously been detected in a 
dorsal root ganglia cell line (Rimmerman et al 2008), where the 
distribution of AEA and 2-AG in lipid rafts were investigated. Levels of 
AEA (26 pmol/g) and 2-AG (9 nmol/g) were also measured using LC-API-
MS/MS in DRGs (Mitrirattanakul et al 2006). Levels of AEA and 2-AG in 
the DRGs reported previously were considerably higher than those 
measured with this method (Table 11), which may be due to differences 
in extraction methods (Mitrirattanakul et al 2006, Huang et al 1999). The 
eicosanoids however have not been measured in the DRGs, but the EETs 
have been measured in trigeminal ganglion neurons (Iliff et al 2010). 
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Spinal Cord 
Lipid profiling in the spinal cord has previously been conducted using two 
separate methods; one measuring eicosanoids using GC-MS/MS and one 
measuring the endocannabinoids using LC-MS/MS (Buczynski et al 2010). 
However, a comparison of the lipid levels in the spinal cord (Table 11) 
found that the lipids measured were much lower than those reported 
previously (Buczynski et al 2010). As discussed earlier, this could be due 
to differences in extraction technique, therefore a direct comparison 
cannot be drawn. There is little information on eicosanoid levels in the 
spinal cord apart from work by Buczynski et al; only PGD2 has previously 
been measured in mouse spinal cord (Kihara et al 2009). In terms of the 
endocannabinoids, 2-AG has also been detected in the rat spinal cord 
using a number of LC-MS/MS methods (Staniaszek et al 2010, Petrosino 
et al 2007, Jhaveri et al 2006, Huang et al 1999), as well as AEA (Jhaveri 
et al 2006). The endocannabinoid-like compounds OEA and PEA have also 
been measured (Jhaveri et al 2006). Again, a comparison of spinal cord 
lipid levels quantified with our method, found that concentrations 
reported previously were higher than this method. Although the 
concentrations discussed here were control values, there are still species 
differences and other study factors, alongside different methodologies 
that may also influence the lipid amounts detected. 
Brain 
Rat brain has been used as part of a full validation for an eicosanoid 
profiling LC-MS/MS method, however levels of these were not reported 
(Masoodi et al 2008). Lipid profiling in the rat brain or different regions of 
the rat brain has yet to be investigated. 5-, 8-, 12-, 20-HETE have 
previously been measured in whole rat cortex ranging from 2.6-
12.14pg/mg, along with PGD2 and PGE2 at 1.76 and 3.97 pg/mg 
respectively (Yue et al 2007). As mentioned previously, 20-HETE had 
reduced sensitivity compared with the other analytes in our method, and 
that this should be noted in view of the lack of detection of 20-HETE in 
any of the biological samples studied. Since 20-HETE was measured in a 
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previous method (Yue et al 2007), where 5-, 8- and 12-HETE 
concentrations were also reported to be higher than those reported in our 
method (Table 10), this may be due to a sensitivity factor between 
methods. AA, PGD2, PGE2, TXB2 , 5- and 12-HETE were all measured in 
ischaemic rat brain, however PGD2 and PGE2 were not detected in control 
brains (Farias et al 2008). PGE2 (11 ng/g) and PGD2 (25 ng/g) were both 
also detected in mouse brain (Brose et al 2011). AEA, OEA, PEA, 2-AG 
and arachidonic acid have also been measured in the rat frontal cortex, 
where !evels of these lipids were significantly higher than this method 
(Williams et al 2007). AEA and 2-AG have been measured in the 
prefrontal cortex and hippocampus in rats (Malinen et al 2009). The 
endocannabinoids 2-AG, AEA, PEA, OEA and 2-linoleoyl glycerol (2-LG) 
have also previously been measured in several different brain regions, 
where AraGly was analysed but not detected (Richardson et al 2007). 
Although levels of the bioactive lipids are lower in this method (Table 11) 
compared to those previously published (Yue et al 2007, Richardson et al 
2007, Williams et al 2007), a wider range of lipids are detected and 
measured in our method including AraGly. A combination of LC and MS 
optimisation meant that AraGly is analysed in negative electrospray 
ionisation mode rather than positive electrospray ionisation mode as 
previous (Richardson et al 2007). Furthermore, it may be for this reason 
that levels of AraGly are detected in all five brain regions analysed using 
this method. 
It is difficult to draw comparisons with other methods, due to the lack of 
detailed literature in this area and the frequent use of separate methods 
for individual lipids. Differences in reported absolute levels of lipids can 
result from many different factors, ranging from tissue collection, 
differences in timings, sex, ages and strain of animals to the 
methodology, such as differences in extraction methods and efficiencies. 
Evidence from previous publications along with good validation results 
have shown that the methodology is capable of measuring lipids in a 
particular tissue, yet there is limited literature to allow further 
comparison. This combined with differences between methodologies also 
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makes it extremely difficult to draw direct comparisons of lipid 
concentrations with other publications. However, the strength of the 
newly developed method is in its ability to provide a comprehensive 
profile of bioactive lipids from a single sample, thus providing consistent 
and comparable data for comparisons of different tissues or 
interventions. 
2.4 Conclusions 
The sensitive and selective LC-MS/MS method described allows 
comprehensive profiling of a wide range of bioactive lipids ranging from 
pro-inflammatory to anti-inflammatory. The use of polarity switching has 
enabled simultaneous analysis of a structurally diverse range of 
compounds and provides a more representative picture of the in vivo 
inflammatory process. This method shows that careful manipulation of 
factors such as pH to chromatographically separate a large range of 
compounds has provided a useful analytical tool for biological 
investigation. The key advantage of using a single method for 
comparative profiling studies not only eliminates the problem of 
comparing across different published data sets but also between different 
analytical methods. A wide range of samples have been analysed using 
this validated method which includes rat brain, spinal cord, knee joint, 
DRGs, plasma, hindpaw, mouse brain and colon and human plasma and 
colon. This has provided useful information on the distribution of lipids in 
different tissues, which has previously not been shown, in relation to 
their biological function and involvement in biological processes. As 
shown in subsequent chapters of this thesis, the method has been used 
to investigate changes in levels of bioactive lipids in different disease 
states and also monitored for changes in these lipids following drug 
treatment. Additionally the method can be used to investigate ligands of 
receptor targets such as TRPVl and PPAR, to explore the significance of 
these targets in different disease models. Finally to conclude, this LC-
MS/MS method is a valuable analytical tool that can be applied to a 
diverse range of tissues, disease states and biological targets in different 
areas of research. 
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Chapter 3. 
Investigation of 
endogenous ligands for 
peroxisome proliferator 
activated receptors 
(PPARs) 
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3. Investigation of endogenous ligands for peroxisome 
proliferator activated receptors (PPARs) 
3.1 Introduction 
Peroxisome proliferator activated receptors (PPARs) have well established 
anti-inflammatory actions (discussed later). A number of ligands present 
in the body have been shown to activate PPARa (see below), but in most 
cases their biological contribution to PPARa activation is yet to be 
ascertained. In this chapter the further application of the novel validated 
LC-MS/MS analytical method described in Chapter 2 to measure levels of 
endogenous ligands for PPAR alpha (PPARa) was undertaken to 
investigate which of these ligands may modulate inflammatory pain 
responses. This included investigating the effects of carrageenan-induced 
inflammation on levels of PPARa ligands in the hindpaw, spinal cord and 
brain. 
3.1.1 Identification of endogenous PPARa ligands 
A number of PPARa ligands have been identified in vitro such as AEA, 
OEA, PEA, 8-HETE, 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, arachidonic 
acid (AA), linoleic acid (LA), palmitic acid (AA) and oleic acid (OA). In 
transactivation assays, AA, LA, PA and OA have been shown to activate 
PPARa when assayed at 100 ~ M M (Kliewer et al 1997) and AA and LA bind 
to PPARa in the range of 25-30 ~ M M in ligand-induced complex formation 
assays (Forman et al 1997). 8-HETE, an 8-lipoxygenase product 
produced in skin, and a product of CYPs, also activates PPARa in 
transactivation assays (Yu et al 1995, Kliewer et al 1997). 5,6-EET, 8,9-
EET, 11,12-EET, 14,lS-EET and 20-HETE have been shown to displace 
cis-parinaric acid in ligand-receptor binding assays of PPARa (Cowart et al 
2002). OEA also activates PPARa in transactivation assays with a half-
maximal concentration (ECso) of 120 ± 1 nM compared to the synthetic 
PPARa agonists of Wy-14643 and GW7647 which activated PPARa with 
ECso values of 1.4 ± 0.1 ~ M M and 150 ± 20 nM, respectively (Fu et al 
2003). The half-maximal inhibitory concentration (ICso) of OEA in binding 
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competition experiments was 120 ± 10.7 nM and saturation binding 
studies showed that [3H]OEA associated with the ligand binding domain 
(LBO) of human and murine PPARa with dissociation constants (Kd) of 
43.3 ± 1.6 nM and 37.4 ± 0.1 nM, respectively (Fu et al 2003). AEA has 
been shown to displace cis-parinaric acid in ligand-receptor binding 
assays for PPARa to give an ICso between 10-30 IJM, which is as potent 
as OEA (ICso of 30 IJM) for ligand occupancy, but gave a bigger reporter 
gene (agonist) response (Sun et al 2007). PEA has also been shown in 
transactivation assays to activate PPARa with an ICso of 3.1 ± 0.4 IJ M. 
Once again Wy-14643 and GW7647 were used as positive controls to 
give ICso values of 187 ± 42 nM and 1.4 ± 0.1 IJM, respectively (LoVerme 
et al 200S). Palmitic acid, a product of PEA hydrolysis was found not to 
activate PPARa (LoVerme et al 200S). There are however, other 
inflammatory mediators which may also target this receptor. The HETEs 
(hydroxyeicosatetraenoic acids) and EETs (mentioned earlier) are 
biologically active arachidonic acid derivatives produced through the 
action of lipoxygenases, epoxygenases and CYPs. Some HETEs, such as 
8-HETE activates PPARa in vitro, but binding to PPARa has yet to be 
described (Yu et al 1995). The potential role (s) of these novel PPARa 
ligands in vivo remains to be characterised. 
3.1.2 Principles of TR-FRET 
The principles of TR-FRET or time-resolved Forster resonance energy 
transfer is a phenomenon first described by Morrison (Morrison 1988). It 
is a recognised method for screening compounds and for overcoming 
interference from compound autofluorescence from preCipitated 
compounds (Hemmila and Webb 1997). The principles of a TR-FRET 
assay are similar to that of a standard FRET assay where a suitable pair 
of fluorophores once brought within close proximity of one another will 
result in excitation of the first fluorophore (donor) and subsequent 
energy transfer to the second f1uorophore (acceptor). An increase in the 
fluorescence emission of the acceptor and decreased emission of the 
donor is detected as a transfer in energy (Morrison 1988, Hemmila and 
Webb 1997). 
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In the Lanthascreen TR-FRET assays, a long-lifetime lanthanide chelate is 
used as the donor species, whereas in standard FRET assays this is not 
the case. The most common lanthanides used are terbium and europium 
(Hemmila and Webb 1997). Terbium is used in this particular assay and it 
offers several advantages over europium. Terbium-based TR-FRET assays 
can use fluorescein, a common fluorophore, as the acceptor. It is 
straightforward to label a molecule such as a peptide with fluorescein and 
it is not expensive. Directly labelled molecules may also be used in 
terbium-based assays which reduces cost, improves kinetics and avoids 
steric interactions when using large allophycocyanin (APC) conjugates; 
the acceptor needed if using europium. APC requires the use of 
biotinylated molecules that must be indirectly labelled via a streptavidin-
mediated recruitment of APC and is more complicated (Blomberg et al 
1999, Hemmila and Webb 1997). The excited-state lifetime (the average 
time that the molecule spends in the excited state after accepting a 
photon) of lanthanide chelates is a millisecond or longer. Other common 
fluorophores have a lifetime typically within the nanosecond range. 
Interference or scattered light from autofluorescent compounds are also 
within the nanosecond range, so this can be problematic and can 
negatively impact the assay. This can be overcome by measuring FRET 
after a suitable delay (Hemmila and Webb 1997). 
The terbium-labelled anti-glutathione-S-transferase (anti-GST) antibody 
binds to the GST tag of the PPARa receptor, a nuclear receptor labelled 
NR (Figure 1) and is used to indirectly label this receptor. A fluorescent 
ligand or tracer in this case, the fluormone Pan-PPAR Green once bound 
to the receptor, leads to an energy transfer from the antibody to the 
tracer resulting in a high TR-FRET ratio. Competitive ligand binding is 
reflected in the ability of the test compound to displace the tracer from 
the receptor and results in a loss of TR-FRET signal. 
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~ ~
Tracer Bound Tracer Displaced 
High TR·FRET ratio Low TR·FRET ratio 
Figure 1. Principle of the this Lanthascreen competitive binding assay. 
Image from Invitrogen Lanthascreen® Terbium Instrument and protocol booklet 
3.1.3 Carrageenan model of inflammatory pain 
The carrageenan model of inflammatory pain uses A-carrageenan, a 
complex polysaccharide extract of the red algae, Chrondus crispus, first 
described by Winter et al 1962. It does not gel strongly at room 
temperature and produces a local inflammatory response on injection 
(Winter et al 1962, Di Rosa 1972). Classic signs of inflammation can be 
observed with this model, including oedema, hyperalgesia and erythema, 
and the inflammation induced is acute and a non-immune response 
(Hargreaves et al 1988). The level of inflammation is usually quantified 
by change in paw size and is maximal five hours post-injection (Morris 
2003). During the inflammatory process, in response to the tissue 
damage, inflammatory mediators are generated in situ at the site of 
injury or by infiltrating cells such as neutrophils and mast cells (Morris 
2003). These include prostaglandins, bradykinin, S-hydroxytryptamine 
(S-HT) (Di Rosa et al 1971), histamine (AI-Haboubi and Zeitlin 1983), 
nerve growth factor (NGF) (Leon et al 1994), reactive oxygen and 
nitrogen species (Salvemini et al 1996) and prO-inflammatory cytokines 
(Loram et al 2007, Morris 2003) that all contribute to the inflammatory 
process. In addition to this, carrageenan-induced mechanical 
hyperalgesia is apparent, which can be assessed through changes in 
weight bearing and paw pressure sensitivity (Hargreaves et al 1988). 
This induction in pain behaviour is linked to the dependent release of 
histamine, S-HT (Di Rosa et al 1971, AI -Haboubi and Zeitlin 1983) and 
NGF (Leon et al 1994) from infiltrating mast cells. These mediators can 
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activate and/or sensitise receptors and primary afferent fibres and 
contribute to hyperalgesia and expansion of peripheral receptive fields 
(Elmes et al 2004). Previous studies have reported inflammatory 
hyperalgesia and increased paw volume at 3 hours post-carrageenan 
(Hargreaves et al 1988, Hedo et al 1999) and levels of PGE2, an 
important inflammatory mediator in this model, peaked 6 hours post-
carrageenan (Guay et al 2004). 
3.1.4 Effects of PPARa ligands in inflammation 
PPARa regulates systemic inflammation by inducing the expression of 
anti-inflammatory proteins such as I kappa B alpha (IKB-a), reducing the 
expression of pro-inflammatory proteins such as tumour necrosis factor-
alpha (TNF-a) and limiting immune cells recruitment to inflammation 
sites and cytokine production (See General Introduction, Delerive et al 
2002, Delerive et al 2000). These effects are mediated through changes 
in gene expression by induction of responsive target genes and inhibition 
of transcription factor activities (Delerive et al 2002, Delerive et al 2000). 
Importantly, PPARa stimulates the catabolism of pro-inflammatory 
eicosanoids such as lTB4 by inducing gene transcription (Devchand et al 
1996). Activation of PPARa has also been shown to modulate 
inflammatory responses. PPARa ligands demonstrated inhibition of 
interleukin (Il) -l(3-induced Il-6 secretion and 6-keto-prostaglandin Flo 
production, and decreased gene expression of vascular cell adhesion 
molecule-1 (VCAM-1) and tissue factor in endothelial cells and monocytes 
(Marx et al 1999, Neve et al 2001). Studies focussing on the molecular 
mechanisms of PPARa showed that activation of this receptor also 
negatively interferes with the inflammatory response by antagonising 
nuclear factor-KB (NF-KB) signalling (Delerive et al 1999, Marx et al 
1999). A number of endogenous ligands shown to activate PPARa in 
transactivation assays have also been shown to modulate inflammatory 
responses in vivo (See General Introduction). Oleoyl ethanolamide (OEA) 
and palmitoyl ethanolamide (PEA) reduced O-tetradecanoylphorbol-13-
acetate induced oedema in mice, as effect absent in PPARa knockout 
mice (lo Verme et al 2005). PEA prevented IKB-a degradation and NF-KB 
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nuclear translocation in the spinal cord, and also attenuated the 
development of carrageenan-induced hindpaw oedema (D'Agostino et al 
2007). 
3.1.S Aims and Objectives 
• To investigate the interaction of putative ligands with PPARa and to 
compare the affinity of putative PPARa ligands in a PPARa ligand 
binding assay 
• To determine the levels of PPARo ligands in biological tissue. 
• To determine whether the levels of PPARo ligands are altered in 
the carrageenan model of inflammatory pain 
3.2 Materials and Methods 
3.2.1 Chemicals 
Dimethyl sulfoxide (DMSO) and ethanol were purchased from Sigma 
Aldrich (Gillingham, UK) and GW7647, a PPARo agonist used as a positive 
control was purchased from Tocris Bioscience (Bristol, UK). 9-
hydroxyeicosatetraenoic acid (9-HETE), 11-hydroxyeicosatetraenoic acid 
(ll-HETE), 12-hydroxyeicosatetraenoic acid (12-HETE), 15-
hydroxyeicosatetraenoic acid (15-HETE), 16-hydroxyeicosatetraenoic acid 
(16-HETE), 20-hydroxyeicosatetraenoic acid (20-HETE), arachidonic acid 
(AA), linoleic acid (LA), palmitic acid (PA), oleic acid (OA), 2-linoleoyl 
glycerol (2-LG), 2-arachidonoyl glycerol (2-AG), N-arachidonoyl 
ethanolamide (AEA), N-palmitoyl ethanolamide (PEA) and N-oleoyl 
ethanolamide (OEA) were purchased from Cambridge Bioscience 
(Cambridge, UK). 5-hydroxyeicosatetraenoic acid (S-HETE), 8-
hydroxyeicosatetraenoic acid (8-HETE), S,6-epoxyeicosatrienoic acid 
(5,6-EET), 8,9-epoxyeicosatrienoic acid (8,9-EET), 11,12-
epoxyeicosatrienoic acid (11,12-EET), 14,15-epoxyeicosatrienoic acid 
(14,15-EET), 12-hydroperoxyeicosatetraenoic acid (12-HPETE) and 15-
hydroxyeicosatetraenoic acid-d8 (lS-HETE-d8) were all purchased from 
Biomol International (Exeter, UK). The Lanthascreen TR-FRET peroxisome 
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proliferator receptor alpha competitive binding assay kit was purchased 
from Invitrogen Ltd (Paisley, UK) and contains the items in Table 1. 
Table 1. 
Component Composition Amount Storage 
Temperature 
Fluormone Pan- 2 IJM in 95% 200 IJL -80°C 
PPAR Green ethanol/water 
PPARa-LBO (GST) Human PPARa ligand- 10 I-Ig -80°C 
binding domain in buffer 
(ph 8.0) contains protein 
stabilising agents and 
glycerol. Concentration 
differs between kit. 
Lanthascreen Tb- Terbium labelled anti-GST 251-1g -20°C 
anti-GST antibody antibody in HEPES 
buffered saline (137 mM 
NaCI, 2.7 mM KCI, 10mM 
HEPES pH 7.5) 
TR-FRET PPAR Proprietary buffer (pH 7.5) 25 mL 4°C 
assay buffer 
OTT (dithiothreitol), In water 1 mL -20°C or 
1 M -80°C 
Table 1. Kit contents of the Lanthascreen TR-FRET peroxisome proliferator receptor alpha 
competitive binding assay. 
3.2.2 Materials 
An Envision 2102 fluorescence multi label plate reader from PerkinElmer 
(Cambridge, UK) was used for detection of fluorescent emission signals of 
terbium at 495 nm and fluorescein at 520nm. This was coupled with a 
Wallac Envision manager software program, version 1.12 to scan the 
plates and record the data. Black 384-well round-bottom, non-binding 
assay plates were purchased from Greiner Bio One (Stonehouse, UK). 
Multi-channel pipettes were used throughout the experiment. 
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3.2.3 TR-FRET PPARa assay 
The TR-FRET assay was conducted according to the manufacturer's 
protocol (Invitrogen Ltd; Paisley, UK). 
In summary, concentrations of test compounds and the control 
competitor (GW 7647) were made up according to the concentration 
range of interest, along with the Fluormone Pan-PPAR Green and the 
PPARa/Tb-Anti-GST Ab mixture. 20IJL of test compound, control 
competitor, or test compound solvent (DMSO) were pipeted into a 384-
well non-binding assay plate. 10 IJL of Fluormone Pan-PPAR Green was 
then added to each well, followed by 10 IJL of the PPARa/Tb-Anti-GST Ab 
mixture. The assay plate was then placed on an orbital plate shaker for 
30 seconds to ensure an even mix of all the components and left to 
incubate at room temperature. After 3 hours, the plate was read at 
520nm and 495nm using an Envision multi-label plate reader, which 
measured the fluorescent emission signal of each well at both these 
wavelengths. The settings of the Envision instrument and filters were set 
to specific bandwidths to minimise interference. Finally, the 520 nm/495 
nm TR-FRET ratio for each well was calculated in Microsoft Excel and 
these ratios were plotted against concentration using Graphpad Prism 5.0 
to create a one-site competition sigmoidal dose-response curve to 
calculate the ICso (concentration of the ligand that displaces the binding 
of the Fluormone Pan-PPAR Green by 50%) of the test compound. 
3.2.4 Animals 
Experiments were performed on male Sprague Dawley rats (180-200g 
Charles River, UK) in accordance with the UK Scientific Procedures Act 
(1986). All animals were group housed and maintained on a 12 hour 
light/dark cycle with access to food and water ad libitum. 
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3.2.5 Experimental overview 
Rats received an intraplantar injection of 2% carrageenan in saline 
(100IJL), or saline (n=6 rats per group) and were killed 5 hours post-
injection. Paw volume was measured before injection and prior to tissue 
collection to determine the level of oedema. This was carried out using a 
plethysmometer (Figure 2), which requires calibration using 19 and 2g 
probes. 
Figure 2. An image of a plethysmometer used for measuring paw volume (em3) and 
determining the level of oedema in the hind paw. 
Plethysmetry fluid is made up by dissolving 0.5 9 of sodium chloride and 
3 mL of wetting compound (Ornano, IMBIBENTE, SSC7) in 1 L of distilled 
water. The rat was anaesthetised using isoflurane and a mixture of 
oxygen and nitric oxide (1:2). Laying the animal on its front and 
measuring from the tip of the toe upwards, a 4cm line is marked with 
permanent black pen. This line is used to ensure all paw volume 
measurements are consistent between readings and different animals. 
The rat hind paw is inserted into the fluid up to the marked line of the 
first tube and the paw volume is measured by the plethysmometer. This 
measures the fluid displaced by the paw, a volume change that is 
precisely mirrored by a second smaller tube containing a transducer. 
Three readings were recorded for both the ipsilateral and contralateral 
hind paws at each timepoint, including baseline values and immediately 
prior to tissue collection. 
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Five hours post-carrageenan injection, the rats were killed by stunning 
and decapitation by Professor David Kendall. Hindpaw, spinal cord, brain 
regions (frontal cortex, hippocampus, midbrain, rest of cortex and rest of 
brain) were rapidly dissected with help from Professor David Kendall 
(brain regions) and Professor Vicky Chapman (spinal cord) and frozen 
immediately with liquid nitrogen as described in Chapter 2. All samples 
were stored at -80 DC until needed. 
3.2.6 LC-MS/MS analysis of lipids 
The samples were extracted and analysed using the LC-MS/MS method 
detailed in Chapter 2 to quantify levels of PPARa ligands in the spinal 
cord, brain and hindpaw. However, when this study was conducted only 
18 analytes were measured using this same method. These included 5-, 
8-, 9-, 11-, 12-, 15-, 16-, 20-HETE, 5,6-, 8,9-, 11,12-, 14,15-EET, 12-
HPETE, 2-AG, AEA, DEA, PEA and NADA, with 15-HETE-d8 as the internal 
standard. In summary, extraction of lipids was with ethyl acetate/hexane 
(9: 1 v/v), followed by slow vortexing and centrifugation before the 
supernatants were collected and pooled. These were then evaporated 
under nitrogen and reconstituted with acetonitrile: water (50:50 v/v) and 
analysed immediately.Simultaneous measurement of bioactive lipids was 
performed using liquid chromatography tandem mass spectrometry (LC-
MS/MS) using the methodology described in Chapter 2. Quantification 
was performed using Analyst 1.4.1 and imported into Microsoft Excel and 
Graphpad Prism. 
3.2.7 Data Analysis 
For the studies measuring hindpaw volume differences these were 
presented as mean ± SEM, statistical analysis was performed using one-
way ANOVA and a Bonferonni post hoc test. LC-MSjMS data were 
expressed as mean ± SEM, statistical analysis was performed with a 
Mann Whitney test. 
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3.3 Results 
3.3.1 TR-FRET PPAR alpha competitive binding assays 
Previous studies using transactivation assays for PPARa have shown that 
some of the endocannabinoids and eicosanoids are also PPARa ligands. 
Transactivation studies confirm that the compound activates PPARa, 
however this does not demonstrate direct binding of the ligand to the 
receptor. Indeed, the effects of some ligands on PPARa activation may be 
indirect due to actions on other ligands. To address this question the TR-
FRET PPAR alpha competitive binding assay was used, which is a 
sensitive and robust method for screening of potential PPARa ligands. 
This assay was used to investigate the interaction of different test 
compounds with the LBO of PPARa in TR-FRET -based competitive ligand 
binding assay. In this Lanthascreen assay (See Introduction for details), 
the Terbium-labelled PPARa LBO interacts with the Fluormone Pan-PPAR 
Green (acts as a PPAR ligand), which produces FRET. The fluorescent 
Fluormone Pan-PPAR Green can then be displaced by unlabelled ligands 
resulting in a quantifiable attenuation of FRET. GW 7647 was chosen as 
the positive control because it was identified as having the highest 
activity and being the most selective for PPARa, with 200-fold selectivity 
over PPARy and P P A R ~ ~ (Brown et al 2001). The negative control used 
was DMSO as this was the test compound solvent. 
A number of test compounds were investigated, which were chosen 
based on evidence in the literature. These included the fatty acids 
arachidonic acid, linoleic acid, palmitic acid, oleic acid, the 
endocannabinoids 2-AG and AEA and the endocannabinoid-like 
'entourage' compounds OEA, PEA and 2-LG. A selective number of HETEs 
were also chosen including 5-, 8-, 12-, 15-, 16-, 19- and 20-HETE and 
the four EETs. The positive control, GW 7647 showed detectable 
competition and displacement of the Fluormone Pan-PPAR Green, with an 
ICso of 0.3 nM (Table 2, Figure 3). The fatty acids that were shown to 
competitively displace Fluormone Pan-PPAR Green were arachidonic acid 
and linoleic acid, with an ICso of 0.4 JJM and 0.1 JJM respectively (Table 2, 
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Figure 3) and bind to the PPARa LBD. Oleic acid and palmitic acid 
however were not found to be PPARa ligands (Figure 4). 
Table 2. 
GW AA LA 8- 5,6- 11,12- 14,15- AEA OEA 
7647 HETE EET EET EET 
IC50 0 .3 nM 0.4 IJM O.lIJM 30 nM 2 IJM O.S IJM 13 nM 30 IJM 8 IJM 
Table 2. leso values of endogenous ligands shown to bind to PPARa in the in vitro TR-
FRET binding assay 
Fatty Acids 
E 1.75 • • GW7647 
c: 
• Arachidonic It') 1.50 0') 
~ ~ T Linoleic E 1.25 
c: A Oleic 
0 1.00 ~ ~ Palmitic 
c: 0.75 
.2 
III 0.50 
III 
'E 0.25 
Q) 
0.00 
-11 -10 -9 -8 -7 -6 -5 -4 
[Fatty Acid] (log M) 
Figure 3. The curves were generated using a sigmoidal dose response (variable slope) 
equation in GraphPad™ Prism 5.01. GW 7647 (Ieso of 0.3 nM) was used as a positive 
control. Arachidonic acid (leso of 0.4 IJM) and linoleic acid (Ieso of 0.1 IJM) were shown to 
be PPAR alpha ligands in this TR-FRET assay. There were 2 repeats of each fatty acid and 
positive control for each assay and these were plotted as individual replicates. The TR-
FRET assay was repeated twice to ensure reproducibility of the data. 
8-HETE was found to competitively displace Fluormone Pan-PPAR Green 
with an leso of 30nM (Table 2, Figure 4a) and bind to the PPARa LBD. 
However, displacement of the Fluormone Pan-PPAR Green was 
undetectable for 5-, 12-, 15-, 16-, 19- and 20-HETE, which were not 
found to be PPARa ligands (Figure 4a and 4b). 
PEA 
>30 IJ M 
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Figure 4. The curves were generated using a sigmoidal dose response (variable slope) 
equation in GraphPad™ Prism 5.01. GW 7647 (ICso of 0.3 nM) was used as a positive 
control. Figure Sa. 8-HETE (lCso of 30 nM) was shown to be a PPARa ligand in this TR-
FRET assay. Figure Sa and 5b. However, 5-, 12-, 15-, 16-, 19- and 20-HETE were not 
found to be PPARa ligands. There were 2 repeats of each HETE and positive control for 
each assay and these were plotted as individual replicates. The TR-FRET assay was 
repeated twice to ensure reproducibility of the data. 
5,6-, 11,12- and 14,15-EET were found to competitively displace 
Fluormone Pan- PPAR Green with an leso of 2 IJM, 0.5 IJM and 13 nM 
respectively (Table 2, Figure 5) and bind to the PPARa LBD. Unfortunately 
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in both assays, the data points for 8,9-EET were interrupted and an ICso 
was not able to be calculated. 
EETs 
1.5 
E • GW7647 £: • 5,6-EET It) • • • 0') 
v T 8,9-EET E 1.0 
£: • 11,12-EET Q 
N 14,15-EET It) 
£: 0.5 
.2 
en 
en 
'E 
Go) 
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-11 -10 -9 -8 -7 -6 -5 
[EET) (log M) 
Figure 5. The curves were generated using a sigmoidal dose response (variable slope) 
equation in GraphPad™ Prism 5.01. GW 7647 (ICso of 0.3 nM) was used as a positive 
control. s,6-EET (ICso of 2 ~ M ) , , ll,12-EET (ICso of 0 .5 ~ M ) ) and 14,ls-EET (ICso of 13 
nM) were shown to be PPARa ligands in this TR-FRET assay. There were 2 repeats of each 
EET and positive control for each assay and these were plotted as individual replicates. 
The TR-FRET assay was repeated twice to ensure reproducibility of the data. 
AEA, OEA and PEA were found to competitively displace Fluormone Pan-
PPAR Green with an ICso of 30 IJM, 8 IJM and 2 mM respectively (Table 2, 
Figure 6) and bind to the PPARa LBD. However, displacement of the 
Fluormone Pan-PPAR Green was undetectable for 2-AG and 2-LG, which 
were not found to be PPARa ligands (Figure 6). 
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Figure 6. The curves were generated using a sigmoidal dose response (variable slope) 
equation in GraphPad™ Prism 5.01. GW 7647 (IC50 of 0.3 nM) was used as a positive 
control. AEA (IC50 of 30 !-1M), OEA (IC50 of 8 !-1M) and PEA (IC50 of 2 mM) were shown to 
be PPARa ligands in this TR-FRET assay. There were 2 repeats of each EC and positive 
control for each assay and these were plotted as individual replicates. The TR-FRET assay 
was repeated twice to ensure reproducibility of the data. 
Using the TR-FRET PPARa competitive binding assay I have shown that 
arachidonic acid, linoleic acid, 8-HETE, 5,6-, 11,12-, 14,15-EET, AEA, 
OEA and PEA all bind to PPARa (Table 2). 8-HETE and 14,15-EET were 
high affinity PPARa ligands compared to endogenous ligands such as 
arachidonic acid and AEA (Table 2). 
3.3.2 Investigating the effects of saline and carrageenan on 
inflammation and levels of PPARa ligands 
3.3.2.1 Effects of saline or carrageenan injection on hindpaw 
inflammation 
Hindpaw volume was measured to check for the presence of hind paw 
inflammation and to confirm that carrageenan-induced inflammation was 
present in the carrageenan-treated rats. Intraplantar injection of saline 
did not significantly alter hindpaw volume at 5 hours post-injection in the 
ipsilateral hindpaw (Figure 7). Intraplantar injection of carrageenan 
produced a unilateral and significant (P<O.OOl) increase in hindpaw 
volume 5 hours post-injection in the ipsilateral hindpaw (Figure 7). 
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Intraplantar injection of carrageenan induced significant inflammation in 
the ipsilateral hindpaw of carrageenan-treated rats. 
-
I") 
E 
Co) 
-
Change in Hindpaw Volume 
SAL-IPS SAL-CON CAR-IPS CAR-CON 
Treatment 
Figure 7. Intraplantar injection of 2% carrageenan significantly increased ipsilateral 
hindpaw volume five hours post-injection in carrageenan-treated rats compared to control 
(saline). Data were analysed using a one-way Anova with Bonferoni post hoc test, 
***P<O.OOl. Data are expressed as mean ± SEM of ipsilateral (IPS) and contralateral 
(CON) hindpaws (n=6). 
Hindpaw volume remained unchanged at 5 hours post-injection in the 
contralateral hindpaws in both saline and carrageenan-treated rats 
(Figure 7). 
3.3.2.2 Effect of saline or carrageenan injection on levels of PPARa 
ligands in the hindpaw, spinal cord and brain regions 
LC-MS/MS analysis was conducted to first determine the PPARa ligands 
present in different tissues in vivo under non-stimulated control 
conditions (injection of saline), and then to determine whether these 
levels were altered in a model of acute inflammatory pain. 
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3.3.2.3 Effect of non-stimulated conditions (saline injection) on the 
levels of PPARa ligands in the different tissues 
Under non-stimulated conditions (saline-treated rats), 5- and 12-HETE 
were measured in the hindpaw, spinal cord and all brain regions of the 
rat, as were AEA, PEA, OEA and 2-AG. 8-HETE was measured in the 
hindpaw and all brain regions. 9-HETE was measured in the frontal 
cortex, rest of cortex and rest of brain. 11- and 15-HETE were measured 
in the spinal cord and all brain regions. 12-HPETE, 5,6-, 8,9-, 11,12- and 
14,15-EET were measured in all brain regions (Table 3). Intraplantar 
injection of saline did not significantly alter lipid levels between ipsilateral 
and contralateral hindpaws and spinal cords (data not shown) 
Under non-stimulated conditions, the majority of the total amount of lipid 
measured consisted of 2-AG: hindpaw (90%); spinal cord (90%); brain 
(98-99%) (Table 3). Therefore this lipid was excluded from the dataset to 
allow further analysis of the data. 
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Brain Regions 
Hlnclpaw (Ips) Spinal Cord (Ips) FrontlilCortex Midbrain Hippocampus R_t of Cortex RMtofBraln 
Saline I carrageenan Saline I calTllgeenan Saline I carrageenan Saline I carrageenan Saline I carrageenan Saline I carrageenan Saline carrageenan 
AEA 11 % 2 3 % 1 6%1 8±1 12 % 2 12 ± 3 11 ± 2 16 % 4 16 ± 2 14 ± 2 7 ± 1 7 ± 0.5 5 ± 1 7 ± 1 
2-AG 4±2 0.6 % 0.4 38 % 4 33:± 4 27 % 9 34 % 14 85 % 23 84 ± 25 61 :± 12 51 ± 15 16 % 4 20 % 7 30 * 15 17 % 4 
OEA 63 % 12 27 * 5 117 ± 31 151 * 46 25 % 4 24 * 3 30 % 11 50 % 24 11 * 4 13 ± 5 9±2 8±2 9±3 14 ± 7 
PEA 205 % 31 85 * 17 789 * 322 1191 % 615 71 % 35 90 % 42 72 % 22 118 * 49 50 * 19 55 * 27 23 % 10 12 % 5 48 % 31 21 ± 8 
S-HETE 20 % 6 16 * 4 9*3 7*2 8%5 7%3 5 % 1 6 % 2 5%2 7%4 2 % 1 2 % 1 3 % 2 2 % 1 
B-HETE 4%1 2*1 BLOQ 2 ± 1 4 % 1 5 % 1 5 % 1 6 % 1 4 % 1 4±1 2 % 0.4 2 % 0.2 3 ± 1 3 % 1 
'-HETE BLOQ BLOQ BLOQ BLOQ 3 % 1 8LOQ 8LOQ 5*2 BLOQ BLOQ 1 % 0.4 1 % 0.4 1 % 0.5 2 ± 1 
U-HETE BLOQ 7±3 7%2 12 * 3 18 * 2 19 % 2 6±1 10 ± 2 9 ± 1 9 ± 1 10 ± 1 9 ± 1 7±2 7 % 1 
12-HETE 60 % 24 17 * 2 73 * 23 49 * 15 19 % 3 31 % 11 38 % 15 93 * 40 26 ± 5 25 % 8 26 ± 7 23 ± 6 47 ± 14 72 ± 20 
IS-HETE BLOQ 3 ±2 12 ± 4 31 ± 8 18 % 2 16 % 3 15 * 4 20 ± 4 12 % 1 15 % 3 12 % 2 11 % 3 13 % 4 11 % 2 
12-HPETE 8LOQ 8LOQ 8LOQ BLOQ 6±2 11 * 4 1 % 0.4 1 * 0.4 10 % 1 11 ± 4 4%1 3 % 1 2 % 1 2 ± 1 
S,6-EET BLOQ BLOQ 8LOQ BLOQ 69 ± 30 35 ± 10 81 * 40 133 % 66 49 % 9 48 ± 18 12 % 4 11 % 4 21 % 13 12 % 6 
B,'-EET BLOQ BLOQ BLOQ BLOQ 29 % 16 11 % 4 20 * 4 65 % 34 16 ± 9 18 ± 11 3 % 2 6±2 12 % 7 7%3 
U,12-EET BLOQ BLOQ BLOQ BLOQ 185 ± 135 179 ± 88 238 ± 102 185 ± 100 149 ± 48 130 % 58 30 ± 20 19 % 11 6±4 4±2 
14,1S-EET BLOQ BLOQ BLOQ BLOQ 27 % 11 11 % 5 36 % 12 47 % 24 17 % 5 12 % 6 3 % 2 3 % 2 8±5 5%2 
Table 1. Levels of lipids measured per g wet tissue weight (n=6) in hindpaw, spinal cord and brain regions; frontal cortex, midbrain, hippocampus, rest of 
cortex, rest of brain of the rat. Values are expressed as mean ± SEM in pmol/g for all tissues except 2-AG, which is expressed in nmol/g. Some lipids were 
below the limit of quantification (BLOQ). 
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Under non-stimulated conditions, there were clear differences in lipid 
composition between the hindpaw, spinal cord and brain (Figure 8). 
Looking at the individual analytes (Figure 8a), a large proportion of the 
hindpaw consisted of PEA, along with OEA. 12-HETE was also a 
prominent lipid in this tissue. Likewise, in the spinal cord, these 3 lipids 
were also key features, with PEA the most prominent lipid in this tissue. 
In the brain, a large proportion of the total lipid measured consisted of 
the EETs, which were below the limit of quantification in the hindpaw and 
spinal cord, with 11,12-EET the most prominent lipid. There were also a 
larger number of HETEs measured in this tissue, whereas in the hind paw 
and spinal cord a few of these lipids were below the limit of quantification 
(Table 3). 12-HPETE was also a lipid that was only detectable in the 
brain. Levels of the endocannabinoid-like compounds OEA and PEA were 
much lower in the brain compared to the hindpaw and spinal cord. Levels 
of the endocannabinoid 2-AG were similar in the brain and spinal cord, 
but much lower in the hindpaw (Table 3), whereas levels of AEA were 
similar in all tissues. 
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Figure 8. a) Lipid distribution of the analytes per g wet tissue weight (n =6) measured in 
hindpaw (PAW), spinal cord (SC) and brain of saline-treated rats, measured in pmol/g. 2-
AG has been excluded to give a better distribution of remaining analytes, b) Lipid 
distribution of all PPARa ligands found in the TR-FRET assay, grouped to show the 
distribution of these in each tissue compared to other analytes measured. 
Based on the results of the TR-FRET binding assay, the lipids found to be 
PPARa ligands were grouped together, to allow comparison of these 
ligands in the different tissues (Figure 8b). Half the number of lipids 
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measured were PPARa ligands and interestingly, these ligands made up 
the majority of the lipids measured in all three tissues (Figure 8b). 
Further to this, individual lipid distribution between the brain regions 
analysed under non-stimulated conditions was investigated. Looking at 
the individual analytes, the lipid composition is similar in the frontal 
cortex, midbrain and hippocampus, which mainly differ from the rest of 
cortex and rest of brain regions by the amount of EETs detected (Table 3, 
Figure 9a). Higher levels of 12-HETE were observed in the midbrain and 
rest of brain compared to other brain regions (Table 3, Figure 9a). 9-
HETE was below the limit of quantification in the midbrain and 
hippocampus. Higher levels of OEA were found in the frontal cortex and 
midbrain compared to the other brain regions (Table 3, Figure 9a). Lower 
levels of PEA and 2-AG were found in the rest of cortex compared to all 
other brain regions (Table 3). 
Again, the lipids found to be PPARa ligands were grouped together, to 
allow comparison of these ligands in the different brain regions (Figure 
9b). The PPARa ligands made up the majority of the total lipid amount in 
the frontal cortex, midbrain and hippocampus, but to a lesser extent in 
the rest of cortex and rest of brain (Figure 9b). 
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Figure 9. a) Lipid distribution of the analytes measured per g wet tissue weight (n =6) in 
frontal cortex (FC), midbrain (MID), hippocampus (HIP), rest of cortex (ROC) and rest of 
brain (ROB) of saline-treated rats, measured in pmol/g. 2-AG has been excluded to give a 
better distribution of remaining analytes, b) Lipid distribution of all PPARa ligands found in 
the TR-FRET assay, grouped to show the distribution of these in each brain region 
compared to other analytes measured . 
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3.3.2.4 Effect of carrageenan-induced inflammation on the levels of 
PPARa ligands in the different tissues 
Under carrageenan-induced inflammatory conditions, five hours post-
injection, 5-, 8-, 11-, 12- and lS-HETE were measured in the hindpaw, 
spinal cord and all brain regions of the rat, as were AEA, PEA, OEA and 2-
AG. 9-HETE was measured in the midbrain, rest of cortex and rest of 
brain. 12-HPETE, 5,6-, 8,9-, 11,12- and 14,15-EET were measured in all 
brain regions (Table 3). 
Under carrageenan-induced inflammatory conditions, the majority of the 
total amount of lipid measured consisted of 2-AG: hindpaw (90%); spinal 
cord (90%); brain (99%) (Table 3). Therefore this lipid was excluded 
from the dataset to allow further analysis of the data. 
3.3.2.5 Effect of carrageenan-induced inflammation on the levels of 
PPARa ligands in the hindpaw 
Five hours following intraplantar injection of carrageenan, there was a 
significant decrease (P<0.05) in the level of PPARa ligands, AEA, PEA and 
OEA in the ipSilateral hindpaw of carrageenan-treated rats compared to 
saline-treated rats, levels of 2-AG were also significantly decreased 
(P<O.OS) (Figure 10). Levels of 8-HETE and 12-HETE, but not 5-, 11- and 
15-HETE, were also decreased in the hindpaw of carrageenan-treated 
rats, but significance was only reached for 12-HETE (P<0.05) (Figure 10). 
11- and lS-HETE was only detectable in the carrageenan-treated rats 
(Table 3). 
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Figure 10. Levels of the PPARa ligands AEA, PEA, OEA, 8-HETE and levels of S-, 11-, 12-, is-HETE and 2-AG in the ipsilateral hindpaw (assessed per g 
wet tissue weight) following intraplantar injection of saline or carrageenan (n=6). Levels of PPARa ligands AEA, OEA, PEA decreased significantly, 8-HETE 
levels also tended to decrease but was no Significant. Levels of i2-HETE and 2-AG also decreased significantly, whereas S-, 11- and lS-HETE remained 
unchanged. Statistical analysis was conducted using a Mann-Whitney test, *P<O.05. 
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3.3.2.6 Effect of carrageenan-induced inflammation on the levels of 
PPARa ligands in the spinal cord 
Five hours following intraplantar injection of carrageenan, there were no 
significant changes in PPARa ligand lipid levels between saline-treated 
and carrageenan-treated rats in the ipsilateral spinal cord (Table 3). 
However, lS-HETE was found to increase (P<O.OS) significantly in the 
ipsilateral spinal cord of carrageenan-treated rats compared to saline-
treated rats (Figure 11). 
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Figure 11. Levels of 1S-HETE per g wet tissue weight increased significantly in the 
ipsilateral spinal cord of carrageenan-treated rats compared to saline-treated rats (n=6). 
Statistical analysis was conducted using a Mann-Whitney test, *P<O.OS. 
3.3.2.7 Effect of carrageenan-induced inflammation on the levels of 
PPARa ligands in the brain 
Five hours following intraplantar injection of carrageenan, levels of PPARa 
ligand S,6-EET and levels of 8,9-EET were significantly decreased in the 
frontal cortex in the carrageenan-treated rats, compared to saline-
treated rats (Figure 12). There were no Significant changes observed with 
other PPARa ligands or other lipids measured in the brain regions (Table 
3). 
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Figure 12. Levels of S,6-EET and 8,9-EET per g wet weight tissue were shown to decrease 
significantly in the frontal cortex following intraplantar injection of saline or carrageenan 
(n=6). other lipids detected in the frontal cortex and other brain regions were not shown 
to alter in carrageenan-treated rats compared to saline-treated rats. Statistical analysiS 
was conducted using a Mann-Whitney test, *P<O.05. 
3.3.3 Summary of findings 
Experiments using the TR-FRET PPARa competitive binding assay showed 
that arachidonic acid, linoleic acid, 8-HETE, 5,6-, 11,12-, 14,15-EET, AEA, 
OEA and PEA all bind to PPARa. 8-HETE and 14,lS-EET were high affinity 
PPARa ligands compared to endogenous ligands such as arachidonic acid 
and AEA. In the in vivo study, intraplantar injection of carrageenan 
induced significant (P<O.OOl) inflammation in the ipsilateral hindpaw of 
carrageenan-treated rats. Levels of PPARa ligands AEA, OEA and PEA 
were significantly decreased (P<O.OS) in the ipsilateral hindpaw of 
carrageenan-treated rats. Along with significant (P<O.OS) decreases in 2-
AG and 12-HETE. Levels of lS-HETE were increased (P<O.OS) 
significantly in the ipSilateral spinal cord of carrageenan-treated rats. 
Levels of S,6-EET and 8,9-EET were decreased (P<O.Ol and P<O.OS 
respectively) significantly in the frontal cortex of carrageenan-treated 
rats. 
140 
3.4 Discussion 
3.4.1 TR-FRET competitive binding assays 
TR-FRET PPARa competitive binding assays demonstrated significant 
binding of AEA, OEA, PEA, 8-HETE, 5,6-, 11,12-, 14,15-EET, arachidonic 
acid and linoleic acid to PPARa. Previous work has shown that 8-HETE, 
PEA and 5,6-, 11,12-, 14,15-EET activate the PPARa receptor (Yu et al 
1995, Kliewer et al 1997, Cowart et al 2002, Fu et al 2003), results 
presented in this chapter show that these ligands bind directly to the 
receptor. Also, previous work has focussed on individual or, at best, a 
small number of compounds, but investigation of all these ligands 
together allows a useful comparison of the potencies of these 
endogenous PPARa ligands. 14,15-EET (ICso 13 nM) was found to have 
the highest affinity for PPARa, followed by 8-HETE (lCso 30 nM), 
compared to the positive control GW7647 (leso 0.3 nM). The order of 
affinity was found to be 14,15-EET > 8-HETE > LA > AA > 11,12-EET > 
5,6-EET > OEA > AEA > PEA. In previous studies, 5,6-EET, 8,9-EET, 
11,12-EET, 14,15-EET and 20-HETE have been shown to displace cis-
parinaric acid in ligand-receptor binding assays of PPARa (Cowart et al 
2002). Therefore, 20-HETE was investigated using the TR-FRET 
competitive binding assay in the 1 IJM to 100 nM range. There was no 
occupancy at concentrations less than 1 IJM; however, higher 
concentrations could not be investigated due to limitations of commercial 
stock solutions. Previous work looking at cis-parinaric acid displacement 
used a concentration range of 20 IJM to 1 nM to be able to calculate a 
value for 20-HETE (Cowart et al 2002). The order of potency for the EETs 
for cis-parinaric acid displacement was found to be 8,9-EET > 14,15-EET 
> 5,6-EET > 11,12-EET, although in this assay these were found to be 
more potent than Wy-14643 (Cowart et al 2002). 8,9-EET was also 
investigated using the TR-FRET competitive binding assay; however, an 
ICso value could not be calculated for this ligand due to interruption of 
data pOints in both assays. Arachidonic acid (lCso 0.4 IJM) and linoleic 
acid (ICso 0.1 IJM) also bound to PPARa in this assay with a higher affinity 
than previously reported at 25-30 IJM (Forman et al 1997), although the 
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latter values were calculated using ligand-induced complex formation 
assays. The EETs are cytochrome P450 (CYP450) metabolites of 
arachidonic acid, and the identification of both the precursor and 
metabolites as PPARa ligands is important. PPARa is a nuclear receptor 
that induces transcription of a number of gene products that are involved 
in the metabolism of fatty acids such as arachidonic acid, including 
enzymes involved in the metabolism of arachidonic acid to the EETs. 
PPARa also regulates processes such as modulating the rate of fatty acid 
uptake and oxidation (Michalik and Wahlie 1999). Arachidonic acid and 
linoleic acid binding to PPARa provides evidence for metabolic 
intermediate involvement in the regulation of transcription, modulating 
feedback control and promoting allosteric changes in enzyme activity 
(Forman et al 1997). AEA (ICso 30 J,JM), OEA (ICso 8 J,JM) and PEA (ICso 2 
mM) have also been shown to bind to PPARo, whereas, previously, PEA 
has only been shown to activate this receptor (Lo Verme et al 2005). 
AEA, however, has previously been shown to have a higher affinity for 
PPARa than OEA (Sun et al 2007). Overall, the affinity of these 
endocannabinoids were not shown to be as high as the eicosanoids, and 
are known to have other receptor targets (Alexander and Kendall 2007). 
3.4.2 Identification and quantification of PPARa ligands 
Following identification of putative PPARa ligands, these were measured 
in vivo to determine their levels in biological tissue and whether these 
were altered in a model of inflammatory pain. The analytical method 
described in Chapter 2 was used to measure all the 18 lipids detected. 
The results showed that intra plantar injection of 2% carrageenan 
produced erythema and oedema, measured using a plethysmometer. At 
5 hours post-carrageenan injection, this gave an almost 2-fold significant 
increase in ipsilateral hindpaw volume that was not observed in saline-
treated rats. This was a good indication that the carrageenan injection 
produced an inflammatory response. 
Levels of PPARa ligands AEA, OEA and PEA were significantly decreased 
in the inflamed hindpaw, 8-HETE also decreased although this was not 
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significant. Levels of 2-AG and 12-HETE were also significantly decreased 
in the inflamed hind paw. By contrast, levels of 5-, 11- and 15-HETE were 
not significantly altered, suggesting that these changes were due to 
specific modulation of eicosanoid metabolism in this model of 
inflammatory pain. Interestingly, 11- and 15-HETE were also only 
detected in carrageenan-treated rats. 11-HETE has been shown to be 
potent neutrophil chemoattractant in vitro and in experimental models 
(Goetzl et al 1980a, Goetzl et al 1980b). 1S-HETE has been shown to be 
a pro-inflammatory mediator, involved in the stimulation of chemotaxis 
and chemokinesis of neutrophils and eosinophils (Vanderhoek et al 
1982). Previous work in our group also reported decreased levels of AEA 
and PEA in the hind paw, using this experimental paradigm (Jhaveri et al 
2008), although, in those experiments, the tissue was collected 3 hours 
post-carrageenan injection. OEA levels were shown to decrease 
significantly 5 hours post-carrageenan injection, but not at 3 hours 
(Jhaveri et al 2008), which may indicate that this particular lipid is 
involved much later in the inflammatory process. It has been suggested 
that decreased levels of these PPARa ligands is due to increased 
metabolism in the presence of inflammation (Jhaveri et al 2008). 
Cyclooxygenase-2 (COX-2) enzyme expression has been shown to 
increase in the carrageenan-inflamed hind paw (Guay et al 2004), as does 
monoacyl glycerol lipase (MAGL), the enzyme responsible for 2-AG 
metabolism (Jhaveri et al 2008), which may explain the significantly 
reduced levels of 2-AG observed. However, the reverse also applies 
where intracerebroventricular administration of PEA significantly reduced 
the expression of prO-inflammatory enzymes in COX-2 and inducible 
nitric oxide synthase (iNOS), as well as reduced oedema formation in the 
mouse carrageenan model (D'Agostino et al 2007), implying a possible 
feedback mechanism in inflammation. 
Levels of the PPARa ligands AEA, OEA and PEA measured in the spinal 
cord were not significantly altered in the carrageenan-treated animals. 
Levels of the other lipids 5-, 11-, 12-HETE and 2-AG were also unaltered, 
except for 15-HETE, which was significantly increased in the ipsilateral 
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spinal cord. As mentioned earlier, 15-HETE is a pro-inflammatory 
mediator, important in chemotaxis and contributing to the inflammatory 
process. Increased levels of this pro-inflammatory mediator under 
inflamed conditions can be expected. Levels of HETEs and EETs have 
previously been measured in the rat spinal cord (Buczynski et al 2010). 
Levels of the PPARa ligands AEA, OEA, PEA and 8-HETE were also 
unaltered in the brain. In addition to these lipids, 5,6-EET, 8,9-EET, 
11,12-EET, 14,-15-EET and 12-HPETE were also measured, with 5,6-, 
11,12- and 14,15-EET shown to be PPARa ligands. 5,6-EET and 8,9-EET 
were shown to decrease significantly in the frontal cortex of carrageenan-
treated rats compared to saline-treated rats. As mentioned, 5,6-EET has 
been shown to be a PPARa ligand in this study, however 8,9-EET has 
been shown previously to bind to PPARa (Cowart et al 2002). This links in 
with the decreased levels of other PPARa ligands observed in the 
hindpaw. HETEs and EETs have previously been measured in the rat 
cortex (Yue et al 2007) and mouse brain (Amruthesh et al 1992, Roman 
2002), and EETs are considered to be neuroprotective due to their anti-
inflammatory effects (Roman 2002, Larsen et al 2006). 
3.4.3 Distribution of PPARa ligands in rat tissue 
Expression of PPARa has been characterised in mouse brain and spinal 
cord, and has been shown to increase following inflammation (Gofflot et 
al 2007, Benani et al 2003a, Benani et al 2003b). Expression of PPARa is 
highest in the brain stem and cerebral cortex, although it is also found in 
many regions of the brain including the hippocampus (Gofflot et al 2007). 
This may explain the reason for the higher levels of PPARa ligands 
observed in the frontal cortex, midbrain and hippocampus compared to 
the rest of the brain. The expression of PPARa is, however, only present 
in distinct parts of the spinal cord. PPARa expression was found to be 
lower in the spinal gray matter compared to the spinal white matter and 
high expression of PPARa was found in the astrocytes (Benani et al 
2003a). These findings suggest an importance of PPARa in cerebral 
inflammation through modulation of cytokine production, as astrocytes 
act as immune effector cells in cerebral inflammation and immune 
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reactivity (Benani et al 2003a). The fact that the majority of lipid levels 
measured in the spinal cord and brain remained unchanged in the 
carrageenan-treated animals may be due to the time pOints at which the 
tissues were collected (S-hours post-carrageenan injection) not being 
appropriate to enable the detection of change. It is widely accepted that 
lipid turnover is rapid; metabolism in vivo occurs at such a fast rate that 
it is often difficult to capture these moments. Also, the fact that whole 
spinal cord was analysed, rather than the areas where PPARo expression 
is prominent may be a confounding factor. 
The distribution of the lipids measured in the spinal cord comprise mainly 
2-AG (90%), followed by PEA, whereas the brain is made up of 
predominantly 2-AG (98-99%), followed by a much more even 
distribution of the other lipids. However, when the PPARa ligands are 
grouped together, we see a similar distribution of these in the spinal cord 
and brain. It is believed that the CYP4A subfamily is involved in the 
metabolism of arachidonic acid to physiologically important metabolites 
that are active in the brain (Simpson 1997). These CYP enzymes work 
alongside PPARo to modulate fatty acid metabolism in the body and the 
presence of these CYP metabolites (EETs), which are also PPARo ligands 
may act as a method of regulating these processes (Simpson 1997). 
Finally, changes in the levels of PPARo ligands observed in the inflamed 
hindpaw but not in the spinal cord and brain may suggest that 
modulation through PPARa is via a peripheral rather than a central site. 
This has previously been suggested since intraplantar administration of 
PPARa agonists strongly suppresses nociceptive behaviour without them 
entering the central nervous system (LoVerme et al 2006). Therefore, by 
modulating changes in the levels of PPARa ligands peripherally and 
altering the metabolism of these ligands, we may be able to target PPARa 
in inflammation. 
3.5 Conclusions 
A number of PPARo ligands have been shown, some for the first time, to 
bind directly to the receptor using TR-FRET competitive binding assays. 
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The data also showed that levels of PPARa ligands were altered in the 
inflamed hindpaw, suggesting that changes in eicosanoid and 
endocannabinoid metabolism may influence the role of PPARa in 
inflammatory pain states. 
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Chapter 4. 
Investigating the role of 
15-lipoxygenase in the 
generation of endogenous 
ligands that activate 
transient receptor potential 
vanilloid-l channels 
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4.1 Introduction 
4.1.1 TRPV1 channels 
The transient receptor potential vanilloid 1 (TRPV1) receptor is a part of a 
large family of chemically-gated, non-selective cation channels (See 
General Introduction). TRPV1 are activated by different stimuli such as 
heat (>43 °c, Caterina et al 1997), capsaicin (Hwang et al 2000), AEA 
(Smart et al 2000) and low pH (Tominaga et al 1998). TRPV1 is mainly 
found in small- to medium-diameter neurons of primary sensory ganglia 
(dorsal root ganglia, trigeminal ganglia and sympathetic ganglia) (Vay et 
al 2012). TRPV1 has also been shown to be expressed on the terminals of 
primary afferent sensory nerve fibres A and C (See General 
Introduction), in addition to being present in the brain, including areas 
involved in nociceptive transmission (Mezey et al 2000, Toth et al 2005). 
Nociceptors also have an efferent function and release pro-inflammatory 
and pro-nociceptive mediators in the periphery in addition to transmitting 
nociceptive information to the spinal cord (See references in Szallasi and 
Blumberg 1999). The ability of TRPV1 to sensitise following exposure to 
painful stimuli has led to the hypothesis that TRPV1 is a prime factor in 
hyperalgesia (See references in Holzer 2008). Sensitisation of the TRPV1 
channel depends on several mechanisms among which phosphorylation of 
the ion channel by protein kinase A, C and other kinases are important 
(Zhang and McNaughton 2006, Bhave et al 2003, Vellani et al 2001). 
Increased TRPV1 activity by bradykinin and nerve growth factor via 
phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-
bisphosphate is another mechanism of TRPVl upregulation (Prescott and 
Julius 2003). Additionally, rapid recruitment of an intracellular pool of 
TRPVl to the cell membrane also sensitises the ion channel, a process 
most importantly involving phosphoinositide 3-kinase and Src kinase 
(Stein et al 2006, Zhang et al 2005). Interestingly, TRPV1 appear to be 
up-regulated in inflammatory conditions in which expression of TRPV1 is 
found on primary sensory neurons that do not normally express the 
channel (Ji et al 2002, Cortright and Szallasi 2004). As mentioned, TRPV1 
is thought to be a prime factor in hyperalgesia, thus this evidence 
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suggests a link between TRPV1 and the development of inflammatory 
hyperalgesia (Cortright and 5zallasi 2004). 
4.1.2 Role of TRPVl in inflammatory pain 
There is substantial evidence for TRPV1 involvement in inflammatory 
hyperalgesia. Expression of TRPV1 is altered under inflammatory 
conditions; TRPV1 mRNA and protein levels are increased in the skin, 
sciatic nerve and dorsal root ganglia (DRGs) following complete Freund's 
adjuvant (CFA) (Kanai et al 2007) or carrageenan (Tohda et al 2001) 
administration. Carrageenan-induced acute inflammation produced a 
decrease, and increase, in TRPV1 mRNA in the DRG and lumbar cord 
respectively (Tohda et al 2001). Intrathecal colchicine-pretreatment 
(axonal transport inhibitor) prevented carrageenan-induced changes in 
the level of TRPV1 mRNA in the DRG and the dorsal part of the lumbar 
cord (Tohda et al 2001). This finding suggests that the inflammation may 
increase the transcription of TRPV1 in the lumbar cord and that this up-
regulation involves axonal transport of TRPV1 mRNA in primary afferent 
terminals during inflammation (Tohda et al 2001). The results of these 
pharmacological studies further confirm the up-regulation of TRPV1 
receptors during inflammation. 
Knockout studies provided clear evidence for TRPV1 involvement in 
inflammatory heat hyperalgesia and TRPV1 antagonists have been shown 
to be effective in reducing inflammatory mechanical hyperalgesia in 
pharmacological studies (See references in Vay et al 2012). TRPV1 
knockout mice largely failed to develop thermal hyperalgesia in response 
to CFA or carrageenan, showing that TRPV1 is a key element in the 
generation of thermal hyperalgesia (Caterina et al 2000, Davis et al 
2000). 
Blockade of TRPV1 receptors attenuates hyperalgesia. For example, 
TRPV1 antagonists BCTC and 5B-366791 administered intraplantarly 
inhibited CFA-induced thermal hyperalgesia but not mechanical 
hyperalgesia. However, intrathecal administration of BCTC and 5B-
366791 inhibited both CFA-induced thermal and mechanical hyperalgesia 
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(Kanai et al 2007). These findings suggest peripheral TRPV1 involvement 
in thermal hyperalgesia and central TRPV1 involvement in thermal and 
mechanical hyperalgesia (Kanai et al 2007). The wide distribution of 
TRPV1 in the CNS raises the possibility that this ion channel can be 
involved in many brain functions (Steenland et al 2006), including 
participation of pain processing within the brain (Palazzo et al 2008, Cui 
et al 2006, Steenland et al 2006). TRPV1 stimulation in the 
periaqueductal grey by anandamide or capsaicin produces analgesia, via 
glutamate release and stimulation of descending anti nociceptive 
pathways (Palazzo et al 2008). Other sites where TRPV1 may modify 
nociception in the brain include the ventral tegmental area (Marinelli et al 
2005) and the anterior cingulate cortex (Steenland et al 2006). Central 
involvement of TRPV1 under inflammatory conditions has also been 
shown. Electrophysiological studies showed that spinal neuronal 
responses were attenuated by treatment with TRPV1 antagonists under 
inflammatory conditions, although this was found to be equally true in 
the absence of inflammation (Kelly and Chapman 2002, Jhaveri et al 
2005). 
Based on a number of findings, TRPV1 antagonists have therefore been 
shown to be a potential treatment for hyperalgesia (Roberts and Connor 
2006). However, TRPV1 antagonism has been shown to affect core body 
temperature and reduced sensitivity to painful or damaging heat stimuli 
and has therefore lost promise in clinical applications (Vay et al 2012, 
Krarup et al 2011, Round et al 2011). 
4.1.3 Endogenous agonists of TRPVl 
Many endogenous TRPVl agonists have been identified, including 
anandamide (AEA) (Smart et al 2000), N-arachidonoyldopamine (NADA) 
(Huang et al 2002), 12(5)-hydroperoxyeicosatetraenoic acid (12(5)-
HPETE), 15(S)-hydroperoxyeicosatetraenoic acid (15(S)-HPETE) (Flores 
et al 2010, Hwang et al 2000). Recently, there has been interest in a 
family of linoleate-derived lipids, shown to selectively activate TRPV1 in 
native and expression systems (Patwardhan et al 2009). 
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Hydroxyoctadecadienoic acids (HODEs) are metabolites generated from 
linoleic acid (LA) by ls-lipoxygenase (ls-LOX, Vangaveti et al 2010). 
They are stable oxidation products of this essential fatty acid, which are 
increased during oxidation stress. (Vangaveti et al 2010, Banni et al 
2002). LA is only available from the diet, including sources such as beef, 
lamb and dairy products, and it is stored in the cell membranes until 
needed (Belury 2002). There are a number of physiological properties 
associated with LA, it is thought to be antiadipogenic (Sisk et al 2001), 
antidiabetogenic (Houseknecht et al 1998), anticarcinogenic (Ip et al 
2001, Hubbard et al 2000), and antiatherosclerotic (Wilson et al 2000). It 
is also thought to be involved in bone formation, gene expression and the 
immune system, along with fatty acid and lipid metabolism (See 
references in Belury 2002). 
Recent in vitro and in vivo studies have investigated the mechanisms by 
which TPRV1 mediates heat-induced hyperalgesia and thermoregulation 
(Patwardhan et al 2009, Patwardhan et al 2010). In vitro, dissected rat 
spinal cords were superfused in modified Hanks buffer followed by 
exposure to high potassium Hanks buffer (50 mM potassium chloride) for 
30 minutes at 37 °C (Patwardhan et al 2009). This resulted in 
depolarisation of the spinal cord and consequent release of an LA 
metabolite, identified as 9-HODE, shown to activate TRPV1 in transfected 
CHO cells and potently activated spinal TRPV1 (Patwardhan et al 2009). 
In mice, skin biopsies were exposed to basal (37 oC, control) and noxious 
(48 oC, heated) temperatures, but intracellular calcium levels only 
increased in the WT cultured trigeminal ganglia (TG) neurons and not in 
the TRPV1 knockout neurons (Patwardhan et al 2010). These results 
indicate that the heated skin released compound(s) that activate TRPV1, 
which were then identified by LC-MS/MS as 9- and 13-HODE (Patwardhan 
et al 2010). In the same publication, the application of synthetic 9-HODE 
to cultured rat TG neurons triggered the release of immunoreactive 
CGRP, which was significantly (P<O.OOl) blocked by I-RTX (TRPV1 
antagonist) pre-treatment. The metabolites of the respective HODEs, 9-
and 13-oxoODE, shown to activate TRPV1 in transfected CHO cells also 
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elevated intracellular calcium levels in cultured TG neurons from WT mice 
(Patwardhan et al 2010). Furthermore, a combination of anti-9- and anti-
13-HODE antibodies (0.06 and 0.012 I-Ig, respectively) significantly 
(P<0.01) decreased cultured TG neuron responsiveness to noxious heat 
(Patwardhan et al 2010). These findings in vitro suggest TRPVl 
involvement in sensory neuron responsiveness to noxious heat and that 
this receptor system is essential in its function. 
In vivo, studies showed that the 1S-LOX metabolites of LA, 9-, 13-HODE, 
9- and 13-oxoODE, produced behavioural pain responses following 
peripheral and spinal administration. Intraplantar injection of 9-HODE in 
rats produced a dose-related increase in spontaneous nocifensive 
behaviour that significantly (P<0.001) increased following co-
administration with 13-HODE, 9- and 13-oxoODE (Patwardhan et al 
2010). Intraplantar injection of 9-HODE induced thermal hyperalgesia 
which was detected in wild-type (WT), but not TRPVl knockout, mice 
(Patwardhan et al 2010). Intraplantar co-administration of anti-9- and 
anti-13-HODE antibodies significantly (P<0.001) attenuated CFA-induced 
mechanical allodynia in the inflamed hindpaw without affecting 
mechanical thresholds in the contralateral hindpaw (Patwardhan et al 
2009). These findings suggest significant attenuation of TRPV1-mediated 
peripheral nociception through a localised site of action of these lS-LOX 
metabolites. However, these TRPVl ligands were not identified or 
measured. Intrathecal administration of the oxidised metabolites of LA, 
9-, 13-HODE, 9-, 13-oxoODE rapidly evoked mechanical allodynia, which 
was blocked by AMG9810 (TRPVl antagonist) cO-injection, demonstrating 
a TRPV1 specific effect (Patwardhan et al 2009). 
Overall there is mounting evidence that increased TRPV1 function 
contributes to inflammatory hyperalgesia, particularly thermal 
hyperalgesia, however the ligands which mediate this sensitisation of 
TRPV1 are yet to be identified. Recent studies have shown that 9- and 
13-HODE can activate TRPV1 in vitro, and can contribute to nociceptive 
responses in vivo, via TRPV1. On this basis, I hypothesised that 9- and 
13-HODE may also mediate the sensitisation of TRPVl associated with 
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inflammatory hyperalgesia. To test this hypothesis LC-MS/MS was used 
to measure levels of 9- and 13-HODE in the paw in the presence and 
absence of inflammation, and then investigated the effects of blocking 
the generation of 9- and 13-HODE (with a is-LOX inhibitor) on 
carrageenan-induced inflammatory pain responses and levels of 9- and 
13-HODE in the paw. To further substantiate this hypothesis, the effects 
of anti-9- and anti-13-HODE antibodies on inflammatory hyperalgesia 
and levels of 9- and 13-HODE were determined. 
4.1.4 Aims and Objectives 
• To investigate the effects of linoleic acid exposure and 1S-LOX 
inhibition on levels of LA, 1S-LOX metabolites and other 
inflammatory mediators in the dorsal root ganglia. 
• To measure the levels of LA, 1S-LOX metabolites and other 
inflammatory mediators in a model of inflammatory pain. 
• To determine the effect of inhibiting 1S-lipoxygenase (is-LOX) on 
levels of LA, 1S-LOX metabolites and other inflammatory mediators 
in a model of inflammatory pain. 
• To investigate the contribution of 9- and 13-HODE to inflammatory 
pain responses. 
4.2 Methods 
4.2.1 Animals 
Experiments were performed using male Sprague Dawley rats (180-200g 
Charles River, UK) in accordance with the UK Scientific Procedures Act 
(1986). All procedures were approved by the University of Nottingham 
Ethical Review Committee and IASP guidelines. All rats were group-
housed in a temperature-controlled environment (22°C ± 1°C) and 
maintained on a 12 hour light/dark cycle with access to food and water 
ad libitum. 
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4.2.2 Weight Bearing 
Weight distribution (change in weight bearing) between the ipsilateral 
(left) and contralateral (right) hindpaws was measured using an 
Incapacitance Tester (Linton Instrumentation, UK) with help from Dr 
Mohammad Alsalem. The Incapacitance Tester consists of two sensitive 
strain gauge transducers; the rats' hind paws were placed on the separate 
sensors, which measure the force exerted by each limb (in grams) on the 
transducer plate over a given time period. In the present study, the 
weight distribution was calculated over a period of 3 seconds, with 
measurements taken three times at each time point and averaged. 
Studies have shown that less weight is applied on the inflamed paw, and 
that the difference in weight bearing is a measure of the hypersensitivity 
to the inflammatory pain (Clayton et al 2002). The experimenter was 
blind to all treatments. 
4.2.3 Paw volume and paw circumference 
Changes in the paw volume (oedema formation) were measured using a 
plethysmometer (Chapter 3, Methods) and increases in paw 
circumference were also recorded with a loop of cotton thread and ruler 
as described in Chapter 3. Weight bearing and paw volume were 
assessed in the same rats in all behavioural studies. 
4.2.4 Overview of in vivo studies 
4.2.4.1 Pilot studies 
Pilot studies were performed to determine the dose of PO 146176 for 
peripheral administration, previously only given systemically (Jeon et al 
2009) or orally (Bocan et al 1998) and also the timing of the injections of 
9- and 13-HODE antibodies. These were carried out with help from Dr 
Mohammad Alsalem. 
In the first pilot study, the dose of PO 146176 was investigated along 
with optimum timepoint for the measurement of changes in weight 
bearing. Intraplantar doses of 1, 50 and 100 1.19 of PO 146176 in 50 IJL of 
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vehicle (30/0 Tween 80 in saline) were given to rats (n=2), 30 minutes 
prior to 100 IJL of 2% carrageenan to determine a suitable dose for the 
main study. Weight bearing was monitored for four hours post-
carrageenan and paw volume and paw circumference were also 
monitored prior to both injections and after the last weight bearing 
measurement (See Methods). 50 IJg of PO 146176 in 50 IJL of vehicle 
(3% Tween 80 in saline) inhibited pain behaviour and was considered a 
suitable dose. To assess this against control groups, we repeated the 
pilot study with rats (n=2), given either 50 IJL of vehicle (3% Tween 80 
in saline) or 50 IJg in 50 IJL of PO 146176, followed by 100 IJL of 2% 
carrageenan. Another group were given 50 IJg in 50 IJI of PO 146176 
followed by 100 IJL of saline. 
In the second pilot study, we investigated the timing of administration of 
the 9- and 13-HOOE antibodies. Rats were given intraplantar injections of 
50 IJL of 9- and 13-HOOE (25 IJg of each) antibodies of 50 IJL of vehicle 
(PBS), followed 30 minutes later by intraplantar injection of 100 IJL of 2% 
carrageenan (2 rats per group). Inhibition of pain behaviour was 
observed on the first repeat but not a second repeat of the study. After 
discussion of these data, the timing of the injection of antibodies was 
changed so that it was given 1 minute after carrageenan. The rationale 
for this was due to concerns about the stability of the antibodies in vivo, 
since they are degradable peptides. Injection of the antibodies 1 minute 
post-carrageenan would eliminate the possibility of the antibodies 
degrading prior to the carrageenan injection and subsequent effects from 
this. 
4.2.4.2 Main study 
These experiments were carried out with help from Or Mohammad 
Alsalem. Weight bearing measurements were recorded 30 minutes prior 
to the first injection. Rats were anaesthetised with isoflurane / N20/ O2 
(1.5-2% in 66% N20 and 33% O2), and received an intraplantar injection 
of either 50 IJI of a 50 IJg/50 IJL solution of PO 146176 made up in vehicle 
(3% Tween 80 in saline) or 50 IJL of vehicle in the left hindpaw 
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(ipsilateral), followed 30 minutes later by an intraplantar injection of 
either 100 IJL of a 2% carrageenan injection or 100 IJL of saline in the 
same hindpaw. A na'ive group (no injections, but anaesthetised) was also 
used as an additional control. This gave a total of five groups of 6 rats. 
For the study investigating the effects of 9- and 13-HODE antibodies, rats 
received an intraplantar injection of either 100 IJL of a 2% carrageenan 
injection or 100 IJL of saline in the left hindpaw (ipsilateral), followed 1 
minute later by either SO IJL of a mixture of the antibodies (25 I-Ig each) 
or SO I-IL of vehicle (PBS) in the same hindpaw. This study also consisted 
of five groups, with a na'ive group as a control (n=6 per group). 
All solutions were made up fresh on the day of the experiment apart from 
2% carrageenan, which was prepared several days beforehand. Effects of 
intraplantar injection of 2% carrageenan (100 IJL) were measured at 1, 2, 
3 and 4 hours post-injection using weight bearing to monitor pain 
behaviour. Paw volume and paw circumference were measured prior to 
the rats receiving the injections and immediately before tissue collection. 
4.2.5 In vitro DRG experiment 
This experiment was designed to investigate the effects of ORG 
stimulation with linoleic acid and whether the levels of the HODEs 
generated were altered after treatment with PO 146176. Rats (n=2) were 
killed using CO2 overdose, the spinal columns removed and the dorsal 
root ganglia (ORGs) were collected by a method previously described 
(Lindsay 1988). Cell culture and preparation methods were similar to 
those described previously (Millns et al 2001) and were conducted by Dr 
Mohammad Alsalem, along with help in this in vitro experiment. The 
ORGs (20-40 in number), were washed in calcium imaging buffer and 
separated into left thoracic, right thoracic, left lumbar and right lumbar 
regions. PO 146176 (PO) was prepared by diluting 11.9 IJL of stock (10 
mg/mL or 42.1 mM) in SO mL of calcium buffer to give a final 
concentration of 10 IJM. Linoleic acid (LA) was prepared by mixing 20 IJL 
of stock (3.2 M) with 36 IJL of ethanol, then 43.6 IJL of the mixture was 
diluted in SO mL of calcium buffer to give a final concentration of 1 mM. 
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Vehicle 1 (veh 1) was 0.024% of 100% ethanol and vehicle 2 (veh 2) 
was 0.057% ethanol, both prepared in calcium buffer. Petri dishes were 
labelled as groups A-H and filled with solution according to the groupings 
shown in Table I, which were designed to investigate the effects of 
linoleic acid and PD 146176 at 15 or 30 minute post-administration. 
Table 1. Different groups of treatment to investigate the timing and effects of LA and PO 
GROUP A B C D E F G H 
DISH 1 Veh 1 Veh 1 Veh 1 Veh 1 PO PO PO Veh 1 
15 mins 15 mins 15 mins 15 mins 15 mins 15 mins 30 mlns 30 mins 
DISH 2 Veh 2 LA Veh 2 LA LA LA LA LA 
15 mins 15 mins 30 mins 30 mins 15 mins 30 mins 30 mlns 30 mlns 
Individual DRGs were cut in the Petri dishes containing the solutions for 
particular groupings, which were arranged to incorporate the different 
timings allocated. Each group (n=6) contained 2 right thoracic, 2 left 
thoracic, 1 right lumbar and 1 left lumbar DRG. Following the allocated 
time intervals in the different solutions, individual DRGs were placed in 
labelled cryovials and snap frozen on dry ice. These samples were kept at 
-80°C until LC-MS/MS analysis. 
4.2.6 LC/MS-MS analysis 
Following the final set of weight bearing measurements, animals were 
killed by stunning and decapitation by Paul Millns. Hindpaw tissue was 
rapidly collected from all rats used in the weight bearing and paw 
diameter and paw volume experiments and frozen immediately with 
liquid nitrogen. These hindpaw samples were then extracted and 
analysed following the methods detailed in Chapter 2. DRG samples 
collected from the in vitro experiment were also extracted and analysed 
following the same method. Simultaneous measurement of bioactive 
lipids was performed using the LC-MS/MS methodology described in 
Chapter 2. Quantification was performed using Analyst 1.4.1 and 
imported into Microsoft Excel and Graphpad Prism. 
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4.2.7 Data Analysis 
For the studies measuring hind paw volume differences these were 
presented as mean ± SEM, statistical analysis was performed using one-
way ANOVA and a Bonferonni post hoc test. LC-MS/MS data were 
expressed as mean ± SEM, statistical analysis was performed with a 
Mann Whitney test, an unpaired t test with f-test and paired t test. 
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4.3 Results 
4.3.1 Investigating the influence of linoleic acid exposure 
and PD 146176 on levels of lipids in rat dorsal root ganglia 
Calcium imaging experiments were performed by Dr Mohammad Alsalem 
(Appendices: Figure 1&2, Table 1). Linoleic acid produced a slow, but 
robust, increase in intracellular calcium in adult rat dorsal root ganglion 
(DRGs) neurones, an effect which was blocked by the TRPV1 antagonist 
capsazepine, demonstrating that these effects were mediated, at least in 
part, by TRPVl. The onset time of the response to linoleic acid, the ability 
of lipoxygenase inhibition to reduce the number of cells responding to 
linoleic acid, and the magnitude of their responses to linoleic acid support 
the proposal that linoleic acid is metabolised to an active TRPV1 ligand. 
Data collected from the calcium imaging experiments involving 9- and 
13-HODE, PO 146176 and anti-9- and anti-13-HODE antibodies also 
supported the notion that the 1s-LOX metabolites of linoleic aCid, 9 and 
13-HODE, activate TRPV1 in sensory neurones. 
Based on these results, the levels of these 1s-LOX metabolites, along 
with other lipids were measured in the DRGs (See Methods). A range of 
treatment groups designed to investigate linoleic acid (1 mM) exposure 
time and the effect of PO 146176 (10 ~ M ) ) at 15 and 30 minutes were 
used, with control groups for the different time intervals included (Table 
1). 
For each treatment group (n = 6), individual ORGs were exposed to 
either vehicle 1 or PO 146176 for 15 or 30 minutes, followed by vehicle 2 
or linoleic acid for 15 or 30 minutes. DRG exposure to vehicle 1 or PO 
146176 and vehicle 2 or linoleic acid for 30 minutes did not alter levels of 
the lipids measured (data not shown). 
Exposure of the ORGs to linoleic acid for either 15 or 30 minutes did not 
alter the levels of linoleic acid measured in the DRGs using LC-MS/MS, 
compared to levels following exposure to vehicle (Figure 1). By contrast, 
pre-exposure to PO 146176 significantly increased the levels of linoleic 
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acid present in the DRGs following exposure to linoleic acid for 15 
minutes, but not 30 minutes (Figure 1). 
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Figure 1. Levels of the LA detected in wet weight tissue of dorsal root ganglia (ORGs) 
following treatment of vehicle (veh) or PO 146176 (PO) followed by vehicle (veh) or 
linoleic acid (LA) exposure for 15 or 30 minutes, represented as mean±SEM and a scatter 
plot (n=6). The two different styles for presenting the information is to allow for 
difference in interpretation and also to clearly show the distribution of data pOints. 
Statistical analysis was conducted using a one-way Anova with Bonferroni post hoc test, 
*P<O.05, **P<O.Ol. All outlier values greater than 2 standard deviations from the mean 
were excluded, maximum of one per tissue group for each lipid measured. 
LC-MS/MS analysis could not detect either 9- or 13-HODE in adult DRGs 
under un-stimulated conditions (Figure 2), the limit of quantification 
(LOQ) in this method was 0.1 pmol/g respectively for both 9- and 13-
HODE (LOQ for 9- and 13-oxoODE = 0.05 pmol/g, LOQ for AA = 2.5 
pmol/g, LOQ for LA = 0.1 pmol/g). By contrast, following exposure to 
linoleic acid, 9- and 13-HODE were detected in the DRGs (Figure 2). Pre-
exposure to PO 146176 did not significantly alter the absolute levels of 9-
and 13-HODE in the DRGs. Similar trends for the effects of treatments 
were observed for 13-oxoODE and 9-oxoODE with the exception that 
levels of 9-oxoODE were decreased in the PD-treated group (15 minutes) 
followed by 15 minute linoleic acid, which was opposite to that observed 
with 9-, 13-HODE and 13-oxoODE (Figure 2). 
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Figure 2. Levels of the lipids detected per g wet tissue weight in the dorsal root ganglia (ORGs) following treatment of vehicle (veh) or PO 146176 (PO) 
followed by vehicle (veh) or linoleic acid (LA) exposure for 15 or 30 minutes (n=6). Statistical analysis was conducted using a one-way Anova with 
Bonferroni post hoc test, *P<O.05, **P<O.Ol. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per 
tissue group for each lipid measured. 
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Given the importance of considering the flux through enzymatic pathways 
and the amount of substrate available, levels of 9- and 13-HODE were re -
analysed as ratios of absolute levels of linoleic acid in the individual DRG 
preparations to take into account for any variance in linoleic acid uptake 
by the DRGs. Interestingly, when expressed in this manner the levels of 
9- and 13-HODE (expressed as a ratio of the levels of linoleic acid) were 
significantly decreased following pre-exposure to PD 146176 for 15 
minutes, but not 30 minutes (Figure 3). 
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Figure 3. Levels of the 9- and 13-HODE detected per g wet tissue weight in dorsal root 
ganglia (DRGs) following pre-exposure to vehicle (veh) or PD 146176 (PD) followed by 
vehicle (veh) or linoleic acid (LA) for 15 or 30 minutes (n = 6). Data were expressed as a 
ratio of linoleic acid in the individual DRG preparation. Statistical analysis was conducting 
using an unpaired t test with f-test to compare variances, where ** P<O.Ol. 
TXB2 and PGDJPGE2 were not measured in these DRG samples and 
arachidonic acid remained unaltered for all treatment groups (Figure 2). 
5-HETE (TRPV1 agonist) was the only HETE detected in these DRG 
samples, although its levels were unchanged by linoleic acid exposure 
(Figure 2). Levels of the endocannabinoids, AEA and 2-AG increased 
significantly (P<O.Ol, Figure 4) following exposure to linoleic acid for 15 
minutes, but not 30 minutes, following pre-treatment with PD 146176 
(Figure 4). PEA and OEA also followed the same trend (Figure 4), 
although these were not shown to be significant. 
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Figure 4. Levels of the AEA, 2-AG, PEA and OEA detected per g wet tissue weight in dorsal 
root ganglia (DRGs) following treatment of vehicle (veh) or PD 146176 (PD) followed by 
vehicle (veh) or linoleic acid (LA) exposure for 15 or 30 minutes (n=6) . Statistical 
analysis was conducted using a one-way Anova with Bonferroni post hoc test, * P<0.05, 
**P<O.01. All outlier values greater than 2 standard deviations from the mean were 
excluded, maximum of one per tissue group for each lipid measured. 
4.3.2 Investigating the effects of saline and carrageenan on 
lipid levels and inflammatory hyperalgesia in the hindpaw 
Hindpaw tissue was collected 1 hour and 4 hours post-saline or -
carrageenan and the samples were analysed by LC-MS/MS (See 
methods). LC-MS/MS analysis was used to measure levels of 15-LOX 
metabolites and other inflammatory mediators to investigate the effects 
of saline and carrageenan on these lipid levels. The same lipids were 
detected at the one hour time-point as for the four hour time-point, apart 
from 15-HETE, which was only detectable at the four hour timepoint. The 
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chromatograms of several of these lipids measured in hindpaw tissue are 
shown in Figure 5. 
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Figure S. Representative selective ion chromatograms. (A) Analyte standards. (6) 
Metabolites extracted from samples. Each chromatogram is individually normalized. 
Samples were analysed on alSO, 2.0 mm C18 column using a gradient of 
methanol:acetonitrile (20:80 vlv) and aqueous formic acid with ammonium hydroxide. 
The mass spectrometer was operated in MRM mode. 
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4.3.2.1 The effects of saline or carrageenan on lipid levels in the 
hindpaw at one hour post-injection 
One hour following intraplantar injection of carrageenan there was a 
significant decrease in the levels of TRPV1 agonists 12-HETE (P<O.OS), 9-
HODE (P<O.OS) and 13-HODE (P<O.OS) in the carrageenan-treated 
hindpaw at one hour post injection, compared to the vehicle saline-
treated group (Figure 6). There were, however, no significant changes in 
the levels of the other lipids measured at this timepoint (Figure 7), 
including TRPV1 agonists s-HETE, 9-oxoODE and 13-oxoODE (Figure 6). 
8-HETE (PPARa agonist) and 1s-HETE (TRPVl agonist) were both below 
the limit of quantification (BLOQ), 0.1 pmol/g and 0.5 pmol/g 
respectively. 
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Figure 6. Levels of the is-LOX metabolites and other TRPVl agonists detected in the ipsilateral hindpaw per g wet tissue weight following intraplantar 
injection of vehicle (VEH) followed by saline (SAL) or carrageenan (CAR) one hour post-carrageenan (n=6). Statistical analysis was conducted using a 
Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for 
each lipid measured. 
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Figure 7. Levels of the lipid mediators detected per g wet tissue weight in the ipSilateral hindpaw following intraplantar injection of vehicle (VEH) followed 
by saline (SAL) or carrageenan (CAR) one hour post-carrageenan (n=6). Statistical analysis was conducted using a Mann Whitney test, *P<O.05. All 
outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for each lipid measured. 
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There was also a significant decrease in the levels of the endocannabinoid 
2-AG (P<O.OS), and the endocannabinoid like compounds PEA (P<O.05) 
and OEA (P<O.OS), where OEA is also a known TRPVl agonist (Figure 8). 
Levels of the endocannabinoid and TRPVl agonist AEA, followed this 
trend, but did not alter significantly. 
Figure 8. Levels of the endocannabinoids AEA and 2-AG, and the endocannabinoid-like 
compounds PEA and OEA detected per g wet tissue weight in the ipsilateral hind paw 
following intraplantar injection of vehicle (VEH) followed by saline (SAL) or carrageenan 
(CAR) one hour post-carrageenan (n=6). Statistical analysis was conducted using a Mann 
Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the 
mean were excluded, maximum of one per tissue group for each lipid measured. 
4.3.2.2 The effects of saline or carrageenan on lipid levels in the 
hindpaw at four hours post-injection 
Four hours post-carrageenan injection, levels of the lS-LOX metabolites, 
9-HODE and 13-HODE, both TRPVl agonists, were significantly decreased 
(P<O.Ol) in the hindpaw, compared to saline-treated rats (Figure 9). 
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There was a similar trend for 9-oxoODE (P<0.05) and 13-oxoODE (Figure 
9), although significance was not reached for 13-oxoODE. Levels of 
linoleic acid and TXB2 were significantly increased (P<0.05) in the 
carrageenan-treated hindpaw, compared to saline-treated hindpaw at the 
four hour timepoint (Figure 10). Levels of linoleic acid increased by nearly 
2-fold, whereas levels of TXB2 increased by nearly 12-fold, compared to 
saline-treated rats, where this lipid was below the limit of detection. By 
contrast, levels of arachidonic acid and PGD2I'PGE2 were not altered in the 
carrageenan-treated hindpaw, compared to saline-treated rats at this 
four hour timepoint (Figure 10). A number of HETEs were also detected, 
these included TRPV1 agonists 5-HETE, 12-HETE and 15-HETE (Figure 9), 
and also levels of 11-HETE (Figure 10), which were all not altered in the 
carrageenan-treated rats, compared to saline-treated rats at this 
timepoint. These data support a specific modulation of the LA / HODE / 
oxoODE pathway during carrageenan inflammation. 
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Figure 9. Levels of the lS-LOX metabolites and other TRPVl agonists detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar 
injection of vehicle (VEH) followed by saline (SAL) or carrageenan (CAR) four hours post-carrageenan (n=6). Statistical analysis was conducted using a 
Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for 
each lipid measured. 
f : ~ ~
~ ~
~ ~
c 
LA 
Ii i 
I i 
, , 
VEH-SAL VEH-CAR 
Treatment 
AA 
I 
• 
YEH-SAL VEH-CAR 
Treatment 
V · : I , . r " u ' : ~ ' , , i, 
170 
PGD21E2 11-HETE 
I 
I I 2 I I 
VEH-SAL VEH-CAR VEH-SAL VEH-CAR 
Treatment Treatment 
TXB2 
I: I 
YEH-SAL VEH-CAR 
Treabnent 
Figure 10. Levels of the lipid mediators detected per g wet tissue weight in the ipsilateral hindpaw following intrapiantar injection of vehicle (VEH) 
followed by saline (SAL) or carrageenan (CAR) four hours post-carrageenan (n=6). Statistical analysis was conducted using a Mann Whitney test, 
*P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for each lipid measured. 
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Levels of the endocannabinoids AEA and 2-AG in the hindpaw were not 
altered at four hours in carrageenan-treated rats, compared to saline-
treated. However, levels of the endocannabinoid-like lipids PEA and DEA, 
were significantly decreased (P<O.Ol and P<O.OS respectively) in the 
carrageenan-treated rats at this four hour timepoint (Figure 11). 
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Figure 11. Levels of the endocannablnoids AEA and 2-AG, and the endocannabinoid-like 
compounds PEA and OEA detected per g wet tissue weight in the ipsilateral hindpaw 
following intraplantar injection of vehicle (VEH) followed by saline (SAL) or carrageenan 
(CAR) four hours post-carrageenan (n=6). Statistical analysis was conducted using a 
Mann Whitney test, *p<O.OS. All outlier values greater than 2 standard deviations from 
the mean were excluded, maximum of one per tissue group for each lipid measured. 
4.3.2.3 The effects of saline and carrageenan on hindpaw 
inflammation at one and four hours 
Hindpaw volume and circumference were measured several times over 
the course of the experiment. For collection of baseline values they were 
measured before injection of drug treatment or vehicle (See methods) 
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and measured immediately before tissue collection, one hour post-
carrageenan in one study and four hours post-carrageenan in another to 
investigate the effects on hindpaw inflammation at both these time 
points. 
Intraplantar injection of saline did not significantly alter paw volume or 
paw circumference at 1 and 4 hours post-injection in the ipsilateral 
hindpaw. Intraplantar injection of carrageenan significantly altered 
hindpaw volume and circumference one hour and four hour post-injection 
(Figure 12). 
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Figure 12. Intraplantar injection of 2% carrageenan significantly increased the hindpaw 
volume at (Figure 12a and b) and hindpaw circumference (Figure 12c and d) in ipsilateral 
hindpaws compared to control (Veh-Sal) at one hour and four hours post-injection. Data 
were analysed using a Mann Whitney test, **P<O.Ol and * P<O.OS. Data are expressed as 
mean ± SEM of ipsilateral hindpaws (n=6). 
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Hindpaw volume and hindpaw circumference remained unchanged in the 
contralateral hindpaws at both timepoints (data not shown). The effects 
of saline and carrageenan on pain behaviour was also investigated, but 
only at the four hour timepoint. 
4.3.2.4 The effects of saline and carrageenan on pain behaviour 
Intraplantar injection of saline in vehicle pre-treated rats did not 
significantly alter weight bearing between ipsilateral and contralateral 
hindpaws throughout the four hours (Figure 13) and weight-bearing was 
comparable to pre-injection baseline values and also to the na'ive group 
(Figure 13). 
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Figure 13. Intraplantar injection of 2% carrageenan increased weight bearing differences 
between ipsilateral and contralateral hind paws. Vehicle-saline (veh-sal) -treated rats did 
not exhibit changes in weight bearing between the ipsilateral and contralateral hind paw 
and were comparable to na'ive rats. Data were analysed using a one-way Anova with 
Bonferoni post hoc test, ** *P<O.OOl. Data are expressed as mean ± SEM of differences 
in weight bearing between ipsilateral and contralateral hindpaws (n =6). 
Intraplantar injection of 2% carrageenan significantly (P<O.OOl) altered 
the difference in weight bearing between ipsilateral and contralateral 
hindpaws (Figure 13). These carrageenan-induced changes in weight 
bearing were accompanied by significant changes in hindpaw 
inflammation. 
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4.3.3 Investigating the effects of is-LOX inhibition on lipid 
levels and inflammatory hyperalgesia in the hindpaw at one 
and four hours-post carrageenan 
4.3.3.1 The effects of 15-LOX inhibition on lipid levels in the 
hindpaw at one hour post-carrageenan 
LC-MS/MS analysis was used to measure levels of 1S-LOX metabolites 
and other inflammatory mediators to investigate whether inhibition of 1S-
LOX with PD 146176 altered the levels of these lipids in the carrageenan 
model of inflammatory pain. 
At the one hour timepoint, PD 146176 did not significantly alter levels of 
the ls-LOX metabolites 9-HODE, 13-HODE, 9-oxoODE, 13-oxoODE in the 
carrageenan-treated hindpaw, compared to vehicle-treated rats (Figure 
14). There were also no significant changes in other lipid levels observed 
at this timepoint (Figure 15). It is noteworthy that PD 146176 did not 
alter the carrageenan-induced decrease in the 1S-LOX metabolites, 9-
HODE and 13-HODE or 2-AG, PEA, OEA and 12-HETE in the carrageenan 
treated hindpaws at this timepoint. 
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Figure 14. Levels of the 1S-LOX metabolites and other TRPV1 agonists detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar 
injection of vehicle (VEH) or PO 146176 (PO) followed by carrageenan (CAR) one hour post-carrageenan (n=6). Statistical analysis was conducted using 
a Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for 
each lipid measured. 
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Figure 15. Levels of the lipid mediators detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar injection of vehicle (VEH) or PD 
146176 (PO) followed by carrageenan (CAR) one hour post-carrageenan (n=6). Statistical analysis was conducted using a Mann Whitney test, *P<O.OS. 
All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for each lipid measured. 
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Four hours following treatment with PD 146176 and carrageenan, there 
were also no significant differences in the levels of lipids in the hind paw 
of PD 146176 carrageenan-treated rats compared to vehicle carrageenan 
treated rats (Figures 16 and 17). It is noteworthy that PD 146176 did not 
alter the carrageenan-induced decrease in the 1S-LOX metabolites, 9-
HODE, 13-HODE and 9-oxoODE or PEA and OEA in the carrageenan 
treated hind paws at this timepoint. In addition, PD 146176 did not alter 
the carrageenan-induced increase in levels of linoleic acid and TXB2 • 
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Figure 16. Levels of the is-LOX metabolites and other TRPVl agonists detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar 
injection of vehicle (VEH) or PO 146176 (PD) followed by carrageenan (CAR) four hours post-carrageenan (n=6). Statistical analysis was conducted using 
a Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for 
each lipid measured. 
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Figure 17. Levels of the lipid mediators detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar injection of vehicle (VEH) or PD 
146176 (PD) followed by carrageenan (CAR) four hours post-carrageenan (n=6). Statistical analysis was conducted using a Mann Whitney test, *P<O.05. 
All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for each lipid measured. 
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4.3.3.2 The effects of 15-LOX inhibition on carrageenan-induced 
inflammatory hyperalgesia in the hindpaw 
PD 146176 pre-treatment did not significantly alter the carrageenan-
induced increase in the hindpaw volume and hindpaw circumference at 
one hour and four hours (Figure 18). However, the change in hindpaw 
volume and hindpaw circumference were still significant in the PD 
146176-carrageenan treatment group four hours post-injection compared 
to control (Appendices: Table 2). 
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Figure 18. PD 146176 pre-treatment did not Significantly alter the carrageenan-induced 
increase in the hindpaw volume (Figure 18a and b) and hindpaw circumference (Figure 18 
c and d) at one hour and four hours. Data were analysed using a Mann Whitney test, 
**P<O.Ol and *P<O.OS. Data are expressed as mean ± SEM of ipsilateral hindpaws 
(n=6). 
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Hindpaw volume and hindpaw circumference remained unchanged in the 
contralateral hindpaws in all measurements (data not shown). 
At 4 hours post-carrageenan injection, there was a significant increase in 
weight bearing difference between the carrageenan-treated rats 
compared to saline-treated rats (Figure 13). To investigate whether 1S-
LOX inhibition alters pain behaviour, we explored the effects of 
intraplantar injection of the 1S-LOX inhibitor PD 146176 (50 ~ g / 5 0 0 ~ L ) ) on 
carrageenan-induced differences in weight bearing. Intraplantar 
administration of PD 146176 30 minutes prior to 2% carrageenan 
significantly (P<0.01) reduced the carrageenan-induced weight bearing 
difference at 4 hours post-injection compared to vehicle pre-treated rats 
(Figure 19). Rats treated with PD 146176 followed by saline did not show 
any changes in weight bearing, which was comparable to the na'ive and 
vehicle-saline treated groups (Appendices: Figure 3) . 
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Figure 19. Pre-administration of PD 146176 significantly reduced the effect of 
carrageenan on differences in weight bearing four hours post-carrageenan in the 
ipsilateral hindpaw. Data were analysed using a one-way Anova with Bonferoni post hoc 
test, **P<O.01. Data are expressed as mean ± SEM of differences in weight bearing 
between ipsilateral and contralateral hindpaws (n= 6). 
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4.3.4 Investigating the effects of 9- and 13-HODE 
neutralisation on lipid levels and inflammatory hyperalgesia 
in the hindpaw four hours-post carrageenan 
4.3.4.1 The effects of 9- and 13-HODE neutralisation on lipid levels 
in the hindpaw four hours post-carrageenan 
LC-MS/MS analysis was used to measure levels of 1S-LOX metabolites 
and other inflammatory mediators to investigate whether 9- and 13-
HODE neutralisation with selective antibodies altered the levels of lipids 
in vivo. This experiment was conducted to complement the 1S-LOX 
investigation. Overall the effects of intraplantar injection of carrageenan 
on levels of lipids in the hindpaw were consistent with the earlier PO 
146176 4-hour study (data not shown). There was however, a significant 
decrease in AEA (P<0.01) in the carrageenan-treated rats compared to 
saline-treated, which did not reach significance in the earlier study 
(Figure 20). 
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Figure 20. Levels of the endocannabinoid AEA detected per g wet tissue weight in the 
ipsilateral hindpaw following intraplantar injection of vehicle (VEH) followed by saline 
(SAL) or carrageenan (CAR) four hours post-carrageenan (n=6). Statistical analysis was 
conducted using a Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard 
deviations from the mean were excluded, maximum of one per tissue group for each lipid 
measured. 
Four hours following treatment with 9- and 13-HODE antibodies and 
carrageenan, there were no significant differences in the levels of lipids in 
the hindpaw of 9- and 13-HODE antibodies-carrageenan-treated rats 
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compared to vehicle-carrageenan-treated rats (Figures 21 and 22). It is 
noteworthy that 9- and 13-HODE antibodies did not alter the 
carrageenan-induced decrease in the lS-LOX metabolites, 9-HODE, 13-
HODE and 9-oxoODE or AEA, PEA and OEA in the carrageenan treated 
hindpaws. In addition, 9- and 13-HODE antibodies did not alter the 
carrageenan-induced increase in levels of linoleic acid and TXB2 . 
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Figure 21. Levels of the 1S-LOX metabolites and other TRPV1 agonists detected per 9 wet tissue weight in the ipsilateral hindpaw following intraplantar 
injection of vehicle (VEH) or 9- and 13-HODE antibodies (AB) co-administered with carrageenan (CAR) four hours post-injection (n=6). Statistical 
analysis was conducted using a Mann Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, 
maximum of one per tissue group for each lipid measured. 
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Figure 22. Levels of the lipid mediators detected per g wet tissue weight in the ipsilateral hindpaw following intraplantar injection of vehicle (VEH) or 9-
and 13-HODE antibodies (AB) co-administered with carrageenan (CAR) four hours post-injection (n=6). Statistical analysis was conducted using a Mann 
Whitney test, *P<O.OS. All outlier values greater than 2 standard deviations from the mean were excluded, maximum of one per tissue group for each 
lipid measured. 
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4.3.4.2 The effects of 9- and 13-HODE neutralisation on 
carrageenan-induced inflammatory hyperalgesia in the hindpaw 
Co-administration of 9- and 13-HODE antibodies did not significantly alter 
the carrageenan-induced increase in the hindpaw volume and hindpaw 
circumference at four hours (Figure 23). However, the change in hindpaw 
volume and hindpaw circumference were still significant in the 9- and 13-
HODE antibodies -carrageenan treatment group four hours post- injection 
compared to control (Appendices: Table 3). Hindpaw volume and 
hindpaw circumference remained unchanged in the contralateral 
hindpaws in all measurements (data not shown). 
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Figure 23 . Co-administration of 9- and 13-HODE antibodies did not significantly alter the 
carrageenan-induced increase in the hindpaw volume (Figure 23a) and hindpaw 
circumference (Figure 23b) at four hours. Data were analysed using a Mann Whitney test, 
** P<O .Ol and *p<O.OS. Data are expressed as mean ± SEM of ipsilateral hindpaws 
(n ;;6). 
To complement the investigation of is-LOX inhibition, we examined the 
role of 9- and 13-HODEs in inflammatory hyperalgesia using a 
combination of antibodies raised against 9- and 13-HODE (2S j.Jg of each) 
and monitored changes in pain behaviour. The effect of intraplantar 
injection of these antibodies on carrageenan-induced difference in the 
weight bearing was examined. Intraplantar injection of saline to the 
vehicle-treated rats did not induce significant changes in weight bearing 
between ipsilateral and contralateral hindpaws throughout the four hours, 
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which were comparable to pre-injection baseline values and also to the 
naIve group (Appendices: Figure 4). Intraplantar injection of the 
antibodies significantly reduced the carrageenan -induced weight bearing 
difference at 4 hours post-injection (Figure 24). Rats treated with 
antibodies followed by saline did not exhibit any weight bearing 
differences between hindpaws which was comparable to the naIve and 
vehicle-saline treatment groups (Appendices: Figure 4) . 
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Figure 24. Co-administration of 9- and 13-HODE antibodies significantly reduced the 
effect of carrageenan on differences in weight bearing four hours post-carrageenan in the 
ipsilateral hindpaw. Data were analysed using a one-way Anova with Bonferoni post hoc 
test, ** P<O.Ol. Data are expressed as mean ± SEM of differences in weight bearing 
between ipsilateral and contralateral hindpaws (n= 6). 
4.3.5 Summary of findings 
In vitro, PD 146176 significantly increased linoleic acid levels in the ORGs 
following exposure to linoleic acid for lS minutes, but not 30 minutes. 
Levels of 9- and 13-HOOE, expressed as a ratio of the levels of linoleic 
acid, were significantly decreased following pre-exposure to PO 146176 
for lS minutes, but not 30 minutes. Levels of the endocannabinoids, AEA 
and 2-AG increased significantly following exposure to linoleic acid for lS 
minutes, but not 30 minutes, following pre-treatment with PD 146176. 
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In vivo, one hour following intraplantar injection of carrageenan there 
was a significant decrease in the levels of TRPV1 agonists 12-HETE, 9-
HaDE and 13-HODE in the carrageenan-treated hindpaw. Levels of the 
endocannabinoid 2-AG, and the endocannabinoid like compounds PEA 
and OEA also significantly decreased in the carrageenan-treated hindpaw. 
Four hours post-carrageenan injection, levels of the 1S-LOX metabolites, 
9-HODE and 13-HODE in the hindpaw were significantly decreased, 
compared to saline-treated hind paw , along with significant increases in 
the levels of linoleic acid and TXB2 . Levels of the endocannabinoid-like 
lipids PEA and OEA, were also significantly decreased in the 
carrageenan-treated rats. Intraplantar injection of carrageenan 
significantly altered hindpaw volume and circumference one hour and 
four hours post-injection. Intraplantar injection of 2% carrageenan 
significantly altered the difference in weight bearing between ipsilateral 
and contralateral hindpaws at four hours post-injection. At both 
timepoints, PO 146176 pre-treatment did not significantly alter levels of 
the 1S-LOX metabolites and other lipid mediators in the carrageenan-
treated hindpaw. PO 146176 pre-treatment did not significantly alter the 
carrageenan-induced increase in the hindpaw volume and hindpaw 
circumference at both timepoints. However, PO 146176 pre-treatment 
significantly reduced the carrageenan-induced weight bearing difference 
at 4 hours post-injection. Four hours following co-administration of 9-
and 13-HODE antibodies and carrageenan, there were no differences in 
the levels of lipids in the hindpaw of 9- and 13-HODE antibodies-
carrageenan-treated rats. Co-administration of 9- and 13-HODE 
antibodies did not significantly alter the carrageenan-induced increase in 
the hindpaw volume and hindpaw circumference. However, co-
administration of 9- and 13-HOOE antibodies significantly reduced the 
carrageenan-induced weight bearing difference at 4 hours post-injection. 
4.4 Discussion 
4.4.1 Effects of linoleic acid exposure and PD 146176 on 
lipid levels in rat dorsal root ganglia 
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Linoleic acid was found to produce slow but robust increases in 
intracellular calcium in adult rat dorsal root ganglia (DRGs) neurones, 
which were blocked by capsazepine, a TRPV1 antagonist and these 
effects are, therefore, likely to be mediated, at least in part, by TRPV1. 
The onset time of the response to linoleic acid, the ability of 1S-
lipoxygenase inhibition to reduce the number of responding cells, and the 
magnitude of their responses to linoleic acid support the proposal that 
linoleic acid is metabolised to an active TRPV1 ligand. Data collected from 
the calcium imaging experiments involving 9- and 13-HODE, PD 146176 
and anti-9- and anti-13-HODE antibodies also show that the 1S-LOX 
metabolites of linoleic acid, 9 and 13-HODE, directly activate TRPV1 in 
sensory neurones. These data also showed that PD 146176 reduced the 
linoleic aCid-mediated calcium responses in DRG neurones and the 
number of neurones responding to linoleic acid (Appendices: Figure 1&2, 
Table 1). Overall, this suggests that the HODEs could be mediators of the 
linoleic acid response and this was investigated. 
Levels of linoleic acid, HODEs and oxoODEs in DRG neurones were 
measured by LC-MS/MS to investigate whether 1S-LOX metabolism of 
linoleic acid to the HODEs might contribute to the TRPV1-mediated 
response produced by linoleic acid. Previous studies have shown that 9 
and 13-HODE are the major 1S-LOX metabolites of linoleic acid (Baer et 
al 1991, Daret et al 1989).The effects of LA in the absence and presence 
of PD 146176 (10IJM), a selective 1S-LOX inhibitor, which lacks 
antioxidant activity (Sendobry et al 1997) were also determined. 
Exposure of the ORG cells to linoleic acid resulted in a time-dependent 
accumulation of linoleic acid. Pre-treatment of PD 146176 altered linoleic 
acid levels in the DRGs, however, this was also dependent of linoleic acid 
exposure time. PO 146176 alone did not affect lipid levels; however, pre-
exposure to PD 146176 tended to reduce the levels of 9- and 13-HODE 
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15 minutes after linoleic acid suprafusion, although this was not 
significant. Pre-exposure to PD 146176 also reduced the levels of the 
oxidised metabolites 9- and 13-oxoODE, 15 minutes after treatment with 
linoleic acid. 30 minutes after suprafusion with linoleic acid, levels of 9-
and 13-HODE had returned to control values. These results suggest that 
the PO 146176 might be blocking the production of the HODEs and 
oxoODEs at 15 minutes and that this is time-dependent because these 
effects were not seen at 30 minutes. 
Linoleic acid can be metabolised via sequential ~ - 6 6 and ~ - 5 - d e s a t u r a s e e
activity to arachidonic acid in many tissues (Sampath et al 2011, 
Horrobin 1993), linoleic acid exposure did not alter the levels of 
arachidonic acid or its lipoxygenase metabolite 5-HETE in the DRGs, 
which shows that any changes observed are due to linoleic acid 
metabolism only. Levels of AEA and 2-AG increased significantly (P<0.01) 
after 15 minutes of PD 146176 treatment suprafused with linoleic acid for 
15 minutes, compared to control. PEA and OEA also followed the same 
trend, although these were not shown to be significant. Increased levels 
of the endocannabinoids can either be due to increased synthesis or the 
levels to be influenced by decreased metabolism. Increased synthesis 
could involve NAPE-phospholipase D (NAPE-PLD), which generates AEA, 
OEA and PEA from their precursors, N-arachidonoyl 
phosphatidylethanolamine (NArPE), N-oleoyl phosphatidylethanolamine 
or N-palmitoyl phosphatidylethanolamine respectively, or through 
alternative synthetic pathways (Sagar et al 2009). However, this cannot 
be confirmed as none of these precursors mentioned are measured with 
this LC-MS/MS analytical method. We also know that 15-LOX can 
metabolise AEA and 2-AG to 15-hydroperoxyeicosatetraenoic acid-
ethanolamide (15-HPETE-EA) and 15-hydroperoxyeicosatetraenoic acid-
glycerol (15-HPETE-G) respectively. 15-LOX oxidation of AEA has been 
shown to produce 15-HPETE-EA in vitro and in vivo (Khairy and Houssen 
2010). By blocking this metabolic pathway with PD 146176, we may 
potentially increase the levels of AEA and 2-AG. 
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4.4.2 Effects of 20/0 carrageenan on lipid levels, 
inflammation and hyperalgesia 
4.4.2.1 Effects of 2% carrageenan on lipid levels at one hour and 
four hours 
The effects of 2% carrageenan on lipids levels was investigated on the 
basis that changes in lipid levels may occur at an earlier timepoint. Levels 
of the LOX metabolites 9-, 13-HODE, 9- and 13-oxoODE were all 
decreased in the one hour carrageenan-treated hindpaw tissue compared 
with saline-treated controls; 12-HETE, linoleic acid and TXB2 were also 
found decreased, while arachidonic acid and PGD2IPGE2 remained 
unchanged. S- and 11-HETE both did not alter significantly at one hour. 
The endocannabinoids 2-AG, PEA and OEA decreased significantly, AEA 
also followed this trend, but was not significant at this one hour time-
point. 
Levels of the 1S-LOX metabolites 9- and 13-HODE were found to 
decrease significantly in the ipsilateral hindpaw following carrageenan 
administration at four hours; which was not as prominent at one hour. 
These data are consistent with earlier reports that levels of 13-HODE are 
reduced in synovial fluid in carrageenan-induced knee arthritis (Herlin et 
al 1988), This trend was also observed with the oxidation products of the 
HODEs, 9- and 13-oxoODE in the ipsilateral hindpaw, which was 
significant for 9-oxoODE at the four hour timepoint. All four 1S-LOX 
metabolites have been shown to activate TPRVi receptors (Patwardhan 
et al 2010). This decrease in is-LOX metabolites was accompanied by an 
increase in linoleic acid levels in the ipsilateral hindpaw, Linoleic acid 
increased by nearly 2-fold, in the carrageenan-treated rats compared to 
saline. Since linoleic acid is an essential fatty acid that is only available 
from the diet, reduced metabolism could explain the increase in linoleic 
acid observed at four hours. If indeed metabolism in the hindpaw at this 
time-point is decreased, we would expect to see a decrease in the levels 
of linoleic acid metabolites, which is confirmed by the significant 
reduction of 9- and 13-HODE and decreased 9- and i3-oxoODE levels. 
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TXB2 also increased significantly in the carrageenan-treated rats 
compared to saline while arachidonic acid and PGD2iPGE2, along with 5-, 
11- and 12-HETE levels remained unchanged at four hours. The elevation 
in TXB2 observed at four hours is consistent with previous reports that 
this is due to increased expression of COX-2 in peripheral inflammation. 
COX-2 mRNA was measured using real time quantitative PCR and was 
found to be elevated in inflamed hindpaws. Western blot analysis also 
measured an increase in COX-2 protein at 3 hours post-carrageenan 
injection (Guay et al 2004). Levels of PGD2iPGE2 remained unchanged at 
this four hour time-point. Previous reports have shown that levels of PGE2 
monitored for 24 hours post-carrageenan remained unchanged between 
1 to 6 hours post-carrageenan with a significant increase observed 
between 6 and 24 hours. This was noticeably different to the transient 
effects on TXB2 whose levels returned to baseline after 12 hours (Guay et 
al 2004). Levels of arachidonic acid also remained unchanged along with 
other metabolites of this pathway i,e. 5- and 11-HETE at four hours. An 
increase in the COX-2 metabolite of arachidonic acid, TXB2, might be 
expected to be associated with a decrease in arachidonic acid levels. 
However, the levels remain unchanged suggesting increased synthesis of 
arachidonic acid from other pathways may compensate for these 
changes. 
As mentioned, 2-AG, OEA and PEA were found to decrease significantly in 
the carrageenan-treated ipsilateral hindpaws at one hour compared to 
control, whereas AEA also followed the same trend, but did not reach 
significance. However, at four hours post-injection, AEA, OEA and PEA 
decreased significantly in the carrageenan-treated ipsilateral hindpaws. 
2-AG levels also followed the same trend but were not significant. 2-AG 
has previously been shown to decrease significantly in the ipsilateral 
hind paw at three hours, which was accompanied by a reduction in levels 
of AEA, PEA and OEA (Jhaveri et al 2008). These changes suggest either 
increased metabolism of these lipids or decreased synthesis. AEA is an 
ethanolamide derivative of arachidonic acid; the level of which does not 
alter, suggesting alternate pathways of metabolism of AEA. The activities 
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of FAAH (fatty acid amide hydrolase) and MAGL (monoacyl glycerol 
lipase) enzymes responsible for the metabolism of AEA and 2-AG 
respectively, were not shown to differ significantly between carrageenan-
and saline-treated rats (Jhaveri et al 2008). However, COX-2, CYP and 
IS-LOX have all been shown to metabolise AEA and 2-AG which may 
suggest that increased metabolism of these lipids may occur through 
these alternative pathways. Interestingly, AEA is also a TRPVl agonist 
(Huang et al 2002) and there have been many established papers on the 
interaction of AEA with TRPVl in pain pathways (Di Marzo et al 2002, 
Iverson and Chapman 2002, Rice et al 2002). Along with other TRPVl 
agonists, 9- and 13-HODE, which were also shown to decrease 
significantly in the carrageenan-treated rats, these data suggests 
involvement of TRPVl in this model of inflammatory pain. 
4.4.2.2 Effects of 20/0 carrageenan on lipid levels, inflammation and 
hyperalgesia 
The significant changes in a number of lipids measured using LC-MS/MS 
was also accompanied by inflammation and hyperalgesia observed in the 
carrageenan-treated rats at four hours. Intraplantar injection of 
carrageenan resulted in significant hind paw oedema and hyperalgesia, 
four hours post-injection. This is consistent with previous studies which 
have also shown that carrageenan administration into the hindpaw 
results in increased hindpaw volume, oedema and hyperalgesia at four 
hours (Thorpe et al 2011, Pabreja et al 2010). This significant change in 
hind paw volume and hindpaw diameter was also observed in the rats one 
hour post-carrageenan injection. Pro-inflammatory agents are generated 
in situ at the site of injury or by infiltrating cells. These include 
bradykinin, tachykinins, histamine, reactive oxygen and nitrogen species 
and complements (Morris 2003). Recently, it has been suggested that 
histamine release sensitises acid-induced responses through TRPVl 
activation via the coupling of the histamine-l receptor to the 
phospholipase C / protein kinase C pathway (Kajihara et al 2010). During 
inflammation, the extracellular pH decreases and this tissue acidosis is at 
least partially responsible for the hyperalgesia observed. TPRVl receptors 
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which are activated by protons are highly expressed in sensory neurons 
and are important in nociception and pain perception. Mice lacking TRPVl 
receptors show signs of impaired nociception and several TRPV1 
antagonists are shown to attenuate hyperalgesia in vivo (Kajihara et al 
2010, Caterina et al 2000). Reactive oxygen species (ROS) such as 
hydrogen peroxide are also produced during inflammation at the affected 
site and increased levels of this were found to be significantly raised in 
the carrageenan-induced inflamed hindpaw (Keeble et al 2009). This 
evidence along with significant changes in lipid levels of TRPVl agonists, 
may suggest involvement of TRPVl in this model of inflammatory pain. 
4.4.3 Effects of selective 15-lipoxygenase inhibition on lipid 
levels, inflammation and hyperalgesia 
Selective is-LOX inhibition with PD 146176 pre-treatment (SOj.Jg jsOj.JI) 
was shown to significantly attenuate hyperalgesia at four hours post-
carrageenan administration; however PD 146176 did not have any effect 
on inflammation, which was reflected by the lack of change in hindpaw 
volume and hindpaw circumference between PD 146176-treated and 
vehicle-treated rats. The precursor of the is-LOX metabolites, linoleic 
acid, is largely distributed in membrane phospholipids (Banni et al 2001), 
whereas is-LOX is present in the cytosol (Spanbroek et al 2001). 
Importantly, in sensory nerve processing of noxious inputs, increases in 
intracellular Ca2+ produces a translocation of is-LOX to the plasma 
membrane (Andersson et al 2006), increasing substrate availability and 
possibly favouring the generation of is-LOX metabolites. Thus, if this 
Ca2+ -mobilising stimuli in sensory nerves may lead to HaDE and oxoODE 
generation, then activation of TRPVl channels may occur, followed by 
further influx of intracellular calcium. In this context, conversion of 
linoleic acid to HODEs and oxoODEs may act as an amplifying mechanism 
to enhance nociceptive stimuli, in a similar manner as proposed for the 
endocannabinoid anandamide (van der Stelt et al 2005). However, PO 
146176 was not shown to have any effect on the carrageenan-induced 
changes in lipid levels at both timepoints measured and may therefore 
add value to the hypothesis that the levels of HODEs and oxoOOEs are 
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affected by physiological processes such as oxidative stress as these 
changes are observed in vitro but not in vivo. 
We hypothesised that a decrease in 1S-LOX metabolites such as 9-, 13-
HODE, 9-, 13-oxoODE would be found in the PO 146176-treated rats, yet 
this was not the case. A decrease in HODE and oxoODE levels through 
1S-LOX inhibition was not observed at this four hour time-point, 
suggesting the analgesia seen in these rats is not due to a change in 1S-
LOX metabolite levels. However, there may be a number of factors that 
may explain the reason for these observations. First, the change in these 
metabolites may be transient and one of the main limitations of LC-
MS/MS is to be able to find the exact time-point for tissue collection and 
to capture this "snapshot moment" to show these changes occur, which 
can be extremely difficult. Second, all the lipids present in the whole 
section of hindpaw tissue collected are extracted so we are unable to 
differentiate as to whether these lipids are intracellular or extracellular or 
the cells involved in the production of these lipids. Measurements in the 
inflamed hindpaw may reflect the most abundant cells, in this case the 
epidermis rather than the sensory nerves and activated immune cells. 
Therefore subtle changes in levels of the bioactive lipids that may explain 
the attenuation of pain behaviour through 1S-LOX inhibition by PO 
146176 may not be detectable. Finally, HODEs are the stable oxidation 
products of linoleic acid, the generation of which is increased in oxidative 
stress, such as atherosclerosis and other inflammatory conditions 
(Vangeveti et al 2010, Banni et al 2002). At the four hour time-point, 
there was a significant amount of oedema and therefore pronounced 
inflammation, which would possibly increase the production of the 
HODEs, which can also be generated through non-enzymatic oxidation of 
linoleic acid (Vangaveti et al 2010). Although we have, in this study, 
inhibited 1S-LOX with PO 146176, the production of these lipids can also 
be generated via alterative pathways. We know 9- and 13-HODE can be 
generated enzymatically by 1S-LOX and this occurs in some tissues (Baer 
et al 1991, Daret et al 1989) or they can be formed spontaneously via 
196 
free radical generation (Yoshida et al 2006), which may explain these 
observations. 
4.4.4 Effects of 9- and 13-HODE neutralisation on lipid 
levels, inflammation and hyperalgesia 
Intraplantar administration of the antibodies of 9- and 13-HODE 
significantly reduced the carrageenan-induced difference in weight 
bearing, attenuating hyperalgesia but had no effect on hind paw oedema 
and inflammation at the four hour time-point. The effects observed with 
the antibodies mimicked those seen with selective lS-LOX inhibition. 
These data provide the first evidence that 9- and 13-HODE may have an 
endogenous role in the peripheral mechanisms of inflammatory 
hyperalgesia and that lS-LOX may contribute to their generation, 
although, lS-LOX involvement was shown only in vitro. These data are 
also consistent with the demonstration that local hindpaw neutralisation 
of 9- and 13-HODE with anti-9- and 13-HODE antibodies attenuates 
thermal nociception (Patwardhan et al 2009) and that spinal 
administration of anti 9- and 13-HODE antibodies attenuates CFA evoked 
mechanical allodynia (Patwardhan et al 2010). However, co-
administration of the 9- and 13-HODE antibodies failed to prevent any of 
the carrageenan-induced changes in lipid levels in the hind paw tissue at 
the four hour time point, again, mimicking the majority of the trends 
observed following lS-LOX inhibition. This included similar trends 
observed for the lS-LOX metabolites; HODEs and oxoODES, linoleic acid 
and the endocannabinoids. These data also adds further value to the 
hypothesis that the levels of HODEs and oxoODEs are affected by 
physiological processes in ViVO, and that changes, if any, in these lipid 
levels may be transient and would require further investigation. 
4.5 Conclusions 
Two independent studies investigating effects of lS-LOX enzyme 
inhibition and neutralisation of the HODEs, both showed significant 
attenuation of hyperalgesia in the carrageenan inflammatory model, 
which was not coupled to changes in inflammation or lipid levels 
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measured. This physiological effect was observed in both cases, but we 
could not relate this to a change in the 1S-LOX metabolites measured. 
Investigation at an earlier time-point also did not show any modulating 
effects of PD 146176 on linoleic acid and its IS-LOX metabolites in vivo. 
A significant reduction in the 1S-LOX metabolites 9- and 13-HODE was 
observed in vitro in DRG neurons, which was shown to be time-
dependent. Thus IS-LOX inhibition has been shown to be analgesic, but 
not anti-inflammatory, which may be due to transient blockade of pro-
inflammatory mediators such as the HODEs acting via TRPV1 pro-
nociceptive channels. Further work may be required to determine 
whether these lipids alter in vivo under other inflammatory conditions 
and to further establish the therapeutic potential of 1S-LOX as a target 
for inflammatory pain responses. 
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Chapter 5. 
Investigating the pain 
behaviour and the lipid 
profile of different tissues 
in a rat model of 
osteoa rth ritis 
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5.1 Introduction 
5.1.1 Osteoarthritis 
Osteoarthritis is a condition that affects the synovial joints and is 
characterised pathologically by damage in focal areas to articular 
cartilage involving the load-bearing areas. It is also associated with new 
bone formation at the joint margins (osteophytosis), variable degrees of 
mild synovitis, changes in the subchondral bone and thickening of the 
joint capsule (See references in Dieppe and Lohmander 2005). These 
biomechanical and biochemical joint changes and the failure of the repair 
process of damaged cartilage are characteristics of OA (Bijilsma et al 
2011). Cartilage is non-vascularised and the supply of nutrients and 
oxygen to the chondrocytes (cells responsible for maintenance of a large 
extracellular matrix) is restricted (Bijilsma et al 2011). Initially, clusters 
of chondrocytes form in the damaged areas of the joint in an attempt to 
repair and increases the concentration of growth factors in the matrix 
(Aurich et al 2005). Increased synthesis of tissue-destructive proteinases 
such as matrix metalloproteinases (MMPs, Baragi et al 2009), coupled 
with inadequate matrix component synthesis, lead to a matrix incapable 
of withstanding normal mechanical stresses (Bijilsma et al 2011). A 
vicious cycle of synthesis and degradation of chondrocyte clusters ends in 
an inbalance which ultimately leads to degradation of the extracellular 
matrix (Bijilsma et al 2011). 
The pathology of osteoarthritis has long been thought to be cartilage-
driven; however, recent evidence shows the involvement of bone and 
synovial tissue (See references in Bijilsma et al 2011). Synovial 
macrophages produce catabolic and pro-inflammatory mediators during 
the inflammatory process, which negatively impacts on the balance of 
degradation and repair of the extracellular matrix. This amplifies synovial 
inflammation, which is linked to joint swelling and inflammatory 
hyperalgesia (See references in Bijilsma et al 2011). In synovitis, 
overproduction of cytokines and growth factors, in particular, tumour 
necrosis factor alpha (TNF-a) and interleukin-l (IL-l, Bondeson et al 
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2006) may contribute to the pathophysiology of OA. Both are thought to 
be key cytokines in synovial inflammation and activation of chondrocytes 
(Fernandes et al 2002), driving their own production and inducing 
synovial cell and chondrocyte production of IL-6, IL-8, leukocyte 
inhibitory factor, proteases and prostaglandins (Bondeson et al 2006). 
These mediators, released from the synovium, bone and other tissues 
induce sensitisation of articular nociceptors, which are not confined to the 
periphery. Pain perception at the site of injury is enhanced, along with 
the development of pain and tenderness in normal tissues adjacent to 
and distant from the primary site. In OA patients, spinal nociceptive 
processing is under the influence of descending inhibitory controls and 
inputs from other somatic structures (Kidd et al 2007). 
5.1.2 Molecular pathways in OA pain 
Chronic pain is often associated with osteoarthritis and the mechanisms 
underlying this are known to be complex; however, recent developments 
have led to improved understanding of molecular pathways in OA pain 
(Sofat et al 2011). Ongoing joint destruction is known to occur in OA 
(Dieppe and Lohmander 2005) including osteophyte and subchondral cyst 
formation and bone sclerosis, which may impair joint motility and induce 
pain (Sofat et al 2011). Physiological mechanisms of pain operate at 
different levels; locally in the joint, in the dorsal root ganglia (DRG) and 
in higher brain processing centres. As stated earlier, prO-inflammatory 
mediators released into the OA joint can cause localised damage to 
tissues such as the synovium and activate peripheral nociceptors (Sofat 
et al 2011, Kidd et al 2007). During chronic activation, the nociceptive 
system becomes sensitised, leading to hyperalgesia (heightened 
sensitivity to noxious stimuli), and allodynia (pain in response to non-
noxious stimuli; Bolay and Moskowitz 2002). Nociceptor activation is 
transmitted via the DRG, up through the spinothalamic tract to higher 
cortical centres where signals are processed and perceived as pain (Woolf 
2004). Mediators of pain at the DRG level in OA include calcitonin gene-
related peptide (CGRP), nerve growth factor (NGF) and transient receptor 
potential cation channel subfamily V member 1 (TRPV1; Schuelert et al 
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2010). In the brain, chemical mediators of pain include substance P, 
glutamate and serotonin (Niissalo et al 2002). Additionally, ion channel-
linked receptors on sensory afferent neurons are activated by primary 
sensory neurons stimulated by prostaglandins, bradykinin and CGRP, 
including heat-sensitive TRPV1 (Sofat et al 2011). Changes in joint 
temperature during chronic inflammation may also activate this particular 
receptor (Sofat et al 2011). 
Another phenomenon, central sensitisation, has also been shown to be a 
component of OA pain with evidence relating to models of 
musculoskeletal pain suggesting that OA is associated with enhanced 
nociceptive transmission at the dorsal horn and secondary hyperalgesia 
(Pinto et al 2007, Naeini et al 2005). Central sensitisation consists of 
several components; increased response to input from an injured or 
inflamed region, increased response from regions adjacent to or remote 
from the injured/inflamed region and expansion of the receptive field of 
the spinal cord neuron (Schaible et al 2006). It is also widely appreciated 
that the descending pain pathways directly modulate nociceptive 
processing in the dorsal horn (Tracey and Mantyh 2007). In chronic pain 
states, in which central sensitisation is a component, descending 
facilitation is thought to playa pivotal role in its maintenance (Suzuki and 
Dickenson 2005, Gebhart 2004). Recently, evidence has emerged that 
central sensitisation occurs in humans (Gwilym et al 2009, Lee et al 
2008). Functional magnetic resonance imaging (fMRI) and quantitative 
sensory testing (QST) methods were used to Identify areas of increased 
brain activity and analyse psychophysical and behavioural aspects in OA 
patients. Increased activity was found in the periaqueductal grey and this 
was associated with stimulation of the skin in referred pain areas of the 
OA patients (Gwilym et al 2009). 
5.1.3 Current treatment for osteoarthritis 
In the early stages of osteoarthritis, pain and stiffness of the joints are 
the most prominent symptoms and treatment is focussed around the 
reduction of these and maintaining function (Bijilsma et al 2011). 
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Paracetamol is the recommended analgesic of choice for mild to 
moderate pain in OA and is generally well tolerated for up to 12 months. 
Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, 
diclofenac and naproxen have been shown to be highly effective in 
treating acute pain, (Bijilsma et al 2011). However, over time, the need 
for stronger analgeSiCS, such as opioids, may be required due to 
decreased effectiveness and the appearance of side effects associated 
with the long-term use of NSAIDs (Scott et al 2000). Adverse effects 
include gastrointestinal bleeding and ulceration, with long-term use 
leading to gastrointestinal damage and renal irritation (Koeberle and 
Werz 2009, Scott et al 2000). Currently there are no treatments that 
delay the onset of OA or repair joint damage and, for this reason coupled 
with inadequate analgesic medication, novel targets are under 
investigation. 
5.1.4 Models of OA pain 
Studies using models of knee joint pathology are important tools for 
understanding the mechanisms underlying osteoarthritis and also to 
investigate new potential targets of treatment. Biochemical, cell or organ 
culture models can only provide information on short-term biological 
events within cartilage, bone, synovium or selective cells investigated. In 
vitro models are not able to simulate the structural and biochemical 
processes that occur within these joint tissues over time. Animal models 
of OA are, therefore, required to study complex changes in the joint 
tissues that evolve over time and other factors such as the environment 
which may have an effect (Pritzker 1994). There are two classes of 
animal models of OA in use; spontaneous or naturally occurring disease 
models and experimentally-induced models. Relevance, availability and 
appropriateness are considered when deciding on the choice of animal 
model. This includes how comparable the animal model is to the human 
form of the disease and depending on the objectives of the study, the 
simplicity and reproducibility of the model. Practical factors such as 
animal supply, maintenance of controlled environments, cost and ease of 
handling are also considered (Neugebauer 2007, Pritzker 1994). 
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5.1.4.1 Spontaneous disease models 
spontaneous OA occurs in a number of different animals such as guinea 
pigs, non-human primates, Syrian hamsters and mice. The OA model in 
Duncan-Hartley guinea pigs is well characterised; damage occurs in the 
medial joint compartment of male and female guinea pigs, although 
pathological alterations are more consistent in males (Little and Smith 
2008, Bendele 2001). Spontaneous OA in the knee joints has also been 
described in non-human primates; however, variability in the severity of 
lesions, availability of adequate animal numbers and ethical issues are 
disadvantages of employing these animals (Bendele 2001). Syrian 
hamsters (Silberberg et al 1952) and mice are also used as spontaneous 
OA models, although the cartilage layers are less substantial compared to 
larger species and are more difficult to analyse for cartilage degeneration 
(Bendele 2001). 
5.1.4.2 Experimentally-induced models 
Models of OA can be experimentally-induced either surgically or 
chemically. A unilateral medial meniscal tear in 300-400g rats, where the 
meniscus is cut at the narrowest pOint, results in chondrocyte and 
proteoglycan loss, osteophyte formation and chondrocyte cloning. 
Progressive cartilage degeneration occurs where the lesions are 
morphologically similar to the human disease, but occurs much more 
rapidly (Bendele 2001). This surgical procedure can also be performed in 
guinea pigs and, since spontaneous OA occurs in this species, the non-
operated joint can also be used to evaluate the model (Little and Smith 
2008, Bendele 2001). Rabbits and dogs have also been used; both 
species, especially rabbits attempt to regenerate the transected meniscus 
with fibrous tissue after the procedure (Bendele 2001). The main 
disadvantage of this technique is that the onset and severity of the 
disease caused by transection is usually much higher than that observed 
in humans (Little and Smith 2008). Transection of the anterior cruciate 
ligament can result in a lesion which mimics naturally occuring OA in 
dogs or in humans following traumatic injury. However, this model of OA 
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progression requires extended periods of time and is more suitable for 
investigating OA of slow progression and representative of the condition 
in humans (Bendele 2001). Subcutaneous administration of naladixic acid 
350mg/kg (quinolone antibiotic) in guinea pigs causes a characteristic 
blister-like lesion in the mid-zone cartilage, in which degenerative 
changes are observed 24 hours post-administration (Bendele 2001). 
Pathological changes can also be induced via intra-articular injection of 
enzymes (papain, collagenase, trypsin, hyaluronidase) cytokines 
(interleukin-1, transforming growth f a c t o r - ~ ) ) and chemicals 
(monosodium iodoacetate). Many of these agents induce significant acute 
local inflammation at the site of injection and may not replicate the 
naturally occurring disease process of OA observed in humans (Little and 
Smith 2008, Bendele 2001). 
The monosodium iodoacetate (MIA) model has emerged as a particularly 
useful model of OA pain as it is reproducible and mimics the 
histopathological changes and pain observed in human OA (Barve et al 
2007). Intra-articular injection of MIA inhibits glycolysis and causes 
chondrocyte necrosis, resulting in decreased articular cartilage thickness 
and fibrillation of the cartilage surface (Little and Smith 2008). This 
separates the necrotic cartilage from the underlying bone, exposing the 
subchondral bone, resulting in osteolysis and swelling of the joint (Little 
and Smith 2008, Neugebauer 2007). Advantages of using rats are the 
rapid speed of onset of the disease, easy management, low cost and ease 
of performing surgical procedures (Little and Smith 2008). Rats are also a 
speCies with virtually no spontaneous knee OA, so the lesions observed 
are usually due to the procedure performed (Bendele 2001). 
5.1.5 MIA model of OA and measurement of lipids 
The majority of OA animal model experiments have investigated the 
pathophysiology and progression of joint damage and have incorporated 
characterisation of pain behaviour (Orita et al 2011, Schuelert et al 2011, 
Takeshita et al 2011, Chu et al 2011, Ferland et al 2011, 1m et al 2010, 
Yoshimi et al 2010, Puttfarcken et al 2010, Baragi et al 2009, Chandran 
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et al 2009, Clements et al 2009, Prochazkova et al 2009, Pulichino et al 
2006). The MIA model of OA, in particular, is commonly used because the 
pathological changes induced by the monosodium iodoacetate injection 
share many similarities with human OA (Guzman et al 2003). The 
injection also leads to chronic degeneration of the joint associated with 
chronic pain behaviour and alteration in hind limb weight bearing 
(Pomonis et al 2005, Guzman et al 2003). The severity of the disease can 
also be easily manipulated by varying the concentration of 
monoiodoacetate injected, and the rapid induction of disease (28 day 
model) in the rats allows evaluation of pain modifying compounds 
(Pomonis et al 2005). At post-operative (PO) day 7 as a result of intra-
articular injection of MIA, mild synovial membrane hyperplasia and sub-
synovial fibroplasia are known to occur (Clements et al 2009). To a lesser 
extent, patellar cartilage necrosis, chondroplasia and bone necrosis have 
also been shown to occur at this timepoint (Clements et al 2009). The 
extent of cartilage damage at this time-point is characterised by loss of 
chondrocytes, with thinning and complete collapse of the cartilaginous 
matrix. Bone lesions consistent with bone resorption also begin to 
develop within 7 days of MIA injection (Guzman et al 2003). In addition 
to further progression of the histological and pathological changes seen 
at PO day 7 and 14, sub-synovial fibroplasia and fibrosis, patellar 
chondral fragmentation and disintegration of necrotic subchondral bone 
are observed at PO day 21, with further progression at PO day 28 
(Clements et al 2009). 
Progressive tactile allodynia and elevated cytokine concentrations have 
been observed in MIA-treated Sprague-Dawley rats (Orita et al 2011, 1m 
et al 2010). Allodynia was detectable in all MIA-treated rats 7 days post-
injection, and was also accompanied by a change in hind limb weight 
distribution, with the greatest effects observed between day 14 and 42 
post-injection (Combe et al 2004). 
Several pain-modifying compounds have been tested in the MIA model 
due to links with the cannabinoid and TRPVl pathways (Sagar et al 2010, 
Schuelert et al 2008). Systemic administration of the FAAH inhibitor 
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URB597 significantly reduced hind limb incapacitance in MIA-treated 
animals, which was abolished by co-administration of a CB1 antagonist 
AM251 (Schuelert et al 2011). Grip force deficit was also shown to 
improve following systemic administration of the selective TRPVl receptor 
antagonist A-889425 (Chu et al 2011). Another area of research involves 
studies that identify target molecules involved in OA onset and 
progression, and these have focussed on genomic and proteomic profiling 
of synovial fluids (Gobezie et al 2007) and cartilage (Iliopoulos et al 
2008, Ijiri et al 2008). However, to date, there has been little focus on 
the bioactive lipids involved in OA, which has a strong inflammatory and 
pain component. In vitro genomic and proteomic profiling of tissues was 
able to show certain classes of molecules to be differentially expressed in 
OA, but the scope was limited (Goldring et al 2011). Also, the 
mechanisms underlying the development of OA and pain are still poorly 
understood and current drug treatments are not targeted to a specific 
mechanism. It is clear that the changes in sensory input in the joint are 
critical in driving the disease and many bioactive lipids have either pro-
or anti-inflammatory actions. The ability to monitor and measure the 
changes in these bioactive lipids may lead to identification of potential 
targets for OA pain and highlight key enzymatic pathways. 
5.1.6 Aims and Objectives 
• To investigate the effects of intra-articular injection of monosodium 
iodoacetate (MIA) on pain behaviour in rats 
• To identify and measure pro- and anti-inflammatory mediators in 
different tissues in the MIA rat model 
• To determine whether any effects on pain behaviour observed are 
associated with changes In the levels of measured lipids in the 
spinal cord, dorsal root ganglia (DRGs), knee jOint, plasma and 
brain 
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5.2 Methods 
5.2.1 Animals 
Experiments were performed on male Sprague Dawley rats (130-150g 
Charles River, UK) in accordance with the UK Scientific Procedures Act 
(1986). All procedures were approved by the University of Nottingham 
Ethical Review Committee and IASP guidelines. All animals were group-
housed in a temperature-controlled environment (22°C ± 1°C) and 
maintained on a 12 hour light/dark cycle with access to food and water 
ad libitum. 
5.2.2 Intra-articular Injections 
This procedure was carried out by Dr Devi Rani Sagar. 
Rats were anaesthetised with isoflurane / N20 / O2 (1.5-2% in 66% N20 
and 33% O2) before receiving an intra-articular injection of either 
monosodium iodoacetate (MIA, 1mg / 50 IJL) in saline or 50 IJL of saline 
(control) through the infra-patellar ligament of the left knee. The dose of 
MIA received by the rats was based on previous work within the group 
and on the published literature (Pomonis et al 2005, Bove et al 2003, 
Kobayashi et al 2003). The rats were then weighed, placed in individual 
cages and allowed to recover in a suitable environment (correct 
temperature, lighting and minimal noise). The animals were then 
monitored throughout the following 28-day period. 
5.2.3 Pain behaviour testing 
The following procedures were carried out by Dr Bright Okine. 
After receiving the intra-articular injections, rats were kept under the 
same conditions as described earlier (see Animals). The animals were 
carefully monitored following recovery from the first post-operative (PO) 
day, when they were weighed following the measurement of pain 
behaviour. The general behaviour of all the rats was also monitored 
throughout the period of the study. Baseline values for weight-bearing 
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and von Frey behavioural testing were taken prior to the intra-articular 
injection (PO day 0). Pain behaviour testing was then conducted 3 days 
post-injection (PO day 3), 7 days post-injection (PO day 7), 14 days 
post-injection (PO day 14), 21 days post-injection (PO day 21) and 28 
days post injection (PO day 28). 
5.2.3.1 Weight Bearing 
Weight bearing measurements using an Incapacitance Tester (Linton 
Instrumentation, UK) were performed to examine the effects of the MIA 
injection on weight distribution between the left (ipSilateral) and the right 
(contralateral) knee. Measurements were taken on PO day 0, PO day 3, 
PO day 7, PO day 14, PO day 21 and PO day 28, following the intra-
articular injection, using the methods previously described in Chapter 4. 
5.2.3.2 Von Frey testing 
Pain behaviour was also tested using von Frey monofilaments (Semmes-
Weinstein monofilaments, applied bending forces used 0.6, 1.0, 1.4, 2.0, 
4.0, 6.0, 6.0, 10.0 and 15.0 g). This test measured the withdrawal 
threshold to a mechanical stimulus (von Frey monofilaments); a decrease 
in withdrawal threshold is indicative of mechanical allodynia. The 
development of mechanical allodynia over the time course measured was 
also monitored. Measurements were taken PO day 0, PO day 3, PO day 7, 
PO day 14, PO day 21 and PO day 28, following the intra-articular 
injection. Rats were placed in plastic transparent cubicles containing a 
mesh floor and allowed to acclimatise to the environment before testing 
commenced. Application of von Frey microfilaments in ascending order of 
bending force to the plantar surface of the left and right hindpaws of each 
rat tested lasted for a period of three seconds per microfilament, until a 
withdrawal reflex was observed. The hindpaw was then re-tested with the 
von Frey microfilament at a lower force (the next lowest microfilament) 
to check that no response occurs. The lowest force required to produce a 
withdrawal reflex was recorded for both the left and the right hindpaw, 
this is known as the paw withdrawal threshold. 
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5.2.4 LC-MS/MS Analysis of lipids 
On PO day 28, following the last set of pain behaviour tests, the animals 
were killed by stunning and decapitation by Professor David Kendall. 
Dissection of the spinal cord (ipsilateral and contralateral) by Dr James 
Burston, dorsal root ganglia (DRGs, ipsilateral and contralateral) by Paul 
Millns, knee jOint (ipsilateral and contralateral) and brain regions (frontal 
cortex, hippocampus, midbrain, rest of cortex and rest of brain) by 
Professor David Kendall and were frozen immediately in liquid nitrogen. 
Blood was also collected from these rats, centrifuged and the plasma 
frozen immediately in liquid nitrogen. All samples were stored at -80°C 
until needed. The samples were then extracted and analysed following 
the methods detailed in Chapter 2. 
5.2.5 Data Analysis 
For the studies measuring weight-bearing, differences are presented as 
means ± SEM; statistical analysis was performed using one-way ANOVA 
and a Bonferonni post hoc test. LC-MS/MS data are expressed as mean 
± SEM, statistical analysis was performed with a Mann Whitney test. 
Principal component analysis (PCA) was used for further data processing 
(See Chapter 2 for details). PCA was performed by importing the levels of 
each individual lipid measured from different tissue types from Microsoft 
Excel into the SIMCA-P software package (Version 11, Umetrics AB, 
Umea, Sweden). Data were reduced to two latent variables (or principle 
components) that will describe the maximum variation within the data 
(Law et al 2008) to create a two-component model expressed as scores 
and loadings plots. The principle components obtained from the scores 
highlighted clusters, trends and outliers within the dataset. 
210 
5.3 Results 
5.3.1 Effect of saline injection on pain behaviour in rats 
Differences in weight distribution between ipsilateral and contralateral 
hindpaws and hindpaw withdrawal threshold in rats were monitored for 
28 days (see methods), during which baseline values were recorded pre-
saline or MIA intra-articular injection (Figure 1). Intra-articular injection 
of saline did not alter weight distribution (Figure 1a) or hindpaw 
withdrawal thresholds in the ipsilateral hind limb (Figure 1b) and 
contralateral hind limb (data not shown). 
5.3.2 Effect of MIA injection on pain behaviour In rats 
Intra-articular injection of 1 mg MIA significantly decreased weight 
bearing on the ipsilateral hind limb (P<O.Ol for day 7 and 14; P<O.OOl 
for day 21 and 28) compared to saline-treated rats (Figure 1a). Intra-
articular injection of MIA also significantly decreased hindpaw withdrawal 
thresholds to mechanical punctuate stimulation at day 21 and 28 
(P<O.Ol) compared to saline-treated rats (Figure 1b). Intra-articular 
injection of MIA did not alter contralateral hind paw withdrawal thresholds 
(data not shown). 
a) 
b) 
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Figure 1. Changes observed in MIA- or saline-treated rats over the 28 day time course in; 
a) weight distribution between ipsilateral and contralateral hindpaws and b) hindpaw 
withdrawal threshold to mechanical punctuate stimulation. Statistical analysis comparing 
weight distribution between ipsilateral and contralateral hind paws was calculated using an 
unpaired t test for comparison of saline and MIA, *P<O.OS, **P<O.Ol, ***P<O.OOl. 
Statistical analysis comparing hindpaw withdrawal was calculated using a paired t test for 
comparison of saline and MIA, **P<O.Ol. Data is expressed as mean ± SEM of differences 
in weight bearing between ipsilateral and contralateral hindpaws (n=8). 
5.3.3 Effects of MIA and saline Injection on lipid levels in 
knee joint, plasma, spinal cord, DRGs and brain regions of 
rats 
Knee jOint, plasma, spinal cord, dorsal root ganglia (ORGs; L3-LS) and 5 
brain regions: frontal cortex, midbrain, hippocampus, rest of cortex and 
rest of brain were collected following saline or MIA intra-articular 
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injection at PO day 28. These samples were analysed using the validated 
LC-MS/MS method described in Chapter 2, the levels of individual 
analytes measured are shown in Table 1. The lipids were grouped 
according to their associated enzyme pathways to enable differences 
between these groups of lipids to be easily visible. These included the 
LOX (Iipoxygenase) group comprised of 9-, 13-HODE, 9-, 13-oxoODE, 
12- and 15-HETE; COX (cyclooxygenase) group of PGD2I'PGE2 and TXB2 , 
CYP (cytochrome P450) group of 5-, 8- and 11-HETE, EC group of AEA, 
OEA, PEA, 2-AG and AraGly and the FA (fatty acid) group of AA and LA. 
5.3.3.1 Effects of saline injection on lipid levels in knee joint, 
plasma, spinal cord, DRGs and brain regions of rats 
In saline-treated rats, 5-, 11-, 12-, 15-HETE, AEA, PEA, OEA, 2-AG, 
PGD2I'PGE2, TXB2, AA, LA and 13-HODE were all detected in the knee 
joint, plasma, DRGs, spinal cord and brain regions. 9-HODE was 
measured in the knee jOint, plasma, DRGs, spinal cord, frontal cortex, 
rest of cortex and rest of brain. 9- and 13-oxoODE were measured in the 
knee joint and plasma. 8-HETE was measured in the knee jOint, plasma 
and brain regions (Table 1). Intra-articular injection of saline did not alter 
lipid levels between ipsilateral and contralateral knee joints, DRGs and 
spinal cords (Appendices: Table 4). In saline-treated rats, the majority of 
the total lipid measured consisted of AA: knee joint (97%); plasma 
(98%); DRGs (98%); spinal cord (87%); brain (97-99%) (Table 1). In 
saline-treated rats, levels of 2-AG also comprised a large proportion of 
the total lipid, particularly in the spinal cord (13%, Table 1). Therefore, 
both lipids were excluded from the graphs, to show a clearer distribution 
of the other lipids in the tissues. 
~ r · w w
I , , ~ : : . ~ ~ t i ~ ! f : ~ ~2 1 ' 3 ' ; ~ ~ ~ ' ' l ' ~ l A ' I " "
Table 1. 
Knee Joint DR&. (13-LS) Spi .... CorcI FI'OfIUII Cortex Midbrain Hippocampus Rest of Cortex Rest of Brain Pla_ 
Saline MIA Sal_ MIA Sal_ MIA Saline MIA Saline MIA Saline MIA Saline MIA Saline MIA Saline MIA 
COX PGD2/ 39 * 5 43 * 3 270 * 187 * 42 30 * 6 33 * 9 27 * 5 30 * 6 19 * 5 18 * 2 14 * 1 13 * 2 32 * 4 28 * 1 13 * 1 15 * 2 2 * 1 3 * 0.5 PGE2 100 
TXB2 8 * 1 9*1 190 * 68 218 * 45 53 * 5 61 * 18 7*2 9*3 7*1 7 * 1 5*2 3*1 7 * 1 6 * 1 9 * 1 11 * 2 5*2 7 * 3 
LOX 13- 49* 7 61 * 7 86 * 29 95 * 36 4*1 2.5 * 1.6 0.6 * 0.1 1 * 0.3 1 * 0.3 0.6 * 0.1 0.7 * 0.1 1 * 0.2 1 * 0.6 2 * 0.5 2 * 0.3 2 * 0.3 6 * 0.7 8*1 MODE 
-
19 * 4 22 * 4 86 * 34 79 * 21 4*1 2.7 * 2.6 0.5 * 0.2 1 * 0.3 BLOQ 0.4 * 0.2 BLOQ 0.5 * 0.2 1 * 0.3 1 * 0.1 1 * 0.1 1 * 0.1 3 * 0.4 3 * 0.5 
13- 0.4 * 0.1 0.5 * 0.1 NO 37 * 16 NO NO NO NO NO NO NO NO NO NO NO NO 0.3 * 0.1 0.4 * 0.1 oxoODE 
.. 0.5 * 0.1 0.5 * 0.1 NO NO NO NO NO NO NO NO NO NO NO NO NO NO 0.5 * 0.1 0.5 * 0.1 oxoODE 
15- 6*1 11 * 2 5*2 31 * 12 4*2 BLOQ 1 * 0.2 2 * 0.3 1 * 0.1 0.6 * 0.1 1 * 0.2 1 * 0.3 1 * 0.1 1 * 0.1 1 * 0.1 1 * 0.1 0.6 * 0.1 1 * 0.3 METE 
12- 10 * 1 23 * 5 262 * 67 428 * 16 * 2 17 * 4 3*1 4*1 5*1 6*2 3*1 4*1 3 * 0.5 4*1 7 * 1 8*2 8*3 25 * 8 HETE 144 
CYP 11- 4 * 0.5 4 * 0.4 40 * 20 39*11 14 * 1 18 * 4 2 * 0.3 5*2 1 * 0.1 1 * 0.1 1 * 0.6 1 * 0.1 2 * 1 1 * 0.2 1 * 0.4 1 * 0.5 2 * 0.4 2 * 0.7 HETE 
8-HETE 1 * 0.2 1 * 0.3 BLOQ BLOQ BLOQ BlOQ 0.3 * 0.1 0.5 * 0.2 0.2 * 0.1 0.3 * 0.1 0.2 * 0.1 0.3 * 0.1 0.3 * 0.1 0.2 * 0.1 0.2 * 0.1 0.3 * 0.1 0.1 * 0.1 * 0.03 0.03 
5-HETE 1 * 0.2 1 * 0.1 10 * 5 18 * 6 2*1 2*1 1 * 0.1 1 * 0.2 1 * 0.1 1 * 0.1 0.6 * 0.1 0.6 * 0.1 0.5 * 0.1 0.5 * 0.1 0.5 * 0.1 0.6 * 0.1 0.3 * 0.4 * 0.1 0.02 
EC AnIGIr 0.1 * 0.1 * BlOQ BLOQ 13 * 3 18 * B 0.5 *0.1 0.5*0.1 0.6 * 0.1 0.7 * 0.1 0.7 * 0.3 0.7 * 0.2 0.8*0.1 0.8 * 0.1 0.6 ± 0.1 0.7 * 0.1 0.02 * 0.03 ± 0.02 0.02 0.002 0.003 
AVo 2 * 0.4 2 * 0.3 14 ± 6 13 * 4 9±1 21 * 11 6 * 1 5 * 0.3 6 * 1 5 * 0.5 6 * 1 5 * 0.5 5 * 0.5 4 * 0.3 4 * 1 4 * 0.5 0.7 * 0.1 0.7 * 0.1 
2-AG 1 * 0.2 1 * 0.1 4*1 3*1 24 * 3 24 * 3 4 % 0.3 4 * 1 11 * 1 10 * 1 9±1 7 ± 0.5 5 % 0.5 4 * 0.3 5 * 0.5 6 % 0.6 31 * 0.3 43 * 8 
PEA 6 % 0.5 6%1 323 * 93 163 ± 49 176 % 22 299 * 65 46 ± 7 40 * 9 47 ± 9 55 ± 5 33 * 5 32 * 4 16 * 2 17 * 2 18 ± 3 19 % 2 3 * 0.3 3 * 0.4 
OEA 4 * 0.4 4 ± 0.5 122 ± 35 79 * 24 128 ± 14 184 * 39 35 ± 5 31 * 5 41 ± 9 44 * 3 26 * 4 21 ± 2 15 * 2 15 ± 2 19 ± 2 19 ± 2 5 ± 0.5 5 ± 0.3 
FA 1-' 480 * 61 471 % 36 230 ± 82 303 * 95 154 ± 14 135 * 19 63 ± 11 49 * 6 60 % 15 55 ± 9 41 * 9 39 ± 9 59 * 3 51 ± 4 55 ± 5 58 ± 4 332 % 23 352 % 32 
AA 44 * 4 46 ± 3 376 * 261 * 74 156 ± 28 162 * 21 328 * 29 338 * 18 354 * 84 318 % 38 355 * 35 301 ± 31 285 ± 17 239 ± 20 212 * 16 233 ± 22 25 ± 1 26 % 2 126 
Table 1. Levels of lipids measured per g wet tissue weight in the spinal cord, DRGs, knee joint, brain regions; frontal cortex, midbrain, hippocampus, rest of cortex, 
rest of brain and plasma (n=8). Values are expressed as mean ± SEM in pmol/g for all tissues except AA, which is expressed in nmol/g. Values for plasma are 
expressed in pmol/mL except AA, which is expressed as nmol/mL. Upids have also been grouped according to enzymatic pathways and common groups; 
COX=cycloxygenase, LOX=lipoxygenase, CYP=cytochrome-p450, EC=endocannabinoids and FA=fatty aCids. 
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5.3.3.2 Effects of MIA injection on lipid levels in knee joint, plasma, 
spinal cord, DRGs and brain regions of rats 
In MIA-treated rats, 5-, 11-, 12-HETE, AEA, PEA, OEA, 2-AG, PGD:JPGE2 , 
TXB2, AA, LA, 9- and 13-HODE were all detected in the knee joint, 
plasma, DRGs, spinal cord and brain regions. 9-oxoODE was measured in 
the knee joint and plasma. 13-oxoODE was measured in the knee joint, 
plasma and DRGs. 8-HETE was measured in the knee jOint, plasma and 
brain regions. 15-HETE was measured in the knee joint, plasma, DRGs 
and brain regions (Table 1). 
In MIA-treated rats, the majority of the total amount of lipid measured 
consisted of AA and 2-AG (Table 1), comparable to saline-treated rats 
and both lipids were excluded from the graphs, to show a clearer 
distribution of the other lipids in the tissues. 
Principle component analysis (PCA) was used to investigate differences 
between saline- and MIA-injected rats and for identification of trends and 
outliers. Each individual sample represented a value from either the MIA-
or saline-treated group (variable 1) from a tissue type (variable 2) of the 
lipid measured (variable 3). As described in Chapter 2, individual pOints 
were then mapped in the space spanned by principal components 1 and 2 
and colour coded for tissue type (Figure 2). Any variance, or connection 
between individual pOints, is clearly mapped into distinct areas of the 
plot. 
In Figure 2.A the scores plot illustrates visible groupings of samples into 
each distinct tissue type, with separation apparent between knee jOint, 
plasma, DRGs, spinal cord and brain. Individual brain samples measured 
for the five brain regions; frontal cortex, midbrain, hippocampus, rest of 
cortex and rest of brain are also clearly grouped together in this plot. The 
groupings between the different tissue types are consistent with previous 
work discussed in Chapter 2. The lipids that contribute to the mapping of 
these samples in the scores plot are shown in the loadings plot (Figure 
2.B), which is also consistent with previous work discussed in Chapter 2. 
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Figure 2. Individual samples were independently analysed using Principle Component 
Analysis (PCA) to look at variation between samples represented by (A) scores plot of a 
two-component PCA model of the dataset and (8) loadings plot of the same model 
dataset. Each sample was colour coded according to tissue type : yellow= knee joint, 
green=plasma, red = DRGs, black=spinal cord, lime= frontal cortex, blue= hippocampus, 
purple= midbrain, maroon=rest of cortex and turquoise= rest of brain . These tissue groups 
have been circled in black for better visualisation. Samples that fit within the 95% 
confidence interval are included within the blue circle. Each sample was also labelled 
m=MIA and s=Saline to look at differences between these two treatment groups. 
Minimal variation was observed between saline- and MIA-treated samples 
in the knee joint, plasma and brain regions. There was, however, an 
obvious disconnection between the saline- and MIA-treated samples in 
the DRGs (Figure 2.A). This variation may be due to differences in 12-
and lS- HETE lipid levels between MIA- and saline-treated groups, and, to 
0.4 
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a lesser extent, 5-HETE (Figure 2.B and Table 1). Variation between 
saline- and MIA-treated samples was also observed in the spinal cord 
(Figure 2.A), where the variation may be due to a difference in the lipid 
levels of AEA, OEA and PEA. PCA analysis showed distinct separation 
between the tissues; however, the changes in lipid levels between saline-
and MIA-treated rats required further analysis. 
5.3.4 Differences in lipid levels in the rat knee joint 
following saline or MIA injection 
Levels of the fatty acids, AA and LA did not differ between saline- and 
MIA-treated rats in the ipsilateral knee joint (Table 1, Figure 3). Levels of 
the COX metabolites, PGD;JPGE2 and TXB2 did not alter between saline 
and MIA-treated rats (Figure 3.b), or between ipsilateral and 
contralateral knee jOints (data not shown). Lipid levels for the EC and 
CYP groups were also unaltered between saline- and MIA-treated rats. 
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Figure 3. a) Lipid distribution per g wet tissue weight of the metabolites of COX, LOX, 
CYP450 (CYP) and the endocannabinoids (EC) in knee joint in saline and MIA rats, 
excluding 2-AG and AA (n=8), b) Lipid distribution per g wet tissue weight of the 
metabolites of COX, LOX, CYP450 (CYP) and the endocannabinoids (EC) in knee joint in 
saline and MIA rats, excluding LA, 2-AG and AA (n=8). 
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There was, however, a clear difference for the LOX group of lipids 
between saline and MIA-treated rats. Levels of 12- and lS-HETE were 
significantly (P<O.OS) increased in the MIA-treated compared to saline 
(Figure 4). 
12-HETE 15-HETE 
* * 
SALINE MIA SALINE MIA 
Treatment Treatment 
Figure 4. Increases in LOX metabolites 12- and lS-HETE were observed in the knee joints 
(wet weight tissue) of MIA-treated rats compared to saline (n =8). Values are expressed 
as mean ± SEM. Statistical analysis was conducted using a Mann Whitney test, where 
* P<O.OS . 
S.3.S Differences in lipid levels in the rat plasma in saline 
and MIA treated rats 
LA was found to be the major lipid present in plasma, following exclusion 
of AA and 2-AG. Levels of LA were not different between saline- and 
MIA-treated rats (Figure 5. a). Levels of COX, EC and CYP lipids were 
unaltered between saline- and MIA-treated rats (Figure S.b). 
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Figure 5. a) Lipid distribution per g wet tissue weight of the metabolites of COX, LOX, 
CYP450 (CYP) and the endocannabinoids (EC) in plasma in saline and MIA rats, excluding 
2-AG and AA (n=8), b) Lipid distribution per g wet tissue weight of the metabolites of 
COX, LOX, CYP450 (CYP) and the endocannabinoids (EC) in plasma in saline and MIA rats, 
excluding LA, 2-AG and AA (n=8). 
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The distribution of the remaining lipids measured in plasma was similar to 
the knee joint and this is reflected in the close proximity positioning of 
both sets of samples in the PCA scores plot (Figure 2.A). Plasma levels of 
the LOX group of lipids were increased in the MIA-treated rats compared 
to saline-treated rats. Levels of 12- and lS-HETE were increased in MIA-
treated rats compared to saline-treated rats, although only lS-HETE 
reached significance (P<O.OS, Figure 6). 
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Figure 6. Increases in LOX metabolites 12- and lS-HETE were observed in the plasma of 
MIA-treated animals compared to saline (n=8), however only lS-HETE was found to be 
significant. Values are expressed as mean ± SEM. Statistical analysis was conducted 
using an unpaired t-test, where *p<O.OS. 
5.3.6 Differences in lipid levels in the rat dorsal root ganglia 
(DRGs) in saline and MIA-treated rats 
Levels of the fatty acids AA and LA (Table 1, Figure 7) remained 
unchanged between saline- and MIA-treated rats. Likewise, levels of 
lipids in the COX and CYP group also remained unaltered between saline-
and MIA-treated rats (Figure 7). 
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Figure 7. Lipid distribution per g wet tissue weight of the metabolites of COX, LOX, 
CYP450 (CYP) and the endocannabinoids (EC) in DRGs in saline and MIA rats, excluding 
2-AG and AA (n=8). 
For the LOX group, there was a 4-fold increase in lipid levels in the MIA-
treated rats compared to saline-treated rats. Further analysis showed 
that the increases in total LOX metabolites were due to increased levels 
of 12- and lS-HETE (P<O.OS, Figure 8) and, also, 13-oxoODE in the MIA-
treated rats, as this lipid was not detectable in saline-treated rats (Table 
1). In the DRGs, lipid levels in the EC group decreased in the MIA-treated 
rats compared to saline, mainly due to changes in levels of PEA and OEA; 
however, these changes were not significant (Figure 8). 
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Figure 8. Increases in 12- and lS-HETE, along with decreases in PEA and OEA were 
observed in the DRGs (g wet weight tissue) of MIA-treated rats compared to saline (n =8). 
Values are expressed as mean ± SEM. Statistical analysis was conducted using a Mann 
Whitney test, where * P<O.OS . 
5.3.7 Differences in lipid levels in the rat spinal cord in 
saline- and MIA-treated rats 
Levels of the fatty acids AA and lA (Table 1, Figure 9) in the spinal cord 
remained unchanged between saline and MIA-treated rats. Likewise, 
levels of LOX- and CYP-associated lipids in the spinal cord were unaltered 
between saline- and MIA-treated rats (Figure 9). 
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Figure 9. Lipid distribution per g wet tissue weight of the metabolites of COX, LOX, 
CYP450 (CYP) and the endocannabinoids (EC) in the spinal cord in saline and MIA-treated 
rats, excluding 2-AG and AA (n=8). 
The EC group were the main group of lipids found in the spinal cord, 
comprising 2-AG, AEA, OEA, PEA and AraGly. Increased lipid levels were 
observed mainly in the EC group but also in the COX group in the MIA-
treated rats compared to saline-treated rats (Figure 9); increased levels 
of AEA (P<O.OOl), PEA (P<O.OS), OEA (P<O.OS) and TXB2 (P<O.Ol) in the 
spinal cord of MIA-treated rats were significant (Figure 10). 
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FigurelO. Increases in AEA, PEA, OEA and TXB2 were observed in the spinal cord (wet 
weight tissue) of MIA-treated animals compared to saline (n=8). Values are expressed as 
mean ± SEM. Statistical analysis was conducted using an f-test to compare variances, 
where *P<O.OS, **P<O.Ol and **P<O.OOl. 
5.3.8 Differences in lipid levels in the rat brains regions 
(frontal cortex, hippocampus, midbrain, rest of cortex, rest 
of brain) in saline and MIA-treated rats 
Levels of the fatty acids AA and LA (Table 1, Figure 11) in all five brain 
regions were no different between saline- and MIA-treated rats. Likewise, 
cox- and CYP-associated lipid levels in all five brain regions were 
unaltered between saline and MIA-treated rats (Figure 11). 
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Figure 11. Lipid distribution per g wet tissue weight of the metabolites of COX, LOX, CYP450 (CYP) and the endocannabinoids (EC) in brain regions 
(frontal cortex, hippocampus, midbrain, rest of cortex, rest of brain) in saline and MIA rats (n=8), excluding 2-AG and AA. 
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For the EC group, levels in the frontal cortex, midbrain and rest of brain 
were no different between saline- and MIA-treated rats (Table 1). For the 
rest of cortex brain region, there were no obvious changes in levels of EC 
lipids between saline and MIA-treated rats; however, further analysis of 
individual lipids showed a significant decrease (P<O.OS) in AEA levels in 
the MIA-treated rats compared to saline-treated rats (Figure 12). 
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Figure 12. A decrease in AEA levels was observed in the rest of cortex (g wet weight 
tissue) of MIA-treated rats compared to saline (n = 8). Values are expressed as mean ± 
SEM . Statistical analysis was conducted using a Mann Whitney test, where *P<O.OS . 
In the hippocampus, EC lipid levels were decreased in the MIA-treated 
rats compared to saline-treated rats and this was significant for 2-AG 
(Figure 13). For the LOX group, lipid levels were unchanged in the frontal 
cortex, midbrain, rest of cortex and rest of brain between saline and MIA-
treated rats, although 9-HODE was only detectable in the midbrain of 
MIA-treated rats (Table 1). In the hippocampus, LOX lipid levels were 
increased in MIA-treated rats compared to saline and this was due to a 
significant increase in 13-HODE in the MIA-treated rats (Figure 13). 
Levels of 9-HODE were also only detected in MIA-treated rats and were 
below the limit of quantification (0.1 pmol/g) in saline-treated rats. 
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Figure 13. A decrease in 2-AG levels along with increase in 13-HODE were observed in the 
hippocampus (wet weight tissue) of MIA-treated rats compared to saline (n= 8) . Valu es 
are expressed as mean ± SEM. Statistical analysis was conducted using a Mann Whitney 
test, where * p<O.OS. 
This was not accompanied by any significant changes in the other lipids in 
this particular brain region (Table 1). 
5.3.9 Summary of findings 
The MIA model of OA pain was associated with changes in some bioactive 
lipids in the different rat tissues analysed. In the knee joint, 12- and 15-
HETE levels were increased (P<O.OS) in the MIA-treated rats compared to 
saline-treated rats. Both 12- and lS-HETE levels were increased in the 
plasma and the DRGs, of MIA-treated rats, however only lS-HETE 
reached significant (P<O.OS). Levels of AEA, DEA, PEA and TXB2 
increased in the spinal cord of MIA-treated rats compared to saline-
treated rats (P<O.OOl, P<O.OS, P<O.OS and P<O.Ol respectively). In the 
hippocampus, 2-AG levels were decreased (P<O.OS) and levels of 13-
HODE were increased (P<O.OS) in the MIA-treated rats, compared to 
saline-treated rats. AEA levels also decreased (P<O.OS) in the rest of 
cortex in the MIA-treated group. 
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5.4 Discussion 
There has been little work on the MIA model in relation to pain and 
inflammation. The link between these is not well known and the identity 
of the lipids involved still needs to be clarified. Previous work (Sagar et al 
2010, 1m et al 2010, Ferland et al 2010, Combe et al 2004, Fernihough 
et al 2004) has shown that intra-articular injection of MIA in rats 
significantly decreases hindpaw withdrawal thresholds to mechanical 
punctuate stimulation, compared to those treated with saline. These 
observations were also accompanied by significant increases in 2-AG, PEA 
and OEA levels in the spinal cord at PO day 14 and 28. In the present 
study, the pain and inflammation experiments were repeated to show 
that the model exhibits pain behaviour consistent with the previous 
studies, and different tissues were collected to investigate, using LC-
MS/MS, possible changes in a larger number of lipids. 
5.4.1 Effects of intra-articular injection of MIA on weight 
bearing 
Consistent with previous work (Sagar et al 2010), intra-articular injection 
of MIA produced a time-dependent increase in weight bearing difference, 
which was significant throughout the 28 day time course of 
measurements and a time-dependent decrease in paw withdrawal 
threshold, significant at PO day 21 and 28, both on the ipsilateral side. A 
significant increase in weight bearing difference was evident from PO day 
7. Since subchondral bone is richly innervated and articular cartilage is 
not, it is thought that the initiation and progression of these bone lesions 
is related to the onset of jOint pain and may account for the significant 
changes in weight bearing observed here (Guzman et al 2003). The 
effects observed at PO day 7 are also not likely to be caused by any 
inflammatory changes as these have been shown to be largely resolved 
by PO day 7 (Pulichino et al 2006, Combe et al 2004). Increases in 
weight bearing difference were also observed at PO day 14, at which time 
the histological features mentioned at PO day 7 remain but to a greater 
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extent, and pathological changes in patellar bone and cartilage are shown 
to be more extensive in distribution and severity (Clements et al 2009). 
5.4.2 Effects of intra-articular injection of MIA on hindpaw 
withdrawal thresholds 
Consistent with previous work (Sagar et al 2010), decreases in hindpaw 
withdrawal thresholds were not shown to be significant until PO day 21 of 
the study as peripheral sensitisation and allodynia developed at a later 
stage following intra-articular injection of MIA. This change in hind paw 
withdrawal threshold was also accompanied by a sharp increase in weight 
bearing difference at PO day 21. Peripheral sensitisation as a result of 
increased nociceptor activity (1m et al 2010), elevates cytokine release 
(1m et al 2010, Combe et al 2004) and contributes to hyperalgesia and 
allodynia at this stage (1m et al 2010, Schuelert and McDougall 2009, 
Combe et al 2004), which extends further to PO day 28. This is shown by 
the significant changes seen in weight-bearing and paw-withdrawal 
thresholds at PO day 28. 
5.4.3 Changes in lipid levels in different rat tissues 
Quantification and profiling of lipids in different tissues in the MIA model 
of OA pain has not previously been explored. The work presented in this 
thesis demonstrates that, when individual lipid levels of each analyte 
measured is analysed using principle component analysis (PCA), tissue 
types are evident, based on the composition and amount of lipid 
measured in that particular tissue. It is apparent that, for each tissue 
type, there are distinct differences in the lipids measured, which can be 
clearly shown with the peA scores plot. Plasma and knee joints are very 
similar in lipid composition but quite different to neural tissue. Likewise, 
all neural tissue studied (DRGs, spinal cord and brain) are similar in their 
lipid composition. Further analysis showed that the differences between 
the tissues were due to specific lipids, which is shown with the PCA 
loadings plot. Plasma and the knee joints were shown to exhibit a similar 
distribution of lipids and are, therefore, in close proximity to each other 
on the PCA score plot. The LOX metabolites 9-, 13-HODE, 9- and 13-
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oxoODE, which are known TRPV1 agonists (Patwardhan et al 2009, 
Patwardhan et al 2010) are shown on the PCA loadings plot to be the 
lipids that distinguish the knee jOint from the other tissues. In plasma, 
the main lipids that distinguish this tissue from the others investigated 
included high levels of LA, and also 8- and 12-HETE, which can be 
produced via the lipoxygenase or the cytochrome p450 pathways (Yue et 
al 2007). According to the loadings plot, AEA, OEA, PEA, TXB2 , PGD:JPGE2 
were quantified in the spinal cord and the DRGs, and the levels of these 
lipids separated the spinal cord and the DRGs from the other tissues. In 
the brain, high levels of 2-AG and AA were detected and the levels of 
these two lipids were much higher in this particular tissue compared to 
the other tissues analysed. 
5.4.3.1 Changes in lipid levels in the rat knee joint 
Analysis of the individual tissues revealed significant changes in certain 
lipids when comparing MIA- to saline-treated rats, in which most levels 
were found to be increased and these changes occurred at a time when 
there was pronounced hyperalgesia and allodynia present. In the knee 
jOint, there was a greater proportion of LOX metabolites found in the 
MIA-treated rats compared to saline-treated rats. These included the LOX 
metabolites of LA; 9-, 13-HODE, 9-, 13-oxoODE and the LOX metabolites 
of AA; 12- and 15-HETE, of which the AA metabolites were both found to 
increase significantly. As described previously, the majority of research 
investigating expression of LOX in bone has been conducted in mouse 
models, where increased expression is shown to be detrimental to 
skeletal development (Almeida et al 2009, Klein et al 2004). It is known 
that, at PO day 28, the pathological changes in the knee joint in MIA-
treated rats include focal compression and fragmentation of subchondral 
bone with replacement of bone and marrow by dense fibrous tissue 
(Guzman et al 2003). These pathological changes in the knee joint may 
be linked to increased LOX expression and the increased levels of LOX 
metabolites of LA and AA present in the jOint. Both 12-HETE and 15-HETE 
are known to be TRPV1 receptor agonists (Shin et al 2002, Caterina and 
Julius 2001, Hwang et al 2000) and there is a strong link between TRPV1 
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and hyperalgesia as discussed in Chapter 4. TRPVl is highly expressed on 
the terminals of primary afferent A ~ ~ and C-fibres, as well as being 
present in the brain, including areas involved in nociceptive transmission 
(Patwardhan et al 2009, Toth et al 2005). In the knee jOint, where the 
subchondral bone is richly innervated, the resulting hyperalgesia may be 
caused by increased TRPVl activation in the MIA-treated animals due to 
increased 12- and lS-HETE ligand production. TRPVl expression has 
been found in articular chondrocytes and synovial fibroblasts of human 
OA patients (Chu et al 2010) and TRPVl expression is elevated in MIA-
induced rats on the primary afferent neurons of the knee (Fernihough et 
al 2005). Expression of TRPVl receptors has been shown in the mouse 
DRGs and that these TRPV1-positive fibres also innervate the knee joints 
of these animals (Cho and Valtschanoff 2008). 
5.4.3.2 Changes in lipid levels in rat plasma 
In plasma there was also a higher proportion of LOX metabolites in 
samples from MIA-treated rats, compared to saline-treated rats. As 
stated previously, lipooxgenases are highly expressed in blood and 
immune cells (Hampson and Grimaldi 2002), which may account for the 
high levels of LOX products in plasma. The TRPVl ligands 12- and 15-
HETE were also increased, with changes in the levels of lS-HETE being 
significant, complimenting the data observed in the knee jOint. 
5.4.3.3 Changes in lipid levels in the DRGs 
The DRGs had a higher proportion of the LOX metabolites, similar to the 
knee joint and plasma, and a lower proportion of the endocannabinoids 
compared to the spinal cord. Further analysis of the LOX metabolites 
found that levels of the TRPVl ligands 12- and lS-HETE were significantly 
increased in the DRGs from MIA-treated rats compared to saline-treated 
rats, whereas the apparent decreases in PEA and OEA were not 
significant. In the MIA model, enhanced spontaneous firing of spinal wide 
dynamic range neurons is reduced by systemic administration of a TRPVl 
antagonist A-88942S, an effect absent in sham-operated control rats, 
indicating an enhanced role of TRPVl in this form of chronic injury (Chu 
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et al 2010). Furthermore, antibody staining of DRGs showed co-
localisation of TRPVl and cannabinoid CB2 receptor expression in the 
small and medium diameter neurons in both sham-operated and MIA-
treated animals (Schuelert et al 2010). It may be possible, therefore, 
that the TRPVl and CB2 receptor systems work synergistically in the 
DRGs. An increase was observed in the pro-nociceptive TRPVl ligands, 
12- and 15-HETE, along with an increase in LOX metabolites as a whole, 
most of which are also TRPVl ligands, coupled with a decrease in the 
endocannabinoids, some of which mediate anti-nociceptive effects via an 
action at CB2 receptors. 
5.4.3.4 Changes in lipid levels in the spinal cord 
In the rat spinal cord, there were significant increases in AEA, OEA and 
PEA in MIA-treated rats, which is consistent with previous work (Sagar et 
al 2010). In addition, there was also a significant increase in TXB2 in 
MIA-treated rats. The increases in AEA, OEA and PEA may be due to 
increased expression or activity of N-acyl phosphatidylethanolamine 
phospholipase D (NAPE-PLD), the enzyme responsible for the synthesis of 
these lipids, which has been shown to be increased in the spinal cord of 
MIA-treated rats, compared to saline-treated rats (Sagar et al 2010). In 
the MIA model, it is well known that jOint nociceptors are sensitised 
leading to the generation of joint pain. One of the main mechanisms 
responsible for this is activation of nociceptors located on A ~ ~ and C 
primary afferent nerve fibres, which show increased activity in this 
particular OA model (Schuelert and McDougall 2009). It is a possibility 
that this increased neuronal activity may be responsible for the increased 
synthesis of these lipids. In the spinal cord, a significant increase was 
observed in TXB2, a COX-2 metabolite of AA, whose levels are found to 
increase under inflammatory conditions (Guay et al 2004). Increased 
levels of TXB2 in the spinal cord are seen when spinal cord injury is 
present (Mitsuhashi et al 1994). 
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5.4.3.5 Changes in lipid levels in the rat brain 
In the brain, a larger proportion of the COX metabolites TXB2, PGDdPGE2 
were present, compared to the knee joint and plasma. PGE2 is the main 
product of the COX pathway, in which COX-1 and COX-2 convert 
arachidonic acid to prostaglandin H2 which is further metabolised by 
prostaglandin E2 synthases into PGE2 (See references in Alix et al 2008). 
In the brain, COX-2 is constitutively expressed in several neuronal cell 
populations, especially in hippocampal and cortical glutamatergic 
neurons. COX-2 is involved in brain maturation and the regulation of 
synaptic activity and plasticity (Alix et al 2008). Comparison of the 
different regions in the brain, revealed no significant changes in lipid 
levels in the frontal cortex, midbrain and rest of brain when comparing 
MIA-treated and saline-treated rats. However in the hippocampus, there 
was a significantly higher level of 13-HODE, a LOX metabolite of LA and a 
known TRPV1 agonist, in MIA-treated rats, compared to saline-treated 
rats. Another LOX metabolite of LA, the TRPV1 agonist 9-HODE, was also 
only detected in MIA-treated rats and not saline-treated rats. There is 
evidence for the existence of TRPV1 receptors in the brain including the 
hippocampus, although its function is still unclear (Gibson et al 2008, 
Steenland et al 2006). Intracerebroventricular administration of A-
784168 (a TRPVl antagonist) significantly attenuated MIA-induced 
differences in weight bearing, which suggests that TRPV1 receptors in the 
CNS playa role in OA pain (Cui et al 2006). There is also evidence for 
TRPVl receptors in the CNS having a role in pain mediated by central 
sensitisation (Cui et al 2006). TRPV1 receptors expressed by hippocampal 
neurons can be activated in several ways, one of which includes 
lipoxygenase derivatives that are synthesized as a result of glutamate 
receptor activation (Gibson et al 2008). There is also evidence linking 
TRPVl to long-term synaptic depression or LTD in hippocampal neurons, 
although these excitatory synapses were not blocked by AM251 (a CBl 
receptor antagonist), suggesting that CBl involvement was not required 
for this form of LTD (Gibson et al 2008). This may be a possible reason 
for the significant decrease in 2-AG in the hippocampus in the MIA-
234 
treated animals. 2-AG is a crucial retrograde messenger mediating on-
demand forms of LTD via CB1 activation (Ludanyi et al 2011); however, 
in this case, if CB1 involvement is not required for this form of LTD, it 
may explain the change in 2-AG levels in the hippocampus. Finally, in the 
rest of the cortex, there was a significant decrease in levels of AEA in 
MIA-treated rats, compared to saline-treated rats. The cortex is involved 
in pain processing, in the formation of pain-associated memory and the 
descending modulation of nociception (Steenland et al 2006). At PO day 
28, hyperalgesia and allodynia were evident in the MIA-treated rats and 
there were significant changes in levels of lipids involved in pain 
processing, which may suggest CNS modulation of pain processing in 
different regions of the brain. 
5.5 Conclusions 
This study illustrates that the MIA model of OA pain produces robust pain 
behaviour, with rats exhibiting signs of hyperalgesia and allodynia at day 
28 following model induction. It demonstrates an increase in the levels of 
endogenous ligands for TRPV1 at multiple levels in this model of OA pain, 
which is consistent with the previous reports that blockade of TRPVl with 
various antagonists blocks the associated pain behaviour. The data 
supports the proposal that blockade of TRPV1 may provide a novel 
pharmacological target for the reduction of OA pain. 
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6. General Discussion 
Bioactive lipids or lipids that activate specific signalling pathways are 
involved in the regulation and maintenance of normal bodily functions. 
Furthermore, bioactive lipid targets have been implicated in a number of 
conditions such as cancer, asthma and arthritis, all of which contain an 
inflammatory element (Evans and Hutchinson 2010). It is widely 
recognised that the regulation of inflammation is a highly complex 
biological process that involves many receptors, cells and molecules. The 
presence of bioactive lipids contributes to the biological response to 
tissue injury or insult and governs distinct mechanisms such as 
vasodilatation, increased capillary permeability and infiltration of immune 
cells (Chopade and Mulla 2010). Macrophages, neutrophils and dendritic 
cells are the main producers of eicosanoids typically in sub-nanomolar 
concentrations, which target local receptors (Harizi et al 2008, Mbvundula 
et al 2004). The synthetic, metabolic and signalling pathways of these 
bioactive lipids are activated in response to the multicellular signalling 
status of the environment (Evans and Hutchinson 2010). 
The measurement of levels of bioactive lipids in these biological systems 
is essentail for understanding their role in cell function and pathological 
events. In this thesis, a validated LC-MS/MS that allows the simultaneous 
identification and measurement of 42 bioactive lipids is described. This 
analytical method is capable of measuring known lipid mediators of the 
inflammatory response, including COX metabolites; PGD/PGE, TXB, LOX 
metabolites; 5-, 12-, 15-HETE, HODEs, oxoODEs, CYP metabolites; 8-
and ll-HETE, EETs and the endocannabinoids; AEA and 2-AG and 
endocannabinoid-like compounds PEA and OEA. 
The sites of action of bioactive lipids include various different receptors, 
including G-protein coupled receptors such as the cannabinoid receptors, 
the nuclear PPAR receptors, and the cation channel TRPVl. Experiments 
in this thesis using the TR-FRET PPARa competitive binding assay showed 
that 8-HETE and PEA bind to PPARa, along with other lipids such as fatty 
acids and EETs. However, previous work have only demonstrated 
237 
activation of the PPARa receptor by 8-HETE and PEA (Yu et al 1995, Fu et 
al 2003). Furthermore, 8-HETE was shown to be a high affinity PPARa 
ligand compared to endogenous ligands such as arachidonic acid and 
AEA. 
In this thesis, the carrageenan model of inflammation and pain was used 
to investigate how levels of bioactive lipids altered at different stages of 
the inflammatory process. In view of this, the changes in lipid levels can 
be compared at 1, 3, 4 and 5 hours post-carrageenan for selective lipids 
measured (Table 1). 
Z3l!I 
Table 1. 
Time (post-
carrageenan) AEA 2-AG PEA OEA 12-HETE 9-HODE 13-HODE 9-oxoODE LA TXB2 
(hr) 
1 ~ ~ , ~ ~ ~ ~ ~ ~
'" '" '" 
~ ~ ~ ~ ~ ~
3 
" 
~ ~ ~ ~ , , unknown unknown unknown unknown unknown unknown 
'If 
4 
" 
~ ~
" 
' \ ~ . . ~ ~ ~ ~ - ~ ~ ~ ~ t t. 
5 ~ ~ ~ ~ , ~ ~ 'If + unknown unknown unknown unknown unknown 
Table 1. Summary of the significant effects of intraplantar injection of 2% carrageenan on bioactive lipid levels in the hind paw at different timepoints, 1, 
3, 4 and 5 hour post-carrageenan. The changes of some of these lipids were unknown, because they were not measured at that particular timepoint. 
Data from the 1, 4 and 5 hour timepoints are presented in this thesis in Chapter 3 and Chapter 4. Data at the 3 hour timepoint is from previous work 
conducted in our group (Jhaveri et al 2008). 
I 
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Previous work investigated the changes in prostanoid levels at 0, 1, 3, 
5, 6, 12 and 24 hours post-carrageenan compared to saline in rat 
hindpaw (Guay et al 2004). Levels of TXB2 were significantly increased 
at 3 hours, but by 5 hours, had returned to baseline (Guay et al 2004). 
This thesis reports that levels of TXB2 remained unchanged at 1 hr, 
which is consistent with previous work (Guay et al 2004) and are 
significantly elevated at 4 hours. Levels of PGE2 were previously 
reported to be significantly raised in hindpaw tissue from 1 hour post-
carrageenan, which was maintained to 6 hours, before increasing 
sharply at 12 hours, and again at 24 hours (Guay et al 2004). In my 
experiments, levels of PGD:JPGE2 were unaltered at 1 or 4 hours post-
carrageenan. However, limitations in the analytical methodology 
presented in this thesis meant that measurements of this prostanoid are 
expressed as a sum of PGD2 and PGE2. Therefore, any subtle changes in 
PGE2 may not have been detectable. Levels of PGE2 and TXB2 have also 
been analysed previously by GC-MS and shown to peak at 3 hours post-
carrageenan in pleural exudate of rats (Harada et al 1982) and PGD2 
was undetectable in these samples. 
In the carrageenan model of inflammation, significant reductions in lipid 
levels were observed for AEA, 2-AG, PEA, OEA, 12-HETE, 9-HODE, 13-
HODE and 9-oxoODE, which were also time-dependent. The N-acyl 
ethanolamines (NAEs) AEA, PEA and OEA have been measured 
previously over a time course of 24 hours and changes in lipid levels 
were also time-dependent, following inhibition of AEA hydrolysis (Fegley 
et al 2005). This data is consistent with earlier reports that levels of 13-
HODE are reduced in synovial fluid in carrageenan-induced knee 
arthritis (Herlin et al 1988). However, to date, the levels of bioactive 
lipids in the carrageenan model have not been profiled using LC-MS/MS 
until now. Additionally, HODEs and oxoODEs have not previously been 
measured in the carrageenan model. Therefore, it is difficult to draw 
comparisons with my data and previous studies. However, it does 
provide confidence that the changes in these LOX metabolites mirror 
those seen with the endocannabinoids, changes of which have been 
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shown previously (Jhaveri et al 2008). Data in this thesis also found 
significant carrageenan-induced hyperalgesia at 4 hours. This is 
consistent with previous studies which have also shown that 
carrageenan administration into the hindpaw results in increased 
hindpaw volume, oedema and hyperalgesia at 4 hours (Thorpe et al 
2011, Pabreja et al 2010) and 3 hours (Jhaveri et al 2008). Increased 
metabolism and/or decreased synthesis during inflammation may 
explain these time-dependent reductions in lipid levels. The metabolism 
of bioactive lipids are achieved either by COX, LOX or CYP enzymes and 
the endocannabinoids AEA and 2-AG are also metabolised by fatty acid 
amide hydrolase (FAAH) and monoacyl glycerol lipase (MAGL) 
respectively. However, elevated activity of FAAH and MAGL was not 
observed in carrageenan-treated rats compared to saline-treated, 
suggesting that these metabolic pathways were not responsible for 
reduced levels of AEA and 2-AG (Jhaveri et al 2008, Holt et al 2005). It 
is established from in vitro studies that COX-2 can metabolise AEA and 
2-AG (Yu et al 1997, Kozak et al 2004) and under conditions of 
peripheral inflammation, hindpaw injection of the COX-2 inhibitor 
rofecoxib enhances the inhibitory effects of AEA on pain behaviour. Also, 
levels of AEA, PEA and OEA were elevated in the hindpaw, indicating a 
role of peripheral COX-2 in the modulation of endocannabinoid function 
under these conditions (Guindon et al 2006). However, previous work in 
our group did not find overt increases in AEA and OEA, but found 
significant decreases in these lipids following COX-2 inhibition with 
nimesulide, suggesting involvement of other metabolic pathways. 
Indeed, metabolism of AEA and 2-AG via the LOX enzymes (Hampson et 
al 1995, Ueda et al 1995) and CYP enzymes (Snider et al 2007, Snider 
et al 2009, Awumey et al 2008, Stark et al 2008) has been reported. 
Involvement of LOX and metabolites of this enzyme in behavioural pain 
responses has recently been presented in vitro and in vivo. 9-HODE has 
been shown to activate TRPV1 in transfected CHO cells and produces 
behavioural pain responses following spinal administration, released 
following depolarisation of the spinal cord in vitro (Patwardhan et al 
2009). Noxious thermal stimulation also increases levels of 9- and 13-
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HODE in the skin and HODE-evoked TRPV1 responses of neurones are 
absent in cells from TRPV1 knockout mice (Patwardhan et al 2010), 
further supporting a potential role of these lipids in LOX-mediated 
nociception. Data in this thesis showed that inhibition of lS-LOX with PO 
146176 and co-administration of 9- and 13-HODE antibodies, 
significantly reduced the carrageenan-induced weight bearing difference 
at 4 hours post-injection, suggesting lS-LOX mediated nociception. 
However, PO 146176 pre-treatment did not significantly alter the 
carrageenan-induced increase in the hindpaw volume and hindpaw 
circumference, suggesting that PO 146176 alters nociceptive pathways, 
rather than inflammatory pathways. In vitro, levels of 9- and 13-HODE, 
expressed as a ratio of the levels of linoleic acid, were significantly 
decreased following pre-exposure to PO 146176 for 15 minutes, but not 
30 minutes, suggesting that PD 146176 may block the production of the 
HODEs. Levels of the endocannabinoids, AEA and 2-AG increased 
significantly following pre-treatment with PD 146176, suggesting 
reduced metabolism of these endocannabinoids via 1S-LOX. In vivo, 
however, PD 146176 pre-treatment did not significantly alter levels of 
the 1S-LOX metabolites and other lipid mediators in the carrageenan-
treated hindpaw. Therefore, these results may add value to the 
hypothesis that the levels of bioactive lipids are affected by 
physiological processes such as oxidative stress and/or other routes of 
metabolism, as these changes are observed in vitro but not in vivo. It 
also draw attentions to the limitations of the analytical methodology and 
measurement of lipid levels that are a 'snapshot' in time of these 
physiological processes. A reason for this, may be that the changes in 
vivo occur at a different timepoint to those investigated in these studies. 
Therefore, future work may need to repeat these experiments at 
different timepoints or utilise alternative methodology to measure lipid 
changes over a period of time, to be able to provide further clarification 
of the 1S-LOX mediated nociceptive effects. 
Bioactive lipid targets have been implicated in a number of conditions 
such as cancer, asthma and arthritis, all of which contain an 
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inflammatory element. The MIA rat model of OA pain, is a robust model 
of osteoarthritis and this was used to investigate the potential changes 
in bioactive lipids under chronic inflammatory conditions in arthritis. It is 
important to note that, to date, profiling of bioactive lipids in different 
tissues of the MIA rat model has yet to be investigated until now. 
Eicosanoid profiling in the synovial joints of horses has been reported 
(De Grauw et al 2011), along with measurement of the 
endocannabinoids in synovial tissue and fluid (Richardson et al 2008). 
Intra-articular injection of MIA produced a time-dependent increase in 
weight bearing difference and a time-dependent decrease in paw 
withdrawal threshold in the ipsilateral hind paw, consistent with early 
studies (Sagar et al 2010). In the knee jOint, levels of the known 
endogenous TRPV1 agonists, 12- and lS-HETE levels were significantly 
increased in MIA-treated rats compared to saline-treated rats. This 
elevation in levels of 12- and 15-HETE was also observed in plasma and 
in the DRGs of MIA-treated rats. Expression of TRPVl receptors has 
been shown in the mouse DRGs and that these TRPV1-positive fibres 
also innervate the knee joints of these animals (Cho and Valtschanoff 
2008). In addition, TRPV1 expression has been found in articular 
chondrocytes and synovial fibroblasts of human OA patients (Chu et al 
2010) and TRPV1 expression is elevated in MIA-induced rats on the 
primary afferent neurons of the knee (Fernihough et al 2005). Recently, 
TRPV1 activity was reported to be increased in the rat knee joint in the 
MIA model of OA (Puttfarcken et al 2010). In the hippocampus, levels of 
13-HODE, another known TRPV1 ligand, was increased in MIA-treated 
rats, compared to saline-treated rats. These data demonstrate an 
increase in the levels of endogenous ligands for TRPV1 at multiple 
levels, in this model of OA pain and proposes that blockade of TRPV1 
may provide a novel pharmacological target for the reduction of OA 
pain. Previous reports demonstrate that blockade of TRPV1 with various 
antagonists blocks the associated pain behaviour peripherally and 
centrally (For review see: Roberts and Connor 2006, Chu et al 2010, 
Puttfarcken et al 2010). However, TRPVl antagonism has been shown 
to alter core body temperature and reduced sensitivity to painful or 
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damaging heat stimuli and has therefore lost promise in clinical 
applications (Vay et al 2012, Krarup et al 2011, Round et al 2011). 
Therefore, the TRPVl ligands themselves may prove to be potential 
targets for MIA-mediated pain behaviour, although future investigations 
are required to confirm this. 
Levels of AEA, OEA, PEA and TXB2 were increased in the spinal cord of 
MIA-treated rats compared to saline-treated rats. Increases in OEA and 
PEA in the spinal cord have previously been reported in our group in 
MIA-treated rats compared to saline-treated (Sagar et al 2010). Protein 
levels of NAPE-PLD and diacylglycerol lipase alpha (DAGLe), the major 
synthetic enzymes for the NAEs and 2-AG, respectively, were increased 
in the spinal cords of MIA-treated rats compared with saline-treated rats 
(Sagar et al 2010). Therefore, the increased spinal cord levels of AEA, 
PEA and OEA in MIA-treated rats are most likely as the result of 
increased synthesis via NAPE-PLD. Future work investigating the levels 
of precursors of the NAEs via the NAPE-PLD pathway, including N-acyl 
phosphatidyl ethanolamine, would need to be conducted to be able to 
confirm this hypothesis in vivo. 
In conclusion, the development of a novel LC-MS/MS analytical method 
capable of measuring a large number of bioactive lipids in vitro and in 
vivo, have provided novel findings to support the involvement of these 
lipids in inflammation and pain. Furthermore, these data provide 
evidence for the involvement of PPARa and TRPVl receptors in acute 
inflammatory pain and TRPVl in chronic inflammatory pain. Reductions 
in levels of 9-HODE, 13-HODE, 9-oxoODE, AEA and 12-HETE, all known 
TRPVl ligands were detected in the carrageenan model of acute 
inflammatory pain. Interestingly, opposing effects were observed in the 
MIA model of chronic inflammatory pain, where elevation of lipid levels 
of TRPVl ligands 12-, lS-HETE and 13-HODE were detected. Overall, 
the evidence provides support for the proposal of TRPVl receptors and 
also, TRPVl ligands, as potential novel pharmacological targets for the 
reduction of acute and chronic pain. 
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Future Work 
Further work that could be conducted following the results of this thesis 
include repeating the experiment involving intraplantar administration of 
PD 146176, 1S-LOX inhibitor, carried out in exactly the same way, but 
with the addition of a TRPV1 antagonist, either BCTC or 5B-366791 also 
administered intraplantarly. If attenuation of pain behaviour is blocked 
through the use of a TRPV1 antagonist, it would further confirm the 
involvement of TRPVl. Furthermore, collection of hindpaw tissue could 
also be repeated at closer time intervals. In this thesis, results for the 
analysis of lipid levels were shown at 1 hour and 4 hour, post-
carrageenan injection. It may clarify the time course of lipid changes if a 
larger number of rats were used to include 2 and 3 hour timepoints. A 
rapid rise in pro-inflammatory agents may be expected earlier than the 
rise in anti-inflammatory or 'resolution-associated' agents. It may also 
clarify whether changes in HODE and oxoODE levels are occurring 
before the 4 hour timepoint measured. 
In terms of the results observed in the MIA-model, it would be 
interesting to draw comparisons with human data. Since the knee joint 
dissected in the experiments conducted in this thesis contains mainly 
synovial fluid, collection of this particular biological sample from patients 
of OA would provide an interesting comparison between human OA and 
the rat MIA model of the disease. Profiling of human synovial fluid would 
then allow comparison of this to the lipid profile observed in the MIA-
treated rat knee jOints. 
Reviewing the data in a more global sense, PO 146176 may be irritant 
to the mucous membranes and upper respiratory tract, and could 
potentially be harmful through inhalation, ingestion and skin absorption, 
which do not provide confidence for human use and performance in 
clinical trials. However, 1S-LOX inhibition is a potential target for 
analgesia, but a drug that has a better toxicology profile would be 
necessary. 
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Figure 1: Representative traces illustrating changes in intracellular calcium 
concentrations (represented by 340:380 nm ratios) in single DRG cells responding to 
capsaicin, linoleic acid (LA) and 13-HODE. A: the cell was exposed for 1 minute to 
capsaicin (100nm) and for 2 minutes to lmM LA separated by forty five minutes of wash 
with buffer. B: the cell was exposed to capsaicin (100nm) for 1 minute, and pre-
exposed to capsazepine (10IJM) for 3 minutes before LA (lmM) was applied. C: the cell 
was exposed for 2 minute to 13-HODE (100IJm) and for 1 minute to capsaicin separated 
by forty five minutes of wash with buffer. D: the cell was pre-exposed to capsazepine 
(lOIJM) for 3 minutes before 13-HODE (lOOlJm) was applied. 
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Treatment Peak response Percentage of Total number of 
(4RU) responding cell. 
cells Imaged 
Vehicle / LA 0.7=*:0.03 65=*:7 650 
Capsazepine / LA 0.08=*:0.01 *** 10=*:4*** 494 
Vehicle / 13-HODE 0.2=*:0.01 68=*:5 383 
Capsazepine / 13-HODE 0.05=*:0.01### 7=*:4### 281 
Vehicle / 9-HODE 0.3=*:0.03 55=*:8 204 
Capsazepine / 9-HODE 0.05=*:0.01 ttt 10=*:4tt 303 
Table 1: Summary of the changes in [Ca2+lt, represented as differences In 340/380 
ratios, compared with control values (aRU) in DRG cells and the percentage of cells 
responding following suprafusion of the different treatments. Data (means =*: SEM) were 
analyzed using Student's t test (***P<O.OOl vs vehicle / LA, ###P<O.OOl vs vehicle / 
l3-HODE, ttP<O.Ol vs vehicle / 9-HODE). 
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Figure 2. The is-LOX inhibitor PD146i76 significantly decreased the percentage of 
DRG cells responding to linoleic acid, and reduced linoleic acid-evoked peak responses 
(B). Statistical analysis with one way ANOVA test followed by Bonterron! post-hoc: 
**P<O.Ol, ***P<O,OOl). 
----_____ ._ < F _ ~ ~
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Table 2. 
Treatment Paw Circumference (mm) Paw Volume 3 measurements) 
Baseline Second Final Baseline Second Anal (Pre- Baseline Second Final (Pre- Baseline Second Final (Pre-
(Pre-Drug (Pre-Sal ( Pre-tissue (Pre-Drug (Pre-Sal or tissue (Pr'e-Orug (Pre-Sal tissue (Pre-Drug (Pre-Sal tissue 
orVeh orear collection or Veh ear coIlection- orVeh orear collection- orVeh orear collection-
injection) injection) injection)- injection )- 1 injection )- injection )- 2 injection )- injection)- 3 
1 1 2 2 3 3 
Veh-car 26 :J:0.2 29 :J:0.3 33 :J:0.7 1.3 ±0.03 1.6 ±0.01 2.1 :J:O.l 1.4 :J:0.04 1.6 :J:O.Ol 2.1 :J:0.11 1.3 :J:0.04 1.6 ±0.02 2.1±0.1 
...... .... • •• • •• 
po-car 26 ±0.2 28 :J:0.3 32 :J:1.4 1.3 :J:0.02 1.6 ±0.03 1.8 :J:0.14 1.3 :J:0.02 1.6 :J:0.02 1.9 :J:0.15 1.3 ±0.02 1.6 ±0.03 1.8 :J:0.13 1 
..... •• •• • • 
Veh-Sal 26 :J:0.3 29 ±O.S 28 ±0.9 1.3 ±0.02 1.6 ±0.03 1.5 :J:0.l1 1.4 :1:0.03 1.6 :J:0.01 1.5 :J:0.14 1.4:J:0.02 1.6 ±0.02 1.5 ±0.12 
PO-Sal 27 ±0.2 29 :J:0.5 28 :J:0.8 1.3 :J:0.04 1.6 ±0.08 1.4 :J:0.04 1.3 :J:0.03 1.5 :J:0.08 1.4 :J:0.04 1.3 :J:0.02 1.6 :J:0.06 1.3 :J:0.04 
N;'ivp 26 :J:0.3 26:J:0.3 26 :J:0.4 1.3 :J:0.02 1.3 ±0.04 1.3 :J:0.04 1.3 ±0.04 1.3 :J:0.05 1.3 :J:0.03 1.3 :J:0.02 1.3 :J:0.04 1.3 :J:0.03 
Table 2. Intraplantar injection of 2% carrageenan significantly altered hindpaw drcumference and hindpaw volume in vehicle-carrageenan (Veh-ear) and 
PO 146176-carrageenan (PO-Car) groups in the ipsilateral hindpaw compared to control at this four hour timepoint; however, PO 146176 treatment did 
not significantly alter carrageenan-induced increases in hindpaw drcumference or hindpaw volume in these rats (n=6). Data were analysed using a one-
way Anova with Bonferoni post hoc test, • ... P<O.OOl, "P<O.Ol. Data are expressed as mean ± SEM of ipsilateral hindpaws (n=6). 
... 
-.. 01 
~ ~01111 
'Qi ~ ~
~ [ [
C't:l 
.- C 
CIJ'-u ~ ~
c c 
CIJ CIJ 
... CIJ ~ ~ ~ ~
.- .. Q CIJ 
.£) 
297 
Veh-Sal 
-+- Naive 
40 
-+- PO-Sal 
20 
o .... ~ ; ; : a a I c:=:b::I ......  
' > ~ ~ t ~ ~ t O J ~ ~ " , > ~ ~
PO injection Carrageenan 
( 5 0 ~ ) ) Injection 2% 
( 100111) 
Time (min) post-carrageenan administration 
Figure 3. Rats treated with PD 146176 followed by saline (PD-Sal) did not show any 
changes in weight bearing, which was comparable to the na"ive and vehicle-saline (Veh-
Sal) treated groups (n=6). 
------------
Z98 
Table 3. 
Treatment Paw Circumference (mm) Paw Volume (3 measurements) 
Baseline Final (Pre-tissue Baseline Final (Pre-tissue Baseline Final (Pre-tissue Baseline Final (Pre-tissue 
(Pre-injection) collection (Pre-iniection)-1 collection-1 lPre-in;ection)-2 collection-2 (Pre-in;ection )-3 collection-3 
Veh-Car 26 * 0.2 35 * 0.4*** 1.3 ± 0.03 2.1 ± 0.04*** 1.4 ± 0.04 2.1 * 0.05*** 1.4 * 0.03 2.1 * 0.06*** 
AB Car 26 * 0.2 34*1.1*** 1.4 ± 0.02 2.0 * 0.08*** 1.3 * 0.03 2.0 * 0.05*** 1.4 * 0.03 2.1 ± 0.08*** 
Veh-Sal 26 * 0.2 27 * 0.2 1.3 * 0.03 1.4 * 0.04 1.3 * 0.04 1.4 * 0.03 1.4 * 0.04 1.4 * 0.05 
AB-Sal 27 * 0.4 27 ± 0.3 1.3 ± 0.03 1.4 * 0.04 1.3 ± 0.03 1.4 * 0.04 1.3 * 0.03 1.4 * 0.02 
N ~ " i v p p 27 * 0.3 26 ± 0.3 1.3 * 0.04 1.3 * 0.04 1.4 ± 0.05 1.3 * 0.03 1.3 * 0.03 1.3 * 0.04 
--
Table 3. Intraplantar injection of 2% carrageenan significantly altered paw circumference and paw volume in vehicle-carrageenan (Veh-Car) and 
antibodies-carrageenan (AS-Car) groups in the ipsilateral hindpaw compared to control; however, antibodies treatment did not significantly alter 
carrageenan-induced increases in paw Circumference or paw volume in these same rats. Data were analysed using a one-way Anova with Bonferoni post 
hoc test, ***P<O.OO1. Data are expressed as mean ± SEM of ipsilateral hindpaws (n=6). 
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Figure 4. Rats injected with 9- and 13-HODE antibodies followed by saline (AB-Sal) did 
not show any changes in weight bearing, which was comparable to the na'ive and vehicle-
saline (Veh-Sal) treated groups (n=6). 
Table 4. 
Contralatera l 
DRGs ( L3- Spinal 
Knee 'oint L5 Cord 
PGD2/PGE2 27 * 5 142 * 28 24 * 5 
TXB2 7 * 1 155 * 36 42 * 10 
13-HODE 40 * 6 64 * 19 3 * 1 
9-HODE 13 * 2 69 * 16 2 * 1 
13-0lCOODE 1 * 0 .1 NO NO 
9 -0lCOODE 1 * 0.1 NO NO 
15-HETE 5 * 1 17 * 4 4 * 1 
ll-HETE 3 * 0.3 32 * 8 14 * 1 
12-HETE 10 * 2 210 * 59 18 * 7 
8-HETE 1 * 0.2 BLOQ BLOQ 
5-HETE 1 * 0.1 9 * 3 BLOQ 
LA 440 * 41 261 * 58 142 * 53 
AA 43:1: 3 271 * 66 134 * 38 
AEA 2 to.l 13 * 3 8 * 1 
2-AG 0.7 * 0 .03 2 * 1 23 * 4 
PEA 6 * 1 307 * 140 147 * 50 
OEA 4 * 0 .3 89 * 28 144 * 18 
Table 4. Levels of lipids measured per g wet weight tissue in the contralateral knee jOint, 
DRGs and spinal cord (n =8). Values are expressed as mean ± SEM in pmol/g for all 
tissues except AA, which is expressed in nmol/g. BLOQ = below limit of quantification . 
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Chemical Structures 3 
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